Illumina, Inc 8-K/A, filed Oct 29, 2021
Illumina, Inc. (ILMN)
About this 8-K/A
Illumina, Inc filed this 8-K/A on October 29, 2021, reporting on events of August 18, 2021.
Items reported
- Item 2.01: Completed an acquisition or sale of assets
- Item 9.01: Financial statements and exhibits
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form
Current Report
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):

(Exact name of registrant as specified in its charter)
(Commission File Number)
| (State or other jurisdiction of incorporation) |
(I.R.S. Employer Identification No.) |
(Address of principal executive offices) (Zip code)
(Registrant’s telephone number, including area code)
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class |
Trading Symbol(s) |
Name of each exchange on which registered | ||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13a of the Exchange Act. ☐
Item 2.01. Completion of Acquisition or Disposition of Assets.
On August 18, 2021, Illumina, Inc., a Delaware corporation (“Illumina”), filed a Current Report on Form 8-K (the “Original 8-K”) to report the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of September 20, 2020 (the “Original Merger Agreement”) (such transactions, the “Transaction”), as amended on February 4, 2021 by the Amendment to the Agreement and Plan of Merger (the “Merger Agreement Amendment” and the Original Merger Agreement as amended by the Merger Agreement Amendment, the “Merger Agreement”), by and among Illumina, GRAIL, Inc., a Delaware corporation (“GRAIL”), SDG Ops, Inc., a Delaware corporation and a direct, wholly owned subsidiary of Illumina (“First Merger Sub”), SDG Ops, LLC, a Delaware limited liability company and a direct, wholly owned subsidiary of Illumina (“Second Merger Sub” and now known as GRAIL, LLC). Pursuant to the Merger Agreement, First Merger Sub merged with and into GRAIL, with GRAIL continuing as the surviving entity and as a direct, wholly owned subsidiary of Illumina (the “First Merger”). Immediately following the First Merger and as part of the same overall transaction as the First Merger, GRAIL merged with and into Second Merger Sub, with Second Merger Sub being renamed GRAIL, LLC and continuing as the surviving entity and as a direct, wholly owned subsidiary of Illumina.
This Current Report on Form 8-K/A (this “Amended 8-K”) amends and supplements the Original 8-K filed by Illumina, and is being filed to provide the historical statements and the pro forma financial information required pursuant to Items 9.01(a) and 9.01(b) of Form 8-K, respectively. In accordance with the requirements of Items 9.01(a)(3) and 9.01(b)(2) of Form 8-K, this Amended 8-K is being filed within 71 calendar days of the date that the Original 8-K was required to be filed with respect to the above referenced transaction.
Item 9.01. Financial Statements and Exhibits.
(a) Financial statements of business acquired.
The audited consolidated financial statements of GRAIL as of December 31, 2019 and 2020 and for the years ended December 31, 2019 and 2020 are filed as Exhibit 99.1 to this Amended 8-K and are incorporated herein by reference.
The unaudited condensed consolidated financial statements of GRAIL as of June 30, 2021 and for the six months ended June 30, 2021 and 2020 are filed as Exhibit 99.2 to this Amended 8-K and are incorporated herein by reference.
(b) Pro forma financial information.
The unaudited pro forma condensed combined financial information of Illumina giving effect to the Transaction (the “Pro Forma Financial Information”), which combines the historical financial statements of Illumina and GRAIL, after giving effect to the Transaction, is filed as Exhibit 99.3 to this Amended 8-K and incorporated herein by reference. The unaudited pro forma condensed combined financial information of Illumina consists of the unaudited pro forma condensed combined balance sheet as of July 4, 2021, the unaudited pro forma condensed combined statement of income for the year ended January 3, 2021 and the unaudited pro forma condensed combined statement of income for the six months ended July 4, 2021.
Also included in this Amended 8-K is the consent of PricewaterhouseCoopers LLP consenting to the inclusion of its report dated March 29, 2021 relating to the financial statements of GRAIL included as Exhibit 99.1, which is included as Exhibit 23.1.
The pro forma financial information included in this Amended 8-K has been presented for informational purposes only. It does not purport to represent the actual results of operations that Illumina and GRAIL would have achieved had the businesses been combined during the periods presented in the Pro Forma Financial Information and is not intended to project the future results that the combined businesses may achieve.
(d) Exhibits.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: October 28, 2021
| ILLUMINA, INC. | ||
| By: | /s/ Sam A. Samad | |
| Name: Sam A. Samad | ||
| Title: Senior Vice President and Chief Financial Officer | ||
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We hereby consent to the incorporation by reference in the Registration Statement on Form S-3 (No. 333-254195) and Registration Statement on Form S-8 (No. 333-206215) of Illumina, Inc. of our report dated March 29, 2021 relating to the financial statements of GRAIL, Inc., which appears in this Current Report on Form 8-K/A.
| /s/ PricewaterhouseCoopers LLP |
| San Jose, California |
| October 28, 2021 |
Exhibit 99.1
GRAIL AUDITED CONSOLIDATED FINANCIAL STATEMENTS AS OF AND FOR THE YEARS
ENDED DECEMBER 31, 2020 AND 2019
GRAIL, INC.
INDEX TO CONSOLIDATED FINANCIAL STATEMENTS
| Page | ||||
| AUDITED CONSOLIDATED FINANCIAL STATEMENTS: |
||||
| Report Of Independent Registered Public Accounting Firm |
2 | |||
| Consolidated Balance Sheets |
3 | |||
| Consolidated Statements Of Operations |
5 | |||
| Consolidated Statements Of Comprehensive Loss |
6 | |||
| Consolidated Statements Of Redeemable Convertible Preferred Stock And Stockholders’ Deficit |
7 | |||
| Consolidated Statements Of Cash Flows |
9 | |||
| Notes To Consolidated Financial Statements |
11 | |||
1
REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
To the Board of Directors and Stockholders of GRAIL, Inc.
Opinion on the Financial Statements
We have audited the accompanying consolidated balance sheets of GRAIL, Inc. and its subsidiaries (the “Company”) as of December 31, 2020 and 2019, and the related consolidated statements of operations, of comprehensive loss, of redeemable convertible preferred stock and stockholders’ deficit and of cash flows for the years then ended, including the related notes (collectively referred to as the “consolidated financial statements”). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2020 and 2019, and the results of its operations and its cash flows for the years then ended in conformity with accounting principles generally accepted in the United States of America.
Basis for Opinion
These consolidated financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s consolidated financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.
We conducted our audits of these consolidated financial statements in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud.
Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion.
| /s/ PricewaterhouseCoopers LLP |
| San Jose, California |
| March 29, 2021 |
We have served as the Company’s auditor since 2017.
2
GRAIL, INC.
CONSOLIDATED BALANCE SHEETS
(in thousands, except share and per share data)
| As of December 31, | ||||||||
| 2019 | 2020 | |||||||
| Assets |
||||||||
| Current assets: |
||||||||
| Cash and cash equivalents |
$ | 143,189 | $ | 170,192 | ||||
| Short-term marketable securities |
401,155 | 413,286 | ||||||
| Prepaid expenses and other current assets |
12,585 | 11,880 | ||||||
| Prepaid expenses and other current assets—related parties |
584 | 564 | ||||||
|
|
|
|
|
|||||
| Total current assets |
557,513 | 595,922 | ||||||
| Property and equipment, net |
23,078 | 50,017 | ||||||
| Property and equipment, net—related parties |
1,347 | 339 | ||||||
| Operating lease right-of-use assets |
35,036 | 51,030 | ||||||
| Long-term marketable securities |
13,933 | 2,051 | ||||||
| Restricted cash |
1,228 | 4,577 | ||||||
| Other non-current assets |
3,384 | 2,362 | ||||||
|
|
|
|
|
|||||
| Total assets |
$ | 635,519 | $ | 706,298 | ||||
|
|
|
|
|
|||||
| Liabilities, redeemable convertible preferred stock, and stockholders’ deficit |
||||||||
| Current liabilities: |
||||||||
| Accounts payable |
$ | 5,880 | $ | 24,457 | ||||
| Accounts payable—related parties |
207 | 52 | ||||||
| Accrued liabilities |
31,584 | 50,613 | ||||||
| Accrued liabilities—related parties |
— | 248 | ||||||
| Liability for early exercise of unvested stock options, current portion |
1,855 | 632 | ||||||
| Operating lease liabilities, current portion |
4,604 | 5,449 | ||||||
| Other current liabilities |
800 | — | ||||||
| Other current liabilities—related party |
— | 2,520 | ||||||
|
|
|
|
|
|||||
| Total current liabilities |
44,930 | 83,971 | ||||||
| Operating lease liabilities, net of current portion |
36,638 | 57,537 | ||||||
| Liability for early exercise of unvested stock options, net of current portion |
349 | 689 | ||||||
| Other non-current liabilities |
3,075 | 2,265 | ||||||
|
|
|
|
|
|||||
| Total liabilities |
84,992 | 144,462 | ||||||
|
|
|
|
|
|||||
| Commitments and contingencies (Note 7) |
||||||||
| Redeemable convertible preferred stock: |
||||||||
| Series A redeemable convertible preferred stock, $0.001 par value, 85,000,000 shares authorized as of December 31, 2019 and 2020; 85,000,000 shares issued and outstanding as of December 31, 2019 and 2020; aggregate liquidation preference of $85,000 as of December 31, 2019 and 2020 |
68,263 | 68,263 | ||||||
| Series B redeemable convertible preferred stock, $0.001 par value, 309,256,591 shares authorized as of December 31, 2019 and 2020; 309,256,591 shares issued and outstanding as of December 31, 2019 and 2020; aggregate liquidation preference of $1,239,655 as of December 31, 2019 and 2020 |
1,235,404 | 1,235,404 | ||||||
| Series C redeemable convertible preferred stock, $0.001 par value, 63,144,600 shares authorized as of December 31, 2019 and 2020, respectively; 63,144,600 shares issued and outstanding as of December 31, 2019 and 2020; aggregate liquidation preference of $300,000 as of December 31, 2019 and 2020 |
299,557 | 299,557 | ||||||
| Series D redeemable convertible preferred stock, $0.001 par value, 48,942,833 and 76,743,836 shares authorized as of December 31, 2019 and 2020, respectively; 31,323,413 and 76,743,836 shares issued and outstanding as of December 31, 2019 and 2020, respectively; aggregate liquidation preference of $160,000 and $392,008 as of December 31, 2019 and 2020, respectively |
159,836 | 391,694 | ||||||
| Total redeemable convertible preferred stock |
1,763,060 | 1,994,918 | ||||||
3
| Stockholders’ deficit: |
||||||||
| Common stock, $0.001 par value; 863,943,220 (Class A—833,943,220 and Class B—30,000,000) shares and 898,203,200 (Class A—868,203,200 and Class B—30,000,000) shares authorized as of December 31, 2019 and 2020, respectively; 134,663,097 (Class A—109,673,700 and Class B— 24,989,397 and 146,661,691 (Class A—121,672,294 and Class B— 24,989,397) shares issued and outstanding as of December 31, 2019 and 2020, respectively |
138 | 151 | ||||||
| Additional paid-in capital |
90,495 | 180,952 | ||||||
| Accumulated other comprehensive income |
2,465 | 3,602 | ||||||
| Accumulated deficit |
(1,305,631 | ) | (1,617,787 | ) | ||||
|
|
|
|
|
|||||
| Total stockholders’ deficit |
(1,212,533 | ) | (1,433,082 | ) | ||||
|
|
|
|
|
|||||
| Total liabilities, redeemable convertible preferred stock, and stockholders’ deficit |
$ | 635,519 | $ | 706,298 | ||||
|
|
|
|
|
The accompanying notes are an integral part of these consolidated financial statements.
4
GRAIL, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS
(in thousands, except share and per share data)
| Year Ended December 31, | ||||||||
| 2019 | 2020 | |||||||
| Operating expenses: |
||||||||
| Research and development |
158,886 | 181,802 | ||||||
| Research and development—related parties |
8,202 | 11,106 | ||||||
| Marketing |
7,679 | 13,473 | ||||||
| General and administrative |
80,896 | 110,034 | ||||||
|
|
|
|
|
|||||
| Total operating expenses |
255,663 | 316,415 | ||||||
|
|
|
|
|
|||||
| Loss from operations |
255,663 | 316,415 | ||||||
| Interest income, net |
(12,430 | ) | (5,661 | ) | ||||
| Other expense, net |
1,817 | 1,369 | ||||||
|
|
|
|
|
|||||
| Loss before provision for (benefit from) income taxes |
245,050 | 312,123 | ||||||
| Provision for (benefit from) income taxes |
(195 | ) | 33 | |||||
|
|
|
|
|
|||||
| Net loss |
$ | 244,855 | $ | 312,156 | ||||
|
|
|
|
|
|||||
| Net loss attributable to Class A and Class B common stockholders |
||||||||
| Basic and diluted |
$ | 244,855 | $ | 312,156 | ||||
|
|
|
|
|
|||||
| Net loss per share attributable to Class A and Class B common stockholders |
||||||||
| Basic and diluted |
$ | (1.99 | ) | $ | (2.28 | ) | ||
|
|
|
|
|
|||||
| Weighted-average shares of Class A and Class B common stock used in computing net loss per share attributable to Class A and Class B common stockholders |
||||||||
| Basic and diluted |
123,188,351 | 137,205,372 | ||||||
|
|
|
|
|
|||||
The accompanying notes are an integral part of these consolidated financial statements.
5
GRAIL, INC.
CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS
(in thousands)
| Year Ended December 31, | ||||||||
| 2019 | 2020 | |||||||
| Net loss |
$ | 244,855 | $ | 312,156 | ||||
| Other comprehensive income: |
||||||||
| Net unrealized (gain) loss on marketable securities |
(589 | ) | 156 | |||||
| Foreign currency translation adjustment |
(1,748 | ) | (1,293 | ) | ||||
| Comprehensive loss |
$ | 242,518 | $ | 311,019 | ||||
|
|
|
|
|
|||||
The accompanying notes are an integral part of these consolidated financial statements.
6
GRAIL, INC.
CONSOLIDATED STATEMENTS OF REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS’ DEFICIT
(in thousands, except share data)
| Redeemable Convertible Preferred Stock | Common Stock | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Preferred Series A | Preferred Series B | Preferred Series C | Preferred Series D | Class A | Class B | Additional Paid-In Capital |
Accumulated Other Compre- hensive (Loss) Income |
Accumu- lated Deficit |
Total Stockholders’ Deficit |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Shares | Amount | Shares | Amount | Shares | Amount | Shares | Amount | Shares | Amount | Shares | Amount |
|
|
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||
| Balance at January 1, |
85,000,000 | $ | 68,263 | 309,256,591 | $ | 1,235,404 | 63,144,600 | $ | 299,557 | — | $ | — | 105,372,563 | $ | 102 | 24,989,397 | $ | 27 | $ | 57,667 | $ | 128 | $ | (1,060,776 | ) | $ | (1,002,852 | ) | ||||||||||||||||||||||||||||||||||||
| Issuance of shares upon exercise of options |
— | — | — | — | — | — | — | — | 5,158,613 | 5 | — | — | 3,042 | — | — | 3,047 | ||||||||||||||||||||||||||||||||||||||||||||||||
| Repurchases of early exercised |
— | — | — | — | — | — | — | — | (857,476 | ) | — | — | — | — | — | — | — | |||||||||||||||||||||||||||||||||||||||||||||||
| Vesting of early exercised stock options |
— | — | — | — | — | — | — | — | — | 3 | — | 1 | 1,395 | — | — | 1,399 | ||||||||||||||||||||||||||||||||||||||||||||||||
| Issuance of Series D redeemable convertible preferred stock, net of issuance costs |
— | — | — | — | — | — | 31,323,413 | 159,836 | — | — | — | — | — | — | — | — | ||||||||||||||||||||||||||||||||||||||||||||||||
| Stock-based compensation expense |
— | — | — | — | — | — | — | — | — | — | — | — | 28,391 | — | — | 28,391 | ||||||||||||||||||||||||||||||||||||||||||||||||
| Other comprehensive income |
— | — | — | — | — | — | — | — | — | — | — | — | — | 2,337 | — | 2,337 | ||||||||||||||||||||||||||||||||||||||||||||||||
| Net loss |
— | — | — | — | — | — | — | — | — | — | — | — | — | — | (244,855 | ) | (244,855 | ) | ||||||||||||||||||||||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||||||||||||||
| Balance at December 31, 2019 |
85,000,000 | $ | 68,263 | 309,256,591 | $ | 1,235,404 | 63,144,600 | $ | 299,557 | 31,323,413 | $ | 159,836 | 109,673,700 | $ | 110 | 24,989,397 | $ | 28 | $ | 90,495 | $ | 2,465 | $ | (1,305,631 | ) | $ | (1,212,533 | ) | ||||||||||||||||||||||||||||||||||||
| Issuance of shares upon exercise of options |
— | — | — | — | — | — | — | — | 12,251,681 | 12 | — | — | 8,216 | — | — | 8,228 | ||||||||||||||||||||||||||||||||||||||||||||||||
| Repurchases of early exercised |
— | — | — | — | — | — | — | — | (253,087 | ) | — | — | — | — | — | — | — | |||||||||||||||||||||||||||||||||||||||||||||||
| Vesting of early exercised stock options |
— | — | — | — | — | — | — | — | — | 1 | — | — | 1,250 | — | — | 1,251 | ||||||||||||||||||||||||||||||||||||||||||||||||
| Issuance of Series D redeemable convertible preferred stock, net of issuance costs |
— | — | — | — | — | — | 45,420,423 | 231,858 | — | — | — | — | — | — | — | — | ||||||||||||||||||||||||||||||||||||||||||||||||
| Stock-based compensation expense |
— | — | — | — | — | — | — | — | — | — | — | — | 45,991 | — | — | 45,991 | ||||||||||||||||||||||||||||||||||||||||||||||||
7
| Redeemable Convertible Preferred Stock | Common Stock | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Preferred Series A | Preferred Series B | Preferred Series C | Preferred Series D | Class A | Class B | Additional Paid-In Capital |
Accumulated Other Compre- hensive (Loss) Income |
Accumu- lated Deficit |
Total Stockholders’ Deficit |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Shares | Amount | Shares | Amount | Shares | Amount | Shares | Amount | Shares | Amount | Shares | Amount |
|
|
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||
| Other Comprehensive income |
— | — | — | — | — | — | — | — | — | — | — | — | — | 1,137 | — | 1,137 | ||||||||||||||||||||||||||||||||||||||||||||||||
| Continuation payment received from Illumina |
— | — | — | — | — | — | — | — | — | — | — | — | 35,000 | — | — | 35,000 | ||||||||||||||||||||||||||||||||||||||||||||||||
| Net loss |
— | — | — | — | — | — | — | — | — | — | — | — | — | — | (312,156 | ) | (312,156 | ) | ||||||||||||||||||||||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||||||||||||||
| Balance at December 31, 2020 |
85,000,000 | $ | 68,263 | 309,256,591 | $ | 1,235,404 | 63,144,600 | $ | 299,557 | 76,743,836 | $ | 391,694 | 121,672,294 | $ | 123 | 24,989,397 | $ | 28 | $ | 180,952 | $ | 3,602 | $ | (1,617,787 | ) | $ | (1,433,082 | ) | ||||||||||||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||||||||||||||
The accompanying notes are an integral part of these consolidated financial statements.
8
GRAIL, INC.
CONSOLIDATED STATEMENTS OF CASH FLOWS
(in thousands)
| Year Ended December 31, | ||||||||
| 2019 | 2020 | |||||||
| Cash flows from operating activities |
||||||||
| Net loss |
$ | (244,855 | ) | $ | (312,156 | ) | ||
| Adjustments to reconcile net loss to net cash used by operating activities: |
||||||||
| Depreciation and amortization |
10,307 | 7,562 | ||||||
| Stock-based compensation expense |
28,391 | 45,991 | ||||||
| Loss on disposal of property and equipment |
334 | — | ||||||
| Loss on foreign currency |
1,624 | 1,257 | ||||||
| Impairment of property and equipment and other long-term assets |
2,219 | 120 | ||||||
| Write off of deferred offering costs |
— | 932 | ||||||
| Amortization of premium (discount) on marketable securities |
(4,530 | ) | 480 | |||||
| Changes in operating assets and liabilities: |
||||||||
| Prepaid expenses and other assets |
(5,553 | ) | 795 | |||||
| Prepaid expenses and other assets—related parties |
758 | 20 | ||||||
| Accounts payable |
(6,393 | ) | 6,751 | |||||
| Accounts payable—related parties |
(154 | ) | (155 | ) | ||||
| Accrued and other liabilities |
(4,507 | ) | 7,883 | |||||
| Accrued and other liabilities—related parties |
(21,209 | ) | 248 | |||||
| Other current liabilities—related parties |
— | 2,520 | ||||||
| Operating lease right-of-use assets |
4,025 | 5,080 | ||||||
| Operating lease liabilities |
(6,251 | ) | 670 | |||||
|
|
|
|
|
|||||
| Net cash used by operating activities |
(245,794 | ) | (232,002 | ) | ||||
|
|
|
|
|
|||||
| Cash flows from investing activities |
||||||||
| Purchases of property and equipment |
(3,332 | ) | (11,905 | ) | ||||
| Proceeds from the sale of property and equipment |
82 | — | ||||||
| Purchases of marketable securities |
(551,519 | ) | (536,997 | ) | ||||
| Proceeds from maturities of marketable securities |
687,806 | 536,112 | ||||||
|
|
|
|
|
|||||
| Net cash provided by (used by) investing activities |
133,037 | (12,790 | ) | |||||
|
|
|
|
|
|||||
| Cash flows from financing activities |
||||||||
| Proceeds from exercise of stock options |
3,047 | 8,228 | ||||||
| Proceeds from early exercise of unvested stock options |
195 | 1,138 | ||||||
| Repurchases of early exercised stock options |
(261 | ) | (304 | ) | ||||
| Proceeds from issuance of Series D redeemable convertible preferred stock, net |
159,836 | 231,858 | ||||||
| Proceeds from Continuation payment received from Illumina—related party |
— | 35,000 | ||||||
| Payment of deferred offering costs |
(932 | ) | — | |||||
| Repayments of borrowings from finance lease |
(1,559 | ) | (812 | ) | ||||
|
|
|
|
|
|||||
| Net cash provided by financing activities |
160,326 | 275,108 | ||||||
|
|
|
|
|
|||||
| Effect of exchange rate changes on cash, cash equivalents, and restricted cash |
124 | 36 | ||||||
|
|
|
|
|
|||||
| Net increase in cash, cash equivalents, and restricted cash |
47,693 | 30,352 | ||||||
| Cash, cash equivalents and restricted cash—beginning of year |
96,724 | 144,417 | ||||||
|
|
|
|
|
|||||
| Cash, cash equivalents and restricted cash—end of year |
$ | 144,417 | $ | 174,769 | ||||
|
|
|
|
|
|||||
| Represented by: |
||||||||
| Cash and cash equivalents |
$ | 143,189 | $ | 170,192 | ||||
| Restricted cash |
1,228 | 4,577 | ||||||
|
|
|
|
|
|||||
| Total |
$ | 144,417 | $ | 174,769 | ||||
|
|
|
|
|
|||||
9
| Year Ended December 31, | ||||||||
| 2019 | 2020 | |||||||
| Supplemental cash flow information: |
||||||||
| Cash paid for interest |
$ | 85 | $ | 12 | ||||
| Supplemental disclosure of non-cash activities: |
||||||||
| Vesting of early exercised stock options |
1,399 | 1,251 | ||||||
| Right-of-use assets obtained in exchange for new operating lease liabilities |
— | 21,074 | ||||||
| Property and equipment included in accounts payable and accrued liabilities |
138 | 21,846 | ||||||
| Deferred offering costs included in accrued liabilities |
994 | — | ||||||
The accompanying notes are an integral part of these consolidated financial statements.
10
GRAIL, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
NOTE 1. ORGANIZATION AND DESCRIPTION OF BUSINESS
GRAIL, Inc. (GRAIL or the Company) was incorporated in the State of Delaware in September 2015 and began operations as a stand-alone entity in February 2016. GRAIL is a healthcare company focused on developing technologies for early cancer detection. The Company is headquartered in Menlo Park, California.
Since inception, the Company has incurred losses from operations. The Company incurred losses from operations of $255.7 million and $316.4 million during 2019 and 2020, respectively. The Company had an accumulated deficit of $1.6 billion as of December 31, 2020. The Company has not yet launched a commercial product and may never develop a product that will generate revenues, including in amounts that will be sufficient to fund operations. Accordingly, the Company has been dependent on its ability to raise capital through equity issuances.
The Company had $585.5 million of cash, cash equivalents, and marketable securities at December 31, 2020. Based on the Company’s business plans, which includes the receipt of Continuation Payments from Illumina in accordance with the terms of the Merger Agreement discussed below, management believes that this is sufficient to meet its obligations for at least 12 months from the issuance date of these consolidated financial statements.
Illumina Transaction
On September 20, 2020, the Company entered into an Agreement and Plan of Merger with Illumina, Inc. (Illumina), SDG Ops, Inc., a wholly-owned subsidiary of Illumina, and SDG Ops, LLC, a Delaware limited liability company and a wholly-owned subsidiary of Illumina (the Merger Agreement), pursuant to which Illumina will acquire the Company for $8 billion upon closing of the transaction, consisting of $3.5 billion in cash and $4.5 billion in shares of Illumina common stock, subject to a collar. In addition, stockholders of the Company will receive contingent value rights (CVR) to receive future payments representing a pro rata portion of certain revenues related to the Company over a twelve-year period. This will reflect a 2.5% payment right to the first $1 billion of revenue and a 9% payment right to revenues exceeding $1 billion during the same period each year for 12 years. Illumina will offer Company stockholders the option to receive additional cash and/or stock consideration, in an amount to be determined prior to closing, in lieu of the CVR. If the transaction was not consummated on or prior to December 20, 2020, subject to certain terms and conditions, the Merger Agreement provides that Illumina will make cash payments to the Company in the amount of $35 million each month prior to the closing date of the transaction, commencing on December 21, 2020 until the earlier of (1) the closing date of the transaction or (2) the termination of the Merger Agreement (Continuation Payments). In accordance with the terms of the Merger Agreement, the Company received Continuation Payments totaling $35 million from Illumina during December 2020 which was recorded as additional paid in capital on the consolidated balance sheet as of December 31, 2020.
Completion of the transaction is subject to terms and conditions set forth in the Merger Agreement, including (i) the receipt of required approvals from Company’s stockholders, (2) the receipt of required regulatory approvals, including the expiration or termination of the waiting period (and any extension thereof) under the Hart-Scott-Rodino Act, as amended (the HSR Act), (3) the absence of any law, whether temporary, preliminary or permanent, which is then in effect and has the effect of enjoining, restraining, prohibiting or otherwise preventing consummation of the transactions, (4) the effectiveness of the Registration Statement to be filed by Illumina (together with all amendments thereto, the “Registration Statement”), pursuant to which the shares of Illumina common stock to be issued in connection with the transactions will be registered with the Securities and Exchange Commission and (5) the authorization for listing on NASDAQ of the shares of Illumina common stock to be issued in connection with the transactions. As of the date the financial statements are available to be issued, not all of the closing conditions have been satisfied.
No assurance can be given that the required conditions to closing will be satisfied, and, even if all such approvals are obtained and the conditions are satisfied, no assurance can be given as to the terms, conditions and timing of the approvals. The Merger Agreement contains certain termination rights for each of the Company and Illumina, including a termination right for each of the Company and Illumina if the consummation of the transaction does not occur on or before September 20, 2021, subject to a three-month extension for certain limited purposes in
11
connection with obtaining certain required regulatory clearances. Upon termination of the Merger Agreement under specified circumstances, Illumina would be required to pay the Company a termination fee of $300 million and make an additional $300 million investment in the Company in exchange for shares of non-voting Company preferred stock, subject to certain terms and conditions. In the event that the Merger Agreement is terminated, with respect to all Continuation Payments in excess of $315 million, Illumina will make an investment in the Company in exchange of shares of non-voting Company preferred stock, subject to certain terms and conditions. In connection with the completion of the transaction, approximately $48.5 million will become payable to the Company’s financial advisor to the transaction and $40.0 million to employees as part of a pre-closing cash retention program agreed between the parties. If the Company receives the termination fee of $300 million from Illumina, $25 million will become payable to the Company’s financial advisor to the transaction.
NOTE 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Basis of Presentation and Principles of Consolidation
The consolidated financial statements for 2019 and 2020 include the accounts of GRAIL, Inc. and its wholly-owned subsidiaries. The consolidated financial statements are prepared in accordance with United States Generally Accepted Accounting Principles (U.S. GAAP). All intercompany balances and transactions have been eliminated on consolidation.
Use of Estimates
The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts of assets and liabilities, disclosure of contingent assets and liabilities, and the reported amounts of expenses in the consolidated financial statements and accompanying notes. On an ongoing basis, management evaluates its estimates, including those related to accrued clinical studies and research and development expenses, stock-based compensation expense, useful lives of intangible assets and property and equipment, determination of incremental borrowing rate for operating leases, and the provision for (benefit from) for income taxes. Actual results could differ from these estimates, and such differences could be material to the consolidated financial statements.
Concentration of Credit Risk
Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash, cash equivalents, and marketable securities.
Substantially all the Company’s cash and cash equivalents are deposited in accounts with four accredited financial institutions that management believes are of high-credit quality. Such deposits have and will continue to exceed federally insured limits. The Company has not experienced any losses on its cash deposits.
The Company’s investment policy limits investments to certain types of securities issued by the U.S. government and its agencies and institutions with investment-grade credit ratings and places restrictions on maturities and concentration by type and issuer. The Company is exposed to credit risk in the event of a default by the financial institutions holding its cash, cash equivalents, and marketable securities, and by issuers of marketable securities to the extent recorded on the consolidated balance sheets. As of December 31, 2020, the Company had no off-balance sheet concentrations of credit risk.
Risks and Uncertainties
The Company is primarily in the research and discovery stage and has not yet commercially launched a product that will generate revenues in amounts sufficient to fund operations. The market for which the Company is developing products is highly competitive and rapidly changing. Difficulties or delays in the Company’s clinical studies, delays in planned commercial launch of the Company’s products, potential complications with the Company’s sole suppliers, complex regulatory regimes, regulatory issues and other factors could negatively impact the Company’s operating results.
12
The Company may need to raise additional equity or debt financing to fund future operations that may not be available at terms acceptable to the Company, if at all. If the Company does not successfully commercialize its products in development, it will be unable to generate revenue from product sales or achieve profitability.
In December 2019, a novel strain of coronavirus (COVID-19) was reported in Wuhan, China and has since become a global pandemic. The COVID-19 pandemic poses the risk that the Company, its personnel and other partners may be prevented from conducting business activities for an indefinite period of time, including due to spread of the disease within these groups or due to shutdowns that may be requested or mandated by governmental authorities. The ongoing COVID-19 pandemic has delayed anticipated completion of certain of the Company’s clinical studies as the Company had to suspend enrollment of the studies during the second quarter of 2020. While study sites have resumed enrollment, the Company may need to suspend enrollment again in the future. As of the date of issuance of these consolidated financial statements, the Company is not aware of any specific event or circumstance related to COVID-19 that would require it to update its estimates or judgments or adjust the carrying value of its assets or liabilities. Actual results could differ from those estimates and any such differences may be material to the consolidated financial statements. The extent to which the coronavirus outbreak may materially impact the Company’s financial condition, liquidity, or results of operations is uncertain.
The Coronavirus Aid, Relief, and Economic Security Act (the CARES Act) was enacted by the United States on March 27, 2020. The CARES Act did not have a material impact on the Company’s provision for income taxes for the twelve months ended December 31, 2020.
Segments
The Company operates and manages its business as one reportable operating segment. The Company’s chief operating decision maker reviews financial information on an aggregate basis for the purposes of evaluating financial performance and allocating the Company’s resources. Substantially all of the Company’s long-lived assets were located in the United States as of December 31, 2019 and 2020.
Fair Value of Financial Instruments
The Company determines the fair value of financial assets and liabilities using the fair value hierarchy established in Accounting Standards Codification (ASC) Topic 820, Fair Value Measurement (ASC 820). ASC 820 identifies fair value as the exchange price, or exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. The hierarchy describes three levels of inputs that may be used to measure fair value, as follows:
Level 1—Observable inputs, such as quoted prices in active markets for identical assets and liabilities.
Level 2—Observable inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.
Level 3—Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.
A financial instrument’s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.
The Company has not elected the fair value option as prescribed by ASC Topic 825, Financial Instruments, for its financial assets and liabilities that are not otherwise required to be carried at fair value. Under ASC 820, material financial assets and liabilities not carried at fair value are reported at their carrying values.
The carrying amounts for financial instruments such as prepaid expenses and other current assets, prepaid expenses and other current assets—related party, accounts payable, accounts payable—related parties, accrued liabilities and accrued liabilities—related parties approximate fair value due to their short-term maturities.
13
Cash and Cash Equivalents
The Company considers all highly liquid investments purchased with original maturities of three months or less to be cash equivalents. Cash and cash equivalents consist of cash on deposit with banks denominated in U.S. Dollars, Hong Kong Dollars and British Pounds and marketable securities, as described below.
Marketable Securities
The Company generally invests its excess cash in money market funds and investment-grade short- to intermediate-term fixed income securities. Such investments are included in cash and cash equivalents, short-term marketable securities, or long-term marketable securities on the consolidated balance sheets, are considered available-for-sale, and reported at fair value with unrealized gains and losses included as a component of other comprehensive loss (income). The amortized cost of debt securities is adjusted for the amortization of premiums and accretion of discounts to maturity, which is included in interest expense (income), net, respectively, on the consolidated statements of operations. Realized gains and losses and declines in value judged to be other-than-temporary, if any, on marketable securities are included in other expense (income), net. The cost of securities sold is determined using specific identification.
The Company periodically evaluates its available-for-sale debt securities in unrealized loss positions to determine whether any impairment is a result of a credit loss or other factors. This evaluation includes, but is not limited to, significant quantitative and qualitative assessments and estimates regarding credit ratings, significance of a security’s loss position, adverse conditions specifically related to the security, and the payment structure of the security.
Restricted Cash
Restricted cash is comprised of cash and cash equivalents that are restricted as to withdrawal or use related to letters of credit for the Company’s operating lease agreements.
Property and Equipment, Net
Property and equipment, net is stated at cost less accumulated depreciation and amortization. Depreciation is calculated using the straight-line method, and the cost is amortized over the estimated useful lives of the assets. The Company estimates the useful lives of property and equipment by asset classification as described in Note 3, Balance Sheet Components. Leasehold improvements are amortized using the straight-line method over the shorter of the term of the lease agreement or the useful life of the improvements. The Company expenses repairs and maintenance costs as incurred. When an item is sold or disposed of, the cost and related accumulated depreciation or amortization is eliminated and the resulting gain or loss, if any, is recorded in the consolidated statements of operations.
Impairment of Long-Lived Assets
The Company evaluates its long-lived assets, including property and equipment and right-of-use assets, for indications of possible impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability is measured by comparison of the carrying amounts to the future undiscounted cash flows attributable to these assets. Should impairment exist, the impairment would be measured as the amount by which the carrying amount of the assets exceeds the fair value of those assets. The Company recorded $2.2 million in impairment charges during 2019 and $0.1 million in impairment charges during 2020. Refer to Note 3 and Note 6 for further details.
Leases
The Company adopted ASU 2016-02, Leases (Topic 842) as of January 1, 2019. The Company classifies leases as either operating or finance leases at inception and as necessary at modification. Leased assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent its obligation to make lease payments arising from the lease. The Company does not obtain and control its right to use the identified asset until the lease commencement date. Although it may have a right and an obligation to exchange lease payments for a leased asset from the date of inception, the Company is unlikely to have an obligation to make lease payments before the asset is made available for use; therefore, lease classification, recognition, and measurement are determined at the lease commencement date.
14
Operating leases are included in operating lease right-of-use (ROU) assets, and operating lease liabilities on the Company’s consolidated balance sheets. Operating lease ROU assets and liabilities are recognized at lease commencement date based on the present value of lease payments over the lease term. When readily determinable, the Company uses the rate implicit in the lease to discount lease payments; however, when the rate is not readily determinable, the Company uses the incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. The incremental borrowing rate is the rate of interest that the Company would have to pay to borrow an amount equal to the lease payments on a collateralized basis over a similar term and in a similar economic environment. The operating lease ROU asset also includes any initial direct costs, lease payments made prior to lease commencement, and lease incentives received. Variable lease payments are expensed as incurred and are not included within the ROU asset and lease liability calculation. Variable lease payments primarily include reimbursements of costs incurred by lessors for common area maintenance and utilities. The Company’s lease terms are the noncancelable period including any rent-free periods provided by the lessor and may include options to extend or terminate the lease when it is reasonably certain that it will exercise that option. At lease inception, and upon modification or remeasurement, the Company estimates the lease term based on its assessment of extension and termination options that are reasonably certain to be exercised. Lease cost for lease payments is recognized on a straight-line basis over the lease term. The Company has certain lease agreements with lease and non-lease components, which are accounted for separately. For these agreements, lease payments are allocated between the lease- and non-lease components based on the relative stand-alone price of these components.
Finance leases are included in property and equipment, other current liabilities, and other long-term liabilities on the Company’s consolidated balance sheets. Property and equipment under finance leases is generally amortized over the lease term and is included in depreciation expense. The interest on the finance lease liabilities is included in interest expense.
The Company does not recognize ROU assets and lease liabilities for short-term leases, which have a lease term of twelve months or less and do not include an option to purchase the underlying asset that the Company is reasonably certain to exercise. Lease cost for short-term leases is recognized on a straight-line basis over the lease term.
Accrued Clinical Studies and Research and Development Expenses
The Company accrues for the estimated costs of research and development activities conducted by third-party service providers that are conducting clinical studies. The Company records the estimated costs of research and development activities based upon the estimated amount of services provided and includes these costs in accrued liabilities and accrued liabilities—related parties in the consolidated balance sheets and within research and development and research and development—related parties expenses in the consolidated statements of operations. These costs are a significant component of research and development expenses. The Company accrues for these costs based on factors such as estimates of the work completed and in accordance with agreements established with third-party service providers. The Company makes judgments and estimates in determining the accrued liabilities balance in each reporting period.
Research and Development and Research and Development—Related Parties
Research and development and research and development—related parties expenses include costs incurred to develop the Company’s technology (prior to establishing technological feasibility), collect clinical samples, and conduct clinical studies to develop and support the Company’s investigational multi-cancer test. These costs consist of personnel costs, including salaries, benefits, and stock-based compensation expense associated with the Company’s research and development personnel, laboratory supplies, consulting costs, costs associated with setting up and conducting clinical studies at domestic and international sites, and allocated overhead expenses including rent, information technology, and equipment depreciation. The Company expenses both internal and external research and development costs in the periods in which they are incurred. Research and development—related parties expenses are further discussed in Note 12, Related-Party Transactions. Nonrefundable advance payments for goods and services that will be used or rendered in future research and development activities are deferred and recognized as expense in the period in which the related goods are delivered or services are performed.
15
Redeemable Convertible Preferred Stock
The Company records the redeemable convertible preferred stock at fair value on the dates of issuance, net of issuance costs. The Company classifies its redeemable convertible preferred stock outside of stockholders’ deficit on the consolidated balance sheets because, in the event of certain “liquidation events” that are not solely within the Company’s control, the shares would become redeemable at the option of the holders. The Company did not adjust the carrying values of the redeemable convertible preferred stock to the deemed liquidation values of such shares since a liquidation event was not probable at either of the balance sheet dates. Subsequent adjustments to increase or decrease the carrying values to the ultimate liquidation values will be made only if and when it becomes probable that such a liquidation event will occur.
Stock-Based Compensation Expense
Employee stock-based compensation expense is measured at the grant date based on the fair value of the award. For awards with service-based vesting conditions, the portion of the award that is ultimately expected to vest is recognized as an expense on a straight-line basis over the requisite service period, which is generally the vesting period. The vesting period is generally four years. The Company accounts for excess tax benefits from stock-based compensation expense in earnings, which are offset by a valuation allowance. The Company also made a policy election to account for forfeitures as they occur.
The Company determines the fair value of equity awards as follows:
Stock Options: In determining the fair value of the stock-based compensation expense for awards granted under the 2016 Equity Incentive Plan and non-plan incentive awards, the Company uses the Black-Scholes option-pricing model and a Monte Carlo simulation model, which require the input of subjective assumptions. These assumptions include: the fair value of common stock, the estimated length of time employees will retain their vested stock options before exercising them (expected term), the estimated volatility of the Company’s common stock price over the expected term (expected volatility), the risk-free interest rate, and expected dividends. Changes in the following assumptions can materially affect the estimate of stock-based compensation expense:
Expected Term—For awards with service-based vesting conditions, the expected term of stock options represents the period the stock options are expected to remain outstanding and is calculated using the simplified method, due to limited history, which calculates the expected term as the midpoint of the contractual term of the awards and the vesting period. For awards with performance-based vesting conditions, the Company evaluates the award’s service period, contractual term, and its expectations of the projected timing of achievement of milestones in estimating the expected term.
Expected Volatility—As there has been no public market for the Company’s common stock to date, and thus the Company does not have any trading history of its common stock, the expected volatility is estimated based on the average volatility for comparable publicly-traded companies over a period equal to the expected term of the stock option grants. The comparable companies are chosen based on their similar size, stage in the life cycle, or area of specialty.
Risk-Free Interest Rate—The risk-free interest rate is based on the implied yield currently available on U.S. Treasury zero-coupon issues with a remaining term equivalent to the expected term of a stock award.
Expected Dividends—The Company has not paid dividends on its common stock and does not anticipate paying any dividends on its common stock in the near future.
Fair Value of Common Stock—Given the absence of a public trading market, the Company’s board of directors consider numerous objective and subjective factors to determine the fair value of the common stock at each grant date. These factors include, but are not limited to: (i) the most recently available valuations of the common stock performed at periodic intervals by an independent third-party valuation firm; (ii) the prices for the redeemable convertible preferred stock sold to outside investors; (iii) the Company’s capital structure,
16
including the rights and preferences of the Company’s various classes of equity, including the redeemable convertible preferred stock relative to the common stock; (iv) the Company’s stage of development and commercialization as well as developments in the business; (v) the lack of marketability of the common stock for a privately-held company; (vi) the likelihood of achieving a liquidity event for the Company’s shares of common stock, such as the Merger Agreement or an initial public offering (IPO) or sale of the Company, given prevailing market conditions; (vii) the Company’s historical operating results; and (viii) valuations of comparable public companies.
The Company accounts for stock-based compensation arrangements with non-employees using a fair value approach. The Company believes that for stock options issued to non-employees, the fair value of the stock option is more reliably measurable than the fair value of the services rendered. Therefore, the Company estimates the fair value of non-employee stock options using a Black-Scholes option-pricing model with appropriate inputs.
The Company recognizes stock-based compensation expense for awards that contain performance-based and performance- and market-based conditions using the accelerated attribution method when management determines it is probable that the performance condition will be satisfied. For awards with performance- and market-based conditions, the Company uses a Monte Carlo simulation to determine the fair value at the grant date and recognizes stock-based compensation expense over the derived service period when it becomes probable that the performance-based condition will be met. Under the Monte Carlo simulation, stock returns are simulated for the Company to estimate the payouts established by the vesting conditions of the awards and an estimated time that the awards will vest. The assumptions used in the Monte Carlo simulation include: the fair value of common stock, estimating the length of time employees will retain their vested stock options before exercising them (expected term), the estimated volatility of the Company’s common stock price over the expected term (expected volatility), the risk-free interest rate and expected dividends.
The Company grants certain awards that may be settled in fully vested shares of common stock or in cash, at the Company’s election. These awards are accounted for as liability-classified awards because the dollar value of the awards is fixed and the number of shares is variable and is based on the per-share common stock value at the time the underlying performance- and market-based conditions are satisfied. For these awards, once the performance condition is deemed probable, the liability is remeasured on each reporting date using the Monte Carlo simulation until the awards vest. If the Company issues common stock, the liability is remeasured and then reclassified to additional paid-in capital, with a corresponding charge (or credit) to stock-based compensation expense.
Restricted Stock Units (RSUs) and Restricted Stock Awards (RSAs): The fair values of the RSUs and RSAs were determined based on the fair value of the Company’s common stock on the grant date.
Beginning in 2019, the Company granted RSUs that generally vest upon the completion of service-based conditions. Beginning in 2020, the Company granted performance-based RSUs (which contain both a service condition and a Performance Vesting Condition). The service-based vesting condition for these awards is generally satisfied over four years. The Performance Vesting Condition occurs on the earlier to occur of the consummation of the Company’s IPO (IPO Consummation) or the closing of a Corporate Transaction (as defined in the Company’s Equity Incentive 2016 Plan). The Company recognizes stock-based compensation expense over the requisite service period.
Provision for (Benefit from) Income Taxes
The Company records income taxes using the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the consolidated financial statements or tax returns. Deferred tax assets and liabilities are measured using enacted tax rates that are expected to apply to taxable income for the years in which those tax assets and liabilities are expected to be realized or settled.
The Company reduces deferred tax assets, if necessary, by a valuation allowance if it is more likely than not that the Company will not realize some or all of the deferred tax assets. In making such a determination, the Company considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies, and recent results of operations.
17
The Company recognizes the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by taxing authorities, based on the technical merits of the position. The Company recognizes interest and penalties related to uncertain tax positions within the provision (benefit) for income taxes.
Foreign Currency
The functional currencies of the Company’s foreign subsidiaries are the U.S. Dollar, British Pound, and the Hong Kong Dollar. Adjustments resulting from translating the financial statements of the United Kingdom and Hong Kong subsidiaries into U.S. Dollars are recorded as a component of other comprehensive loss in the consolidated statements of comprehensive loss. Monetary assets and liabilities denominated in a foreign currency are translated into U.S. Dollars at the exchange rate on the balance sheet date. Expenses are translated at the weighted-average exchange rates during the period. Equity transactions are translated using historical exchange rates. Gains and losses resulting from translation of foreign currency monetary transactions are reported in interest and other income (expense), net in the consolidated statements of operations and comprehensive loss for all periods presented. Gains and losses resulting from foreign currency transactions that are deemed to be of a long-term investment nature are reported as a separate component of other comprehensive loss.
Comprehensive Loss
Comprehensive loss includes net loss and certain changes in stockholders’ deficit that are excluded from net loss, primarily unrealized losses (gains) on the Company’s marketable securities and foreign currency translation adjustments.
Net Loss Per Share Attributable to Class A and Class B Common Stockholders
Basic and diluted net loss per share attributable to Class A and Class B common stockholders are presented in conformity with the two-class method required for participating securities. The Company considers all series of its redeemable convertible preferred stock and early exercised stock options and restricted stock awards to be participating securities. Under the two-class method, the net loss attributable to Class A and Class B common stockholders is not allocated to the redeemable convertible preferred stock as the holders of the Company’s redeemable convertible preferred stock do not have a contractual obligation to share in losses. Basic net loss per share attributable to Class A and Class B common stockholders is calculated by dividing the net loss adjusted to include deemed dividends paid to the Company’s preferred stockholders and accretion to redemption value of the redeemable common stock awards, to the extent both impact accumulated deficit, by the weighted-average number of shares of Class A and Class B common stock outstanding during the period, less shares subject to repurchase. Diluted net loss per share attributable to Class A and Class B common stockholders is the same as basic net loss per share, since the effects of potentially dilutive securities are antidilutive given the net loss attributable to Class A and Class B common stockholders for each period presented.
Continuation Payments
Pursuant to the terms of the Merger Agreement the Company entered into with Illumina, the Company received a Continuation Payment totaling $35 million from Illumina during December 2020. The Company is accounting for the Continuation Payment as a financing from a related party shareholder that is immediately forgiven (in substance, a capital contribution) which is being recorded to additional paid-in capital on the consolidated balance sheet.
Deferred Offering Costs
The Company capitalizes certain legal, professional, accounting and other third-party fees that are directly associated with in-process equity financings as deferred offering costs until such financings are consummated. After consummation of an equity financing, these costs are recorded as a reduction of additional paid-in capital generated as a result of the offering. Should the in-process equity financing be terminated, the deferred offering costs will be expensed immediately as a charge to operating expenses in the consolidated statements of operations and comprehensive loss. During the year ended December 31, 2020, the Company expensed $4.2 million of costs, within general and administrative expenses, previously capitalized and associated with the Company’s prior efforts to complete an initial public offering in 2020.
18
Recently Adopted Accounting Pronouncements
In February 2016, the Financial Accounting Standards Board (FASB) issued ASU 2016-02, Leases (Topic 842), and subsequent amendments, to increase transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet for those leases classified as operating leases under previous U.S. GAAP. ASU 2016-02 requires a lessee to recognize a liability to make lease payments (the lease liability) and a right-of-use asset representing its right to use the underlying asset for the lease term on the balance sheet. ASU 2016-02 is effective for financial years beginning after December 15, 2018 (including interim periods within those periods) using a modified retrospective approach, and early adoption is permitted.
On January 1, 2019, the Company adopted Topic 842, as amended, under the modified retrospective transition approach, with no cumulative-effect adjustment on the opening balance of accumulated deficit as of the effective date (the effective date method). Under the effective date method, financial results reported in periods prior to January 1, 2019 are unchanged. The Company elected the package of practical expedients, which does not require reassessment of initial direct costs, classification of a lease, and definition of a lease. The Company has elected not to recognize ROU assets and lease liabilities for short-term leases, which have a lease term of twelve months or less and do not include an option to purchase the underlying asset that the Company is reasonably certain to exercise. Upon adoption, the Company recognized $40.4 million of ROU assets and $40.4 million of lease liabilities on the Company’s consolidated balance sheet.
Accounting Standards Update (ASU) 2016-13 and 2020-03, collectively implemented as FASB Accounting Standards Codification 326, Financial Instruments–Credit Losses, provides amended guidance for measuring current expected credit loss. In June 2016, FASB issued ASU 2016-13, Financial Instruments–Credit Losses (Topic 326). ASU 2016-13 requires measurement and recognition of expected credit losses for financial assets. On January 1, 2020, the Company adopted Topic 326 using a modified retrospective approach, which had no material impact on the Company’s consolidated financial statements. In March 2020, the FASB issued ASU 2020-03, Codification Improvements to Financial Instruments, which makes improvements to financial instruments guidance. The adoption of this ASU did not have a material impact on the Company’s consolidated financial statements.
In July 2017, the FASB issued ASU 2017-11, Earnings Per Share (Topic 260): Distinguishing Liabilities from Equity (Topic 480); Derivatives and Hedging (Topic 815), which changes the classification analysis of certain equity-linked financial instruments with down round features. Under historical U.S. GAAP, an equity-linked financial instrument with a down round feature that otherwise was not required to be classified as a liability under Topic 480 was evaluated under the Topic 815 to determine whether it met the definition of a derivative (and was therefore measured at fair value at each reporting period). Under ASU 2017-11, a down round feature no longer precludes equity classification when assessing whether the instrument is indexed to an entity’s own stock under Topic 815. Accordingly, these financial instruments are no longer measured at fair value at each reporting period. ASU 2017-11 also requires entities that calculate earnings per share to recognize the effect of the down round feature when it is triggered (at this time, the effect is treated as a dividend and as a reduction of income available to common stockholders in basic earnings per share). It is effective for annual and interim periods beginning after December 15, 2018 and early adoption is permitted. The Company adopted this standard on January 1, 2019. The impact of the adoption of this ASU did not have a material impact on its consolidated financial statements.
In August 2018, the FASB issued ASU 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurement. The ASU improves the effectiveness of fair value measurements disclosures and modifies the disclosure requirements on fair value measurements in Topic 820, based on the concepts in the FASB Concepts Statement, Conceptual Framework for Financial Reporting - Chapter 8: Notes to Financial Statements, including the consideration of costs and benefits. On January 1, 2020, the Company adopted Topic 820. The adoption of this ASU did not have a material impact on the Company’s consolidated financial statements.
In August 2018, the FASB issued ASU 2018-15, Intangibles - Goodwill and Other - Internal-Use Software (Subtopic 350-40), Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract. ASU 2018-15 amended guidance to align the accounting for costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing costs associated with developing or obtaining internal-use software. Capitalized implementation costs must be expensed over the term of the hosting arrangement and presented in the same line item in the statement of income as the fees associated with the hosting element (service) of the arrangement. The Company adopted ASU 2018-15 as of January 1, 2020 on a prospective basis, and the adoption of this ASU did not have a material impact on the Company’s consolidated financial statements.
19
In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes. ASU 2019-12 modifies ASC 740 to simplify the accounting for income taxes. The Company elected to early adopt the amendments effective January 1, 2019. The adoption of this ASU did not have a material impact on the Company’s consolidated financial statements.
Recent Accounting Pronouncements Not Yet Adopted
In October 2020, the FASB issued ASU 2020-10, Codification Improvements. The purpose of the ASU is to clarify, correct errors in, or make minor improvements to a variety of ASC topics. The ASU is effective for fiscal years beginning after December 15, 2021 with early application permitted. The Company is currently assessing the impact of this update on its consolidated financial statements, but does not expect adoption will have a material impact on the Company’s financial statements.
NOTE 3. BALANCE SHEET COMPONENTS
Property and Equipment, Net
Property and equipment, net consisted of the following:
| Useful Life (in Years) |
As of December 31, | |||||||||||
| 2019 | 2020 | |||||||||||
| (in thousands) | ||||||||||||
| Laboratory equipment |
3 | $ | 23,157 | $ | 24,036 | |||||||
| Computer hardware |
3 | 4,994 | 5,958 | |||||||||
| Computer software |
3 | 257 | 423 | |||||||||
| Furniture and fixtures |
5 | 2,021 | 2,291 | |||||||||
| Leasehold improvements |
Lease term | 21,931 | 22,055 | |||||||||
|
Construction-in-process |
215 | 31,303 | ||||||||||
|
|
|
|
|
|||||||||
| Property and equipment, gross |
52,575 | 86,066 | ||||||||||
| Less accumulated depreciation and amortization |
(28,150 | ) | (35,710 | ) | ||||||||
|
|
|
|
|
|||||||||
| Total property and equipment, net |
$ | 24,425 | $ | 50,356 | ||||||||
|
|
|
|
|
|||||||||
Included within property and equipment, net is $1.3 million and $0.3 million of laboratory equipment purchased from related parties as of December 31, 2019 and 2020, respectively.
During 2019, primarily in connection with the decision to end the Company’s lease in Hong Kong, the Company recorded an impairment charge of $0.9 million relating to laboratory equipment, computer hardware and furniture and fixtures, in research and development expenses. During 2020, the Company recorded impairment charges of $0.1 million relating to laboratory equipment in research and development expenses.
The Company recorded $10.3 million and $7.6 million of depreciation expense during 2019 and 2020 respectively. For more information on finance leases, see Note 6, Leases.
20
Accrued Liabilities and Accrued Liabilities - Related Parties
Accrued liabilities and accrued liabilities–related parties consist primarily of amounts owed to vendors, employees, and professional service firms and are based on the Company’s best estimate. Accrued liabilities and accrued liabilities–related parties consisted of the following:
| As of December 31, | ||||||||
| 2019 | 2020 | |||||||
| (in thousands) | ||||||||
| Accrued compensation expenses |
$ | 14,889 | $ | 21,392 | ||||
| Accrued legal and professional expenses |
4,306 | 3,055 | ||||||
| Accrued clinical studies expenses |
5,119 | 6,097 | ||||||
| Accrued research and development expenses |
3,494 | 7,855 | ||||||
| Accrued construction-in-process |
23 | 9,893 | ||||||
| Accrued research and development expenses––related parties |
— | 248 | ||||||
| Accrued other expenses |
3,753 | 2,321 | ||||||
|
|
|
|
|
|||||
| Total accrued liabilities and accrued liabilities––related parties |
$ | 31,584 | $ | 50,861 | ||||
|
|
|
|
|
|||||
NOTE 4. FAIR VALUE MEASUREMENTS
The following table represents the fair value hierarchy for the Company’s financial assets measured at fair value on a recurring basis as of December 31, 2019 and December 31, 2020:
| As of December 31, 2019 | ||||||||||||||||
| Level 1 | Level 2 | Level 3 | Total | |||||||||||||
| (in thousands) | ||||||||||||||||
| Cash equivalents: |
||||||||||||||||
| Money market funds |
$ | 58,291 | $ | — | $ | — | $ | 58,291 | ||||||||
| Corporate debt securities |
— | 21,001 | — | 21,001 | ||||||||||||
| Commercial paper |
— | 4,988 | — | 4,988 | ||||||||||||
| Short-term marketable securities: |
||||||||||||||||
| U.S. government treasuries |
37,533 | — | — | 37,533 | ||||||||||||
| U.S. government agency securities |
— | 7,504 | — | 7,504 | ||||||||||||
| Corporate debt securities |
— | 236,234 | — | 236,234 | ||||||||||||
| Commercial paper |
— | 119,884 | — | 119,884 | ||||||||||||
| Long-term marketable securities: |
||||||||||||||||
| Corporate debt securities |
— | 5,435 | — | 5,435 | ||||||||||||
| U.S. government agency securities |
— | 8,498 | — | 8,498 | ||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Total marketable securities |
37,533 | 377,555 | — | 415,088 | ||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Total |
$ | 95,824 | $ | 403,544 | $ | — | $ | 499,368 | ||||||||
|
|
|
|
|
|
|
|
|
|||||||||
21
| As of December 31, 2020 | ||||||||||||||||
| Level 1 | Level 2 | Level 3 | Total | |||||||||||||
| (in thousands) | ||||||||||||||||
| Cash equivalents: |
||||||||||||||||
| Money market funds |
$ | 90,747 | $ | — | $ | — | $ | 90,747 | ||||||||
| Commercial paper |
— | 13,996 | — | 13,996 | ||||||||||||
| Short-term marketable securities: |
||||||||||||||||
| U.S. government treasuries |
153,313 | — | 153,313 | |||||||||||||
| U.S. government agency securities |
— | 30,039 | — | 30,039 | ||||||||||||
| Corporate debt securities |
— | 78,532 | — | 78,532 | ||||||||||||
| Commercial paper |
— | 151,402 | — | 151,402 | ||||||||||||
| Long-term marketable securities: |
||||||||||||||||
| U.S. government agency securities |
— | 2,051 | — | 2,051 | ||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Total marketable securities |
153,313 | 262,024 | — | 415,337 | ||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Total |
$ | 244,060 | $ | 276,020 | $ | — | $ | 520,080 | ||||||||
|
|
|
|
|
|
|
|
|
|||||||||
There were no transfers between the fair value measurement levels during 2019 and 2020.
NOTE 5. MARKETABLE SECURITIES
All marketable securities as of December 31, 2019 and 2020 are considered available-for-sale, and the amortized costs, unrealized holding gains or losses, and the fair values of the Company’s marketable securities by major security type are summarized in the table below:
| As of December 31, 2019 | ||||||||||||||||
| Amortized Cost |
Unrealized Holding Gains |
Unrealized Holding Losses |
Aggregate Fair Value |
|||||||||||||
| (in thousands) | ||||||||||||||||
| Cash equivalents: |
||||||||||||||||
| Money market funds |
$ | 58,291 | $ | — | $ | — | $ | 58,291 | ||||||||
| Corporate debt securities |
21,001 | — | — | 21,001 | ||||||||||||
| Commercial paper |
4,988 | — | — | 4,988 | ||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Total cash equivalents |
84,280 | — | — | 84,280 | ||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Short-term marketable securities: |
||||||||||||||||
| U.S. government treasuries |
$ | 37,497 | $ | 37 | $ | (1 | ) | $ | 37,533 | |||||||
| U.S. government agency securities |
7,499 | 5 | — | 7,504 | ||||||||||||
| Corporate debt securities |
236,012 | 259 | (37 | ) | 236,234 | |||||||||||
| Commercial paper |
119,884 | — | — | 119,884 | ||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Total short-term marketable securities |
400,892 | 301 | (38 | ) | 401,155 | |||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Long-term marketable securities: |
||||||||||||||||
| Corporate debt securities |
5,439 | — | (4 | ) | 5,435 | |||||||||||
| U.S. government agency securities |
8,500 | — | (2 | ) | 8,498 | |||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Total long-term marketable securities |
13,939 | — | (6 | ) | 13,933 | |||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Total marketable securities |
$ | 499,111 | $ | 301 | $ | (44 | ) | $ | 499,368 | |||||||
|
|
|
|
|
|
|
|
|
|||||||||
22
| As of December 31, 2020 | ||||||||||||||||
| Amortized Cost | Unrealized Holding Gains |
Unrealized Holding Losses |
Aggregate Fair Value |
|||||||||||||
| (in thousands) | ||||||||||||||||
| Cash equivalents: |
||||||||||||||||
| Money market funds |
$ | 90,747 | $ | — | $ | — | $ | 90,747 | ||||||||
| Corporate debt securities |
||||||||||||||||
| Commercial paper |
13,996 | — | — | 13,996 | ||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Total cash equivalents |
104,743 | — | — | 104,743 | ||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Short-term marketable securities: |
||||||||||||||||
| U.S. government treasuries |
$ | 153,261 | $ | 53 | $ | (1 | ) | $ | 153,313 | |||||||
| U.S. government agency securities |
30,033 | 6 | — | 30,039 | ||||||||||||
| Corporate debt securities |
78,490 | 49 | (7 | ) | 78,532 | |||||||||||
| Commercial paper |
151,402 | — | — | 151,402 | ||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Total short-term marketable securities |
413,186 | 108 | (8 | ) | 413,286 | |||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Long-term marketable securities: |
||||||||||||||||
| U.S. government agency securities |
$ | 2,051 | — | — | $ | 2,051 | ||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Total long-term marketable securities |
2,051 | — | — | 2,051 | ||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Total marketable securities |
$ | 519,980 | $ | 108 | $ | (8 | ) | $ | 520,080 | |||||||
|
|
|
|
|
|
|
|
|
|||||||||
Interest income related to the Company’s cash equivalents and available-for-sale investments included in interest income, net, was $11.7 million and $5.5 million during 2019 and 2020, respectively.
The following table summarizes the maturities of the Company’s available-for-sale securities, excluding cash equivalents, by contractual maturity, as of December 31, 2020.
| As of December 31, 2020 | ||||||||
| Amortized Cost |
Aggregate Fair Value |
|||||||
| (in thousands) | ||||||||
| Mature in less than one year |
$ | 413,186 | $ | 413,286 | ||||
| Mature in one to two years |
2,051 | 2,051 | ||||||
|
|
|
|
|
|||||
| Total |
$ | 415,237 | $ | 415,337 | ||||
|
|
|
|
|
|||||
The following table summarizes the Company’s available-for-sale securities that were in a continuous unrealized loss position for less than 12 months, as of December 31, 2019 and 2020.
| As of December 31, | ||||||||||||||||
| 2019 | 2020 | |||||||||||||||
| Aggregate Fair Value |
Aggregate Unrealized Losses |
Aggregate Fair Value |
Aggregate Unrealized Losses |
|||||||||||||
| (in thousands) | ||||||||||||||||
| U.S. government treasuries |
$ | 7,542 | $ | (1 | ) | $ | 20,217 | $ | (1 | ) | ||||||
| U.S. government agency securities |
8,498 | (2 | ) | — | ||||||||||||
| Corporate debt securities |
62,395 | (41 | ) | 30,716 | (5 | ) | ||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Total |
$ | 78,435 | $ | (44 | ) | $ | 50,933 | $ | (6 | ) | ||||||
|
|
|
|
|
|
|
|
|
|||||||||
As of December 31, 2019 and 2020, some of the Company’s marketable securities were in an unrealized loss position. The Company held a total of 23 and 17 positions that were in an unrealized loss position as of December 31, 2019 and 2020, respectively. The Company determined that no credit losses exist as of December 31, 2019 and 2020, respectively, because the change in market value for those securities related primarily to interest rate shifts rather than significant changes in the underlying credit quality of the securities that it holds. The Company has the ability to hold all marketable securities that have been in a continuous loss position until maturity or recovery.
23
The Company’s short-term marketable securities have an effective maturity date of less than 12 months, and the long-term marketable securities have an effective maturity of greater than 12 months and less than 13 months.
NOTE 6. LEASES
The Company has entered into operating and finance leases for facilities and research and development equipment. As of December 31, 2020, the Company does not have any remaining finance leases. Operating leases have remaining lease terms which range from 2 year to 13 years, and often include one or more options to renew. These renewal terms can extend the lease term from 1 to 5 years and are included in the lease term when it is reasonably certain that the Company will exercise the option. One lease provides the option to terminate the lease under certain conditions with three months’ notice. The Company does not expect to exercise this termination option. The exercise of lease renewal and termination options is at the Company’s sole discretion. The Company also has variable lease payments that are primarily comprised of common area maintenance and utility charges.
During the twelve months ended December 31, 2019, in connection with the decision to exit its Hong Kong facility, the Company recorded an impairment charge of $1.3 million in research and development expenses relating to operating lease right-of-use assets. In November 2019, the Company entered into a surrender agreement to terminate the operating lease of the Hong Kong facility, which released the Company of its residual value guarantees, which amounted to $0.6 million and was recognized as an offset to general and administrative expenses.
In June 2020, the Company entered into a new agreement to lease approximately 200,000 square feet of laboratory and office space in North Carolina, which commenced in September 2020 for a term of 12.5 years with three five-year renewal options. Upon commencement, the Company recognized an operating lease ROU asset of $20.2 million and an operating lease liability of $20.2 million. The total estimated aggregate base rent payments, excluding the renewal options and any tenant improvement allowances, for the North Carolina laboratory and office space are $86.6 million.
Supplemental cash flow information related to leases was as follows:
| Year Ended December 31, 2019 |
Year Ended December 31, 2020 |
|||||||
| (in thousands) | ||||||||
| Cash paid for amounts included in the measurement of lease liabilities: |
||||||||
| Operating cash flows from operating leases |
$ | 7,981 | $ | 2,773 | ||||
| Financing cash flows from finance leases |
1,559 | 812 | ||||||
24
The components of lease expense were as follows:
| Year Ended December 31, | ||||||||
| 2019 | 2020 | |||||||
| (in thousands) | ||||||||
| Operating lease cost |
$ | 7,215 | $ | 8,446 | ||||
| Finance lease cost |
||||||||
| Amortization of leased assets |
32 | — | ||||||
| -Interest on lease liabilities |
107 | 12 | ||||||
| Short-term lease cost |
— | 226 | ||||||
| Variable lease cost |
3,234 | 2,948 | ||||||
|
|
|
|
|
|||||
| Total lease cost |
$ | 10,588 | $ | 11,632 | ||||
|
|
|
|
|
|||||
| As of | ||||||||
| December 31, 2019 |
December 31, 2020 |
|||||||
| (in thousands) | ||||||||
| Weighted-average remaining lease term (years): |
||||||||
| Operating lease |
6.9 | 8.4 | ||||||
| Finance lease |
0.5 | — | ||||||
| -Weighted-average discount rate: |
||||||||
| Operating leases |
7.0 | % | 7.0 | % | ||||
| Finance leases |
5.1 | % | — | % | ||||
As of December 31, 2020, the maturities of the Company’s operating lease liabilities were as follows:
| Year Ended December 31, |
Amount (in thousands) |
|||
| 2021 |
$ | 9,751 | ||
| 2022 |
12,208 | |||
| 2023 |
12,324 | |||
| 2024 |
14,486 | |||
| 2025 |
15,348 | |||
| Thereafter |
68,282 | |||
|
|
|
|||
| Total undiscounted lease payments |
132,399 | |||
| Less: Imputed interest |
(38,653 | ) | ||
| Less: Tenant improvement allowance* |
(30,760 | ) | ||
|
|
|
|||
| Total operating lease liabilities |
$ | 62,986 | ||
|
|
|
|||
| (*) | Tenant improvement allowance is estimated to be received as follows: approximately $19.0 million in 2021, $3.9 million in 2023 and $7.9 million in 2024, respectively. |
25
NOTE 7. COMMITMENTS AND CONTINGENCIES
As of December 31, 2020, the Company’s future non-lease commitments over the next five years and thereafter were as follows:
| Minimum Royalties |
Purchase Commitments |
Total | ||||||||||
| (in thousands) | ||||||||||||
| 2021 |
$ | 525 | $ | 2,400 | $ | 2,925 | ||||||
| 2022 |
575 | 2,448 | 3,023 | |||||||||
| 2023 |
1,075 | 1,458 | 2,533 | |||||||||
| 2024 |
1,075 | — | 1,075 | |||||||||
| 2025 |
1,075 | — | 1,075 | |||||||||
| Thereafter |
5,675 | — | 5,675 | |||||||||
|
|
|
|
|
|
|
|||||||
| Total commitments |
$ | 10,000 | $ | 6,306 | $ | 16,306 | ||||||
|
|
|
|
|
|
|
|||||||
Minimum Royalty Commitments
The Company has certain minimum royalty commitments associated under licensing agreements related to its research efforts.
Purchase Commitments
The Company has open purchase orders primarily related to the purchase of laboratory supplies in the normal course of business.
Contingencies
The Company responds to claims arising in the ordinary course of business. If necessary, the Company will accrue estimates of the amounts it expects to pay upon resolution of such matters, and such amounts will be included in other current liabilities. Should the Company not be able to secure the terms it expects, these estimates may change and will be recognized in the period in which they are identified.
Legal Matters
The Company is subject to various claims, complaints, and legal actions that arise from time to time. The Company does not believe it is a party to any currently pending or threatened legal proceedings that will result in a material adverse effect on its business. There can be no assurance that existing or future legal proceedings arising in the ordinary course of business or otherwise will not have a material adverse effect on the Company’s business, financial position, results of operations, or cash flows.
Indemnification
The Company has agreed to indemnify its directors and officers for certain events or occurrences while the director or officer is, or was serving, at the Company’s request in such capacity. The indemnification period covers all pertinent events and occurrences during the director’s or officer’s service. The maximum potential amount of future payments the Company could be required to make under the applicable indemnification agreements is not specified in the agreements; however, the Company has director and officer insurance coverage that reduces its exposure and enables the Company to recover a portion of any future amounts paid. The Company believes the estimated fair value of these indemnification agreements in excess of applicable insurance coverage is minimal.
The Company enters into standard indemnification arrangements in the ordinary course of business. Pursuant to these arrangements, the Company indemnifies, holds harmless, and agrees to reimburse the indemnified parties for losses suffered or incurred by the indemnified party, in connection with any trade secret, copyright, patent or other intellectual property infringement claim by any third party with respect to the Company’s technology. The term of these indemnification agreements is generally perpetual after the execution of the agreement. The maximum potential amount of future payments the Company could be required to make under these arrangements is not determinable. The Company has not incurred costs to defend lawsuits or settle claims related to these indemnification agreements. As a result, the Company believes the estimated fair value of these agreements is minimal.
26
NOTE 8. COMMON STOCK
The Company has two classes of common stock: Class A and Class B. The voting rights per share of Class A and Class B are 1:1 and 10:1, respectively. Common stockholders are entitled to dividends when and if declared by the board of directors subject to the prior rights of the preferred stockholders. As of December 31, 2020, no dividends have been declared. The shares of Class B common stock are convertible into shares of Class A common stock at a ratio of 0.44 shares of Class A common stock to 0.42 shares of Class B common stock.
As of December 31, 2020, the Company has reserved shares of Class A common stock for issuance upon conversion of the redeemable convertible preferred stock and exercise of options. No shares of Class B common stock have been reserved. The Company has reserved shares of Class A common stock, on an as converted basis, for issuance as follows:
| Class A Shares | ||||
| (in thousands) | ||||
| Conversion of Series A redeemable convertible preferred stock |
85,000 | |||
| Conversion of Series B redeemable convertible preferred stock |
309,257 | |||
| Conversion of Series C redeemable convertible preferred stock |
63,145 | |||
| Conversion of Series D redeemable convertible preferred stock |
76,744 | |||
| Conversion of Class B common stock |
26,179 | |||
| Options and awards outstanding for the 2016 Equity Incentive Plan |
100,580 | |||
| Non-Plan Incentive Awards |
24,486 | |||
| Reserved for future grants |
5,438 | |||
|
|
|
|||
| Total |
690,829 | |||
|
|
|
|||
NOTE 9. REDEEMABLE CONVERTIBLE PREFERRED STOCK
The following tables represent the redeemable convertible preferred stock as of December 31, 2019 and 2020:
| As of December 31, 2019 | ||||||||||||||||||||
| Shares Authorized |
Original Issuance Price |
Shares Issued and Outstanding |
Net Proceeds | Liquidation Value |
||||||||||||||||
| (in thousands, except share and per share data) | ||||||||||||||||||||
| Series A |
85,000,000 | 1.0000 | 85,000,000 | $ | 120,000 | $ | 85,000 | |||||||||||||
| Series B |
309,256,591 | 4.0085 | 309,256,591 | 1,085,404 | 1,239,655 | |||||||||||||||
| Series C |
63,144,600 | 4.7510 | 63,144,600 | 299,557 | 300,000 | |||||||||||||||
| Series D |
48,942,833 | 5.1080 | 31,323,413 | 159,836 | 160,000 | |||||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||||||
| Total |
506,344,024 | 488,724,604 | $ | 1,664,797 | $ | 1,784,655 | ||||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||||||
27
| As of December 31, 2020 | ||||||||||||||||||||
| Shares Authorized |
Original Issuance Price |
Shares Issued and Outstanding |
Net Proceeds | Liquidation Value |
||||||||||||||||
| (in thousands, except share and per share data) | ||||||||||||||||||||
| Series A |
85,000,000 | 1.0000 | 85,000,000 | $ | 120,000 | $ | 85,000 | |||||||||||||
| Series B |
309,256,591 | 4.0085 | 309,256,591 | 1,085,404 | 1,239,655 | |||||||||||||||
| Series C |
63,144,600 | 4.7510 | 63,144,600 | 299,557 | 300,000 | |||||||||||||||
| Series D |
76,743,836 | 5.1080 | 76,743,836 | 391,694 | 392,008 | |||||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||||||
| Total |
534,145,027 | 534,145,027 | $ | 1,896,655 | $ | 2,016,663 | ||||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||||||
During 2019, the Company issued 31,323,413 shares of Series D redeemable convertible preferred stock for gross proceeds of $160.0 million, less $0.2 million of issuance costs. The Series D redeemable convertible preferred stock has substantially similar terms as the Company’s Series A, B, and C redeemable convertible preferred stock except that it has a liquidation preference of $5.108 per share.
During 2020, the Company issued 45,420,423 additional shares of Series D redeemable convertible preferred stock for gross proceeds of $232.0 million, less $0.1 million of issuance costs. The Series D redeemable convertible preferred stock has substantially similar terms as the Company’s Series A, B, and C redeemable convertible preferred stock except that it has a liquidation preference of $5.1080 per share.
Redemption
As of December 31, 2019 and December 31, 2020, the Company classified the convertible preferred stock as redeemable on the consolidated balance sheets. Upon the occurrence of certain change-in-control events that may be outside the Company’s control, including liquidation, sale, or transfer of the Company, holders of the convertible preferred stock could cause a redemption of their stock for cash. The preferred stock does not have a mandatory redemption date.
Conversion
Each share of preferred stock is convertible, at the option of the holder, according to a conversion ratio, which is subject to adjustment for dilutive share issuances as described in the next paragraph. The total number of shares of common stock into which the preferred stock may be converted is determined by dividing the then-applicable conversion price by the initial conversion price. The preferred stock automatically converts into shares of Class A common stock at the then-applicable conversion price in the event of an underwritten public offering of shares of common stock with aggregate gross proceeds of no less than $150 million (Qualifying IPO), provided that, prior to April 17, 2022 (24 months after the Series D extension closing), such automatic conversion shall also require either (i) the per share price of the Qualifying IPO to be at least $5.1080 per share (i.e., the Series D preferred stock original issue price) or (ii) the vote of the holders of a majority of the combined Series C and D preferred stock. The preferred stock also automatically converts into shares of Class A common stock at the then-applicable conversion price upon the vote of a majority of the holders of preferred stock and, if prior to April 17, 2022, the vote of the holders of two-thirds of the combined Series C and D preferred stock shall also be required. As of December 31, 2020, each share of Series A, B, C, and D preferred stock was convertible into one share of Class A common stock.
Subject to certain exceptions, including issuances of shares to employees or consultants pursuant to a stock option plan approved by the board of directors and issuances of shares to lenders or strategic partners or in connection with the acquisition of a company or technology, in each case approved by the board of directors, the conversion price of each applicable series of preferred stock is subject to adjustment to prevent dilution in the event that the Company issues additional shares at a purchase price less than the then-applicable conversion price.
Dividends
Any dividends paid in any fiscal year will be paid among the holders of redeemable convertible preferred stock and common stock then outstanding based on preferences and on an if-converted basis. Dividends are noncumulative, and none were declared as of December 31, 2019 or December 31, 2020.
28
Voting
Each share of redeemable convertible preferred stock is entitled to the number of votes equal to the number of shares of Class A common stock into which such shares could be converted. Holders of redeemable convertible preferred stock and common stock vote as a single class.
Liquidation Preference
In the event of any liquidation, dissolution or winding up of the Company, either voluntary or involuntary, including a merger, acquisition, or sale of assets where the holders of common stock and preferred stock own less than a majority of the resulting voting power of the surviving entity (Liquidation Transaction), the holders of preferred stock will receive in preference to the holders of common stock, an amount per share equal to the liquidation preference, plus any accrued but unpaid dividends. After payment of the liquidation preference to the holders of the preferred stock, the remaining assets of the Company are available for distribution to the holders of common stock on a pro rata basis. The vote of a majority of the holders the preferred stock can waive the liquidation preference; provided that, prior to April 17, 2022, the vote of the holders of two-thirds of the combined Series C and D preferred stock shall also be required to waive such liquidation preference. These liquidation features cause the Series A, B, C, and D preferred stock to be classified as mezzanine equity rather than as a component of stockholders’ deficit.
NOTE 10. STOCK INCENTIVE AWARDS
The Company grants awards under the 2016 Equity Incentive Plan, as amended (2016 Plan) as well as incentive awards not under the 2016 Plan (Non-Plan Equity Incentive Awards).
2016 Equity Incentive Plan
The Company’s board of directors adopted, and its stockholders approved, the Company’s 2016 Plan in January 2016. The 2016 Plan was amended on February 6, 2017, February 27, 2017, September 18, 2019, November 21, 2019, November 25, 2019 and May 7, 2020. Unless the board of directors provides otherwise, beginning on January 1, 2018 and continuing each anniversary thereof, the number of shares of common stock reserved for issuance under the 2016 Plan will automatically increase, if and to the extent necessary, to ensure that the reserve represents at least 4% of the total number of issued and outstanding shares of common stock of the Company on a fully diluted basis as of December 31 of the immediately preceding year. Under the 2016 Plan, any shares that are forfeited or expired are added back to the shares available for issuance.
As of December 31, 2020, the Company had granted options or rights to purchase 170,590,333 shares of its Class A common stock and 24,989,397 shares of its Class B common stock under the Company’s 2016 Plan, of which options or rights to purchase 100,580,453 shares of Class A common stock and no shares of Class B common stock were outstanding. As of December 31, 2020, 5,437,747 shares of Class A common stock and no shares of Class B common stock remained available for future grants. The maximum contractual term of options is generally ten years.
The Company’s 2016 Plan allows for the grant of awards in the form of: (i) incentive stock options, (ii) non-qualified stock options; (iii) stock appreciation rights; (iv) RSAs; (v) RSUs; and (vi) unrestricted stock. Directors, employees, and consultants are eligible to participate in the 2016 Plan.
29
Stock Option Activity—A summary of all stock option activity for the 2016 Plan during 2020 is as follows:
| Class A | ||||||||||||||||||||
| Number of Shares Underlying Outstanding Options |
Weighted- Average Exercise Price Per Share |
Weighted- Average Grant Date Fair Value Per Share |
Weighted- Average Remaining Contractual Term (in Years) |
Aggregate Intrinsic Value |
||||||||||||||||
| (in thousands, except years and per share data) | ||||||||||||||||||||
| Balance as of December 31, 2019 |
77,784 | 1.52 | 9.07 | 44,677 | ||||||||||||||||
| Awards Authorized |
||||||||||||||||||||
| Granted |
33,448 | 2.09 | 1.47 | |||||||||||||||||
| Exercised |
(12,252 | ) | 0.76 | |||||||||||||||||
| Repurchased |
— | — | ||||||||||||||||||
| Forfeited |
(17,167 | ) | 1.36 | |||||||||||||||||
|
|
|
|||||||||||||||||||
| Balance as of December 31, 2020 |
81,813 | 1.89 | 8.73 | 537,108 | ||||||||||||||||
|
|
|
|||||||||||||||||||
| Options vested and expected to vest as of December 31, 2020 |
71,822 | 1.87 | 8.68 | 472,978 | ||||||||||||||||
|
|
|
|||||||||||||||||||
| Options vested and exercisable as of December 31 2020 |
24,714 | 1.61 | 8.05 | 169.224 | ||||||||||||||||
|
|
|
|||||||||||||||||||
Restricted Stock Unit Activity—A summary of all restricted stock unit activity for the 2016 Plan during 2020 is as follows:
| Class A Restricted Stock Units Weighted- |
||||||||
| Restricted Stock Units Outstanding |
Average Grant Date Fair Value Per Share |
|||||||
| (in thousands, except per share data) | ||||||||
| Unvested balance as of January 1, 2020 |
16,516 | 1.97 | ||||||
| Granted |
2,252 | $ | 8.07 | |||||
| Vested |
— | — | ||||||
| Forfeited |
— | — | ||||||
|
|
|
|||||||
| Unvested balance as of December 31, 2020 |
18,768 | 2.71 | ||||||
|
|
|
|||||||
As of December 31, 2020, there was $18.4 million of total unrecognized compensation cost related to restricted stock units that contains service-based conditions granted under the Company’s 2016 Plan. That cost is expected to be recognized over a weighted-average period of 2 years. As of December 31, 2020, the total unrecognized compensation cost related to restricted stock units that contains performance- and service- based condition was $18.1 million.
Awards with Service-Based Vesting Conditions Granted under the 2016 Plan
During 2019 and 2020, the Company granted 62,593,918 and 29,004,127 awards with service-based vesting conditions, respectively.
30
During 2019 and 2020, the Company granted 46,077,816 and 28,998,127 options of Class A common stock under the 2016 Plan with only service-based vesting conditions, respectively. The fair value of these options granted during 2019 and 2020 was estimated using the Black-Scholes option-pricing model with the following weighted-average assumptions:
| Year Ended December 31, | ||||||||
| 2019 | 2020 | |||||||
| Expected term (in years) |
5.94 | 6.06 | ||||||
| Expected volatility |
73.5 | % | 81.2 | % | ||||
| Risk-free interest rate |
1.69 | % | 0.60 | % | ||||
| Expected dividend rate |
— | % | — | % | ||||
The aggregate intrinsic value of options exercised during 2019 and 2020 was $3.5 million and $18.5 million, respectively. During 2019 and 2020, the Company modified 3,271,768 and 1,450,451 awards respectively with service-based vesting conditions from the 2016 Plan. See “Modification of Stock Awards.”
During 2019, of the 62,593,918 awards granted, 16,516,102 were RSUs of Class A common stock under the 2016 Plan. These RSUs have an expiration term of 10 years. 11,285,902 RSUs vest over a period of 3 years with two-thirds vesting upon the second anniversary of the vesting start date and the remaining one-third vesting at the third anniversary of the vesting start date. 5,230,200 RSUs vest over a period of 4 years with 25% vesting upon the first anniversary of the vesting start date and 1/16th vesting quarterly thereafter. During 2020, 5,230,200 restricted units had their vesting terms modified. See “Modification of Stock Awards”. The weighted-average grant date fair value per share for these RSUs was $1.97 and the aggregate grant date fair value was $32.6 million. None of these units vested during 2020.
Awards with Performance-Based Vesting Conditions Granted under the 2016 Plan
The Company has granted awards performance based vesting conditions, all of which, are subject to the holder’s continued employment with, or service as a consultant, to the Company, in either case, through the applicable vesting date.
During 2016, the Company granted restricted stock awards of 5,714,286 shares of Class B common stock that vest upon satisfaction of performance or service-based conditions. The grant date fair value per share of these awards was $0.15 and the aggregate grant date fair value was $0.9 million. Stock-based compensation expense of $0.2 million and $0 was recognized during 2019 and 2020 respectively, for these awards. During 2020, all 5,714,286 shares, with a grant date fair value of $0.9 million, vested upon meeting the service-based condition.
During 2017, the Company granted options to purchase 4,180,021 shares of Class A common stock to consultants that vest upon satisfaction of performance-and service-based conditions. The options vest over a period of 4 years with 25% vesting upon the first anniversary of the grant date and 1/48th vesting at the end of each month thereafter. During 2017, a performance-based condition was satisfied and as a result, vesting of one-third of these options was accelerated. During 2019, a second performance-based condition was satisfied and as a result, vesting of the remaining options was accelerated. The grant date fair value per share of these options was $0.32 and the aggregate grant date fair value was $1.3 million. The total grant date fair value of options that vested during 2019 was $0.4 million. The aggregate intrinsic value of options exercised during 2019 and 2020 was $2.3 million and $0, respectively. Stock-based compensation expense of $0.1 million was recognized during 2019 for these options.
During 2018, the Company granted options to purchase 1,500,000 shares of Class A common stock that vest upon satisfaction of performance-based conditions. During 2018, 500,000 shares vested after the related performance-based condition was met, and stock-based compensation expense of $0.1 million was recognized for these vested options. In addition, 500,000 shares were forfeited due to the related performance-based condition not being met by December 31, 2018. During 2020, the remaining 500,000 shares were forfeited due to the related performance-based conditions not being met prior to the termination of the respective agreement. The grant date fair value per share of these options was $0.26 and the aggregate grant date fair value was $0.4 million. The aggregate intrinsic value of options exercised during 2019 and 2020 was $0 and $0.8 million, respectively.
31
During 2019, the Company granted options to purchase 1,050,000 shares of Class A common stock that vest upon satisfaction of performance-based conditions. The grant date fair value per share of these options was $1.10 and the aggregate grant date fair value was $1.2 million. As of December 31, 2019, those shares were forfeited.
During 2019, the Company granted options to purchase 1,743,300 shares of Class A common stock to one of the Company’s executives. The options will commence vesting upon meeting certain performance-based conditions, over a period of four years, with 1/48th of the total award vesting upon each monthly anniversary of the vesting commencement date. The grant date fair value per share of these options was $1.69 and the aggregate grant date fair value was $3.0 million. As of December 31, 2020, no options have been exercised, no options have vested, and no expense has been recognized for these awards as the performance-based conditions are not yet considered probable of being met.
During 2019, the Company granted options to purchase 3,506,222 shares of Class A common stock to two of the Company’s executives. The options will commence vesting upon the achievement of certain performance-based conditions, over a period of three years, with 1/36th vesting upon each monthly anniversary of such vesting commencement date. The grant date fair value per share of these options was $1.69 and the aggregate grant date fair value was $5.9 million. As of December 31, 2020, no options have been exercised, no options have vested, and no expense has been recognized for these awards as the performance-based conditions are not yet considered probable of being met.
During 2020, the Company granted options to purchase 1,700,000 shares of Class A common stock to one of the Company’s executives. The options will commence vesting upon the achievement of certain performance-based conditions, over a period of three years, with 1/36th vesting upon each monthly anniversary of the vesting commencement date. The grant date fair value per share of these options was $1.68 and the aggregate grant date fair value was $2.9 million. As of December 31, 2020, no options have been exercised, no options have vested, and no expense has been recognized for these awards as the performance-based conditions are not yet considered probable of being met.
During 2020, the Company granted options to purchase 750,000 shares of Class A common stock to one of the Company’s executives. The options will commence vesting upon the achievement of certain performance-based conditions, over a period of two years, with 25% vesting upon the vesting commencement date, and 3.125% vesting upon each monthly anniversary of such vesting commencement date. The grant date fair value per share of these options was $1.68 and the aggregate grant date fair value was $1.3 million. As of December 31, 2020, no options have been exercised, no options have vested, and no expense has been recognized for these awards as the performance-based conditions are not yet considered probable of being met.
During 2020, the Company granted options to purchase 2,000,000 shares of Class A common stock to one of the Company’s executives. Of these awards, 1,000,000 will commence vesting upon the achievement of certain performance-based conditions, over a period of three years with 1/36th vesting on the monthly anniversary of the vesting commencement date. As of December 31, 2020, no expense has been recorded for these awards as the performance condition was not probable of being met. The remaining 1,000,000 awards vest over a period of a year, with 50% vesting upon the achievement of certain performance-based conditions and the remainder 50% vesting upon the first anniversary of such vesting commencement date. As of December 31, 2020, $1.2 million of expense has been recorded for these awards as it was estimated that the performance condition was probable of being met. The grant date fair value per share of these options was $1.74 and the aggregate grant date fair value was $3.5 million. As of December 31, 2020, no options have been exercised and no options have vested for these awards.
During 2020, the Company granted 2,245,438 restricted stock units (RSUs) of Class A common stock that vest upon satisfaction of certain performance- and service-based conditions. The service-based vesting condition for these awards is satisfied over a period of 4 years. The performance-based vesting condition occurs on the earlier to occur of the consummation of the Company’s IPO or the closing of a Corporate Transaction (as defined in the 2016 Plan). The grant date fair value per share of these awards was $8.07 and the aggregate grant date fair value was $18.1 million. As of December 31, 2020, no RSUs have vested, and no expense has been recognized for these awards as the performance-based conditions is not yet considered probable of being met.
32
The fair value of the Company’s stock options with performance-based conditions granted under the 2016 Plan during 2019 and 2020 was estimated using the Black-Scholes option-pricing model with the following weighted-average assumptions:
| Year Ended December 31, | ||||||||
| 2019 | 2020 | |||||||
| Expected term (in years) |
9.45 | 10 | ||||||
| Expected volatility |
78.1 | % | 82.9 | % | ||||
| Risk-free interest rate |
2.01 | % | 0.68 | % | ||||
| Expected dividend rate |
— | % | — | % | ||||
Awards with Performance- and Market-Based Vesting Conditions Granted under the 2016 Plan
During 2018, the Company granted options to purchase 4,883,947 shares of Class A common stock that vest upon satisfaction of performance-and market-based conditions. The performance-based condition is satisfied upon IPO Consummation and achieving certain performance conditions. The market-based condition is satisfied upon the Company maintaining certain market capitalization levels after the IPO. For these options, the Company uses a Monte Carlo simulation to determine the fair value at the grant date and the implied service period. The weighted-average grant date fair value per share for these options was $0.22 and the aggregate grant date fair value was $1.1 million. As of December 31, 2020, no options have been exercised, no options have vested and no expense has been recognized for these awards as the achievement of the performance-based condition was not deemed to be probable. As of December 31, 2020, options to purchase 4,562,445 shares have been forfeited.
Awards Granted to Non-Employees under the 2016 Plan
Awards granted to non-employees are accounted for in the same manner as awards for employees. The Company recorded stock-based compensation expense of $0.4 million and $0.3 million related to awards granted to non-employees during 2019 and 2020, respectively.
Non-Plan Equity Incentive Awards
During 2016, the Company granted restricted stock awards of 1,125,000 shares of Class A common stock outside of the 2016 Plan. These awards have an expiration term of 10 years. Of these awards, 1,000,000 will vest over a period of 4 years with 1/48th vesting on the monthly anniversary of the grant date with the exception of accelerating events relating to certain successful patent claims. The remaining 125,000 of these awards vest over a period of 4 years with 25% vesting upon the first anniversary of the grant date and 1/48th vesting at the end of each month thereafter. During 2019 and 2020, 281,250 and 135,417, respectively, of these awards vested. As of December 31, 2020, these are awards are fully vested. The weighted-average grant date fair value per share for these awards was $0.25 and the aggregate grant date fair value was $0.3 million. The total grant date fair value of awards that vested during 2019 and 2020 was, $0.1 million and $0.1 million, respectively. Stock-based compensation expense of $0.1 million and less than $0.1 million was recognized during 2019 and 2020, respectively, for these awards.
During 2018, the Company granted options to purchase 28,683,500 shares of Class A common stock outside of the 2016 Plan to two of the Company’s executives, of which 476,191 were exercised. Of these options, 21,453,125 have an expiration term of 10 years and vest over a period of 4 years with 25% vesting upon the first anniversary of the grant date and 1/48th vesting at the end of each month thereafter. The weighted-average grant date fair value per share was $0.45 and the aggregate grant date fair value was $9.7 million. No options were exercised in 2019 or 2020. During 2019, 8,279,501 of these options were forfeited. The total grant date fair value of awards that vested during 2019 and 2020 was $4 million and $1.3 million, respectively. Stock-based compensation expense of $1.2 million and $0 was recognized during 2019 and 2020, respectively, for these awards. The 2020 awards that vested were fully expensed at the time of modification in 2019 (as further described below).
33
The remaining 7,230,375 options granted in 2018 vest upon satisfaction of performance- and market-based conditions. The performance-based condition is satisfied upon IPO Consummation and achieving certain performance targets. The market-based condition is satisfied upon the Company maintaining certain market capitalization levels after the IPO. For these options, the Company uses a Monte Carlo simulation to determine the fair value at the grant date and the implied service period. The weighted-average grant date fair value per share for these options was $0.38, and the aggregate grant date fair value was $2.8 million. All of these options were forfeited in 2019.
None of the Non-Plan Equity Incentive Awards using the Monte Carlo simulation vested, none were exercised and no expense had been recognized for these awards.
During 2019, the Company granted restricted stock units of 13,827,568 shares of Class A common stock outside of the 2016 Plan. These units vest over a period of 3 years with 67% vesting upon the second anniversary of the vesting start date and the remaining 33% vesting on the third anniversary of the vesting start date. The weighted-average grant date fair value per share for these units was $1.92 per share and the aggregate grant date fair value was $26.5 million. As of December 31, 2020, none of these units have vested.
During 2019, the Company modified 10,658,214 options granted outside of the 2016 Plan with service-based conditions and 1,631,375 options granted outside of the 2016 Plan with performance- and market-based conditions. See “Modification of Stock Awards”. All remaining options, which were neither modified nor exercised, were forfeited as of December 31, 2019.
The Non-Plan Incentive Awards outstanding as of December 31, 2020 had a weighted-average exercise price of $0.77 per share.
Early Exercise of Stock Options
Certain options granted under the 2016 Plan and Non-Plan Incentive Awards have been early exercised. The unvested shares are subject to a repurchase right held by the Company at the original purchase price. The proceeds initially are recorded as a liability for early exercise of unvested options and reclassified to additional paid-in capital as the repurchase right lapses. The Company issued 164,981 and 670,969 shares of common stock upon the early exercise of options during 2019 and 2020, respectively, for total exercise proceeds of $0.2 million and $1.1 million, respectively. During 2019 and 2020, the Company repurchased 857,476 and 253,087 shares, respectively, of unvested common stock related to early exercised options at the original purchase price due to the termination of employees.
Shares Subject to Repurchase
As of December 31, 2019 and 2020, 7,145,211 and 790,745 shares, respectively, held by employees and directors were subject to the Company’s right of repurchase at an aggregate price of $2.2 million and $1.3 million, respectively.
Modification of Stock Awards
During 2019, the Company modified an employee’s options to purchase 1,631,375 shares of Class A common stock with performance- and market-based conditions. As a result of this modification, the performance-based conditions were changed, and the market-based conditions were eliminated. The Company accounted for the changes to the awards as a modification, and the fair value of these awards was increased by $0.3 million with no impacts recorded in the financial statements. As of December 31, 2019, the awards have been cancelled due to the related performance-based condition not being met prior to the termination of his employment.
During 2019, the Company entered into a consulting agreement with a former employee, as a result of which 1,631,375 of his unvested service-based options to purchase shares of Class A common stock granted as an employee continue to vest on a monthly basis during the consulting period and 2,854,906 options had their exercise period extended. The Company accounted for the changes to the awards as a modification, and the fair value of his service-based stock options increased by $3.0 million which was recorded as an incremental expense during 2019.
34
During 2019, the Company entered into agreements with 10 employees, as a result of which the terms of certain of their service-based options to purchase shares of Class A common stock were modified. As a result of these modifications, the vesting of 4,716,504 options were accelerated as of the date of the agreements, and 10,896,983 of the vested options had their exercise period extended. The Company accounted for the changes to the options as modifications, and the fair value of their service-based options was increased by $6.1 million, which was recorded as an incremental expense during 2019.
During 2020, the Company entered into agreements with 4 employees, as a result of which the terms of certain of their service-based options to purchase shares of Class A common stock were modified. As a result of these modifications, the vesting of 70,578 options were accelerated as of the date of the agreements, and 1,443,623 of the vested options had their exercise period extended. The Company accounted for the changes to the options as modifications, and the fair value of their service-based options was increased by $0.3 million, which was recorded as an incremental expense during 2020.
During 2020, with the agreement of the employee, the Company modified the vesting of 5,230,200 restricted stock units which had originally been granted with a service-based condition only to include performance- and service-based conditions. 25% of the award will commence vesting after the original service component time has passed on the earlier of (i) March 15, 2021, and (ii) the earlier to occur of the IPO Consummation or the closing of a Corporate Transaction, and 1/16th of the shares will vest on the earlier to occur of (x) March 15th of the year following completion of the original service component, and (y) the earlier to occur of the IPO Consummation or the closing of a Corporate Transaction. The Company will continue to recognize the grant date fair value of the award over the expected vesting period. The modification of these awards did not have an additional impact on the financial statements.
Stock-Based Compensation Expense
The following table is a summary of stock-based compensation expense recognized during 2019 and 2020 for employees and non-employees for both the 2016 Plan and non-2016 Plan equity incentive awards:
| Year Ended December 31, | ||||||||
| 2019 | 2020 | |||||||
| (in thousands) | ||||||||
| Research and development |
$ | 3,913 | $ | 6,724 | ||||
| Research and development-related parties |
135 | 263 | ||||||
| Marketing |
202 | 2,587 | ||||||
| General and administrative |
24,141 | 36,417 | ||||||
|
|
|
|
|
|||||
| Total stock-based compensation expense |
$ | 28,391 | $ | 45,991 | ||||
|
|
|
|
|
|||||
As of December 31, 2020, the total unrecognized stock-based compensation expense for awards that contain service-based conditions for both the 2016 Plan and Non-Plan Equity Incentive Awards was $89.3 million, which is expected to be recognized over a weighted-average period of approximately 2.5 years. As of December 31, 2020, the total unrecognized stock-based compensation expense for awards that contain only performance-based or performance- and market-based conditions for both the 2016 Plan and Non-Plan Equity Incentive Awards was $33.5 million.
Liability-Classified Awards with Performance- and Market-Based Vesting Conditions Granted under the 2016 Plan
In 2016, the Company entered into an agreement with a former executive officer pursuant to which he was eligible to receive $10.0 million in incentive awards. During 2020, these incentives awards were forfeited.
In 2017, the Company entered into a transition agreement with the vice chairperson of the board of directors. Under the transition agreement, the individual was eligible to receive up to $130.0 million in incentive awards. During 2020, the transition agreement was modified. The modification changed the performance-based conditions and the market-based conditions were eliminated. See “Liability-Classified Awards with Performance-Based Vesting Conditions Granted under the 2016 Plan”.
35
In 2018, the Company entered into a separation agreement with a former executive. Under the agreement, the individual is eligible to receive up to $8 million in incentive awards. During 2020, these incentive awards were forfeited.
As of December 31, 2020, the Company had not recognized any compensation expense associated with these awards as the achievement of the performance-based condition was not deemed to be probable.
Liability-Classified Awards with Performance-Based Vesting Conditions Granted under the 2016 Plan
During 2020, the Company modified the transition agreement with the vice chairperson of the board of directors, and the under the new agreement, he is eligible to receive up to $78.0 million in incentive awards.
The incentive awards for the vice chairperson of the board of directors are granted subject to the respective individual’s continued service to the Company. The awards are earned upon the satisfaction of certain performance-based conditions based on cumulative net revenues in any period of four consecutive quarters.
The above incentive awards for the vice chairperson of the board of directors will be paid, at the Company’s election, in fully vested shares of Class B common stock (or securities into which the Class B common stock has previously been converted) or in cash. The dollar value of these incentive awards is based on the achievement of the performance-based conditions described above. The number of shares is variable based on the per-share valuation at the time of the respective qualifying event. Accordingly, these awards are accounted for as liability-classified awards, and, once the related performance-based conditions are deemed to be probable, the liability will be remeasured at fair value on each reporting date until the awards vest.
As of December 31, 2020, the Company had not recognized any compensation expense associated with these awards as the achievement of the performance-based condition was not deemed to be probable.
NOTE 11. INCOME TAXES
The components of the loss before provision for (benefit from) income taxes during 2019 and 2020 are as follows:
| Year Ended December 31, | ||||||||
| 2019 | 2020 | |||||||
| (in thousands) | ||||||||
| United States |
$ | 245,430 | $ | 312,285 | ||||
| Foreign |
(380 | ) | (162 | ) | ||||
|
|
|
|
|
|||||
| Loss before provision for (benefit from) income taxes |
$ | 245,050 | $ | 312,123 | ||||
|
|
|
|
|
|||||
36
The components of income tax expense (benefit) consist of the following:
| Year Ended December 31, | ||||||||
| 2019 | 2020 | |||||||
| (in thousands) | ||||||||
| Current taxes: |
||||||||
| Federal |
$ | — | $ | — | ||||
| -State |
||||||||
| Foreign |
(544 | ) | 111 | |||||
| Total current income tax expense/(benefit) |
$ | (544 | ) | $ | 111 | |||
| Deferred taxes: |
||||||||
| Federal |
||||||||
| State |
||||||||
| Foreign |
349 | (78 | ) | |||||
|
|
|
|
|
|||||
| Total deferred income tax expense/(benefit) |
$ | 349 | $ | (78 | ) | |||
|
|
|
|
|
|||||
| Provision for (Benefit from) income taxes |
(195 | ) | 33 | |||||
The following is a reconciliation of the statutory federal income tax rate to the Company’s effective tax rate:
| Year Ended December 31, | ||||||||
| 2019 | 2020 | |||||||
| Federal statutory rate |
21.00 | % | 21.00 | % | ||||
| State income taxes |
6.98 | 6.49 | ||||||
| Change in state tax apportionment |
— | (5.90 | ) | |||||
| Other permanent items |
(0.73 | ) | (1.34 | ) | ||||
| Research and development credit |
3.54 | 3.18 | ||||||
| Change in valuation allowance |
(30.70 | ) | (22.82 | ) | ||||
| Other |
(0.01 | ) | (0.62 | ) | ||||
|
|
|
|
|
|||||
| Effective tax rate |
0.08 | % | (0.01 | %) | ||||
|
|
|
|
|
|||||
The Company’s effective tax rate differs from the federal statutory rate primarily due to the valuation allowance recorded to offset the Company’s net deferred tax assets.
37
The significant components of the Company’s net deferred tax assets as of December 31, 2019 and 2020, are as follows:
| Year Ended December 31, | ||||||||
| 2019 | 2020 | |||||||
| (in thousands) | ||||||||
| Deferred tax assets: |
||||||||
| Net operating loss carryforwards |
$ | 61,259 | $ | 102,685 | ||||
| Research and development credits |
29,292 | 39,177 | ||||||
| Amortization |
203,098 | 217,846 | ||||||
| Depreciation |
8,057 | 5,393 | ||||||
| Accruals and reserves |
5,150 | 6,347 | ||||||
| Stock-based compensation |
10,703 | 15,725 | ||||||
| Lease liabilities |
11,541 | 16,381 | ||||||
|
|
|
|
|
|||||
| Total deferred tax assets |
329,100 | 403,554 | ||||||
| Valuation allowance |
(319,224 | ) | (390,256 | ) | ||||
|
|
|
|
|
|||||
| Net deferred tax assets |
9,876 | 13,298 | ||||||
|
|
|
|
|
|||||
| Deferred tax liabilities |
||||||||
| Right-of-use assets |
(9,804 | ) | (13,271 | ) | ||||
| Other |
(72 | ) | (27 | ) | ||||
|
|
|
|
|
|||||
| Net deferred tax assets (liabilities) |
$ | — | $ | — | ||||
|
|
|
|
|
|||||
As of December 31, 2020, the Company had established a valuation allowance of $390.3 million against its gross deferred tax assets due to the uncertainty surrounding the realization of such assets. The valuation allowance increased by $71.0 million during 2020. The change in the valuation allowance for both years was primarily due to the addition of current year loss carryforwards offset, in part, by a change in the blended state tax rate.
As of December 31, 2020, the Company had $354.7 million of federal net operating loss (NOL) carryforwards. The federal NOL carryforwards begin expiring in 2036 if not utilized. At December 31, 2020, the Company had $415.6 million of state net operating loss carryforwards. The state net operating loss carryforwards begin expiring in 2036, if not utilized. Federal NOLs generated after December 31, 2017 have an indefinite carryforward period subject to the 80% deduction limitation based upon pre-NOL deduction taxable income.
The Coronavirus Aid, Relief, and Economic Security Act (“CARES Act”) signed in to law on March 27, 2020, provided that NOLs generated in a taxable year beginning in 2018, 2019, or 2020, may now be carried back five years and forward indefinitely. In addition, the 80% taxable income limitation is temporarily removed, allowing NOLs to fully offset net taxable income. The CARES Act did not materially impact the Company’s tax position.
In addition, the Company has federal research and development tax credits carryforwards of $29.3 million and state research and development tax credit carryforwards of $24.9 million. The federal credit carryforwards begin expiring in 2036 and the state credits carry forward indefinitely. The Internal Revenue Code contains provisions which limit the amount of NOL and research credit carryforwards that can be used in any given year if a significant change in ownership has occurred. The Company performed a detailed analysis on the changes in the ownership of its shares as of June 30, 2020. The Company does not expect there are tax attributes subject to a permanent restriction and never usable before expiration.
ASC 740-10 prescribes a comprehensive model for the recognition, measurement, presentation and disclosure in financial statements of any uncertain tax positions that have been taken or expected to be taken on a tax return. As of December 31, 2020, the Company had $11.8 million in unrecognized tax benefits which would affect the effective tax rate before consideration of the valuation allowance.
38
The beginning and ending unrecognized tax benefits amounts were as follows (in thousands):
| Year Ended December 31, | ||||||||
| 2019 | 2020 | |||||||
| (in thousands) | ||||||||
| Gross amount of unrecognized tax benefits as of the beginning of the period |
$ | 5,916 | $ | 9,070 | ||||
| Increase related to prior year tax provisions |
740 | — | ||||||
| Increase related to current year tax provisions |
2,414 | 2,753 | ||||||
|
|
|
|
|
|||||
| Gross amount of unrecognized tax benefits as of the end of the period |
$ | 9,070 | $ | 11,823 | ||||
|
|
|
|
|
|||||
It is the Company’s policy to include penalties and interest expense related to income taxes as a component of income tax expense as necessary. Management determined that no accrual for interest and penalties was required as of December 31, 2020.
The Company’s major tax jurisdictions are the United States and California. The Company’s tax years since inception will remain open for examination by the federal and state tax authorities due to historical losses. The Company is not currently subject to income tax examinations by any authority. The Company does not believe that its unrecognized tax benefits will materially change within the next 12 months.
NOTE 12. RELATED-PARTY TRANSACTIONS
Illumina Agreements
Beginning May 4, 2020, Mostafa Ronaghi has served as a member of the Company’s board of directors. Dr. Ronaghi was also the Chief Technology Officer of Illumina through May 2020 and the Senior Vice President of Entrepreneurial Development of Illumina through January 2021. Illumina is a principal owner of the Company and is a major supplier of the Company’s reagents and capital equipment.
As discussed in Note 1, on September 20, 2020, the Company entered into the Merger Agreement pursuant to which Illumina will acquire the Company. Refer to Note 1 for additional details. In accordance with the terms of the Merger Agreement, we received Continuation Payments totaling $35 million from Illumina during December 2020 which was recorded as additional paid in capital in the consolidated balance sheet as of December 31, 2020.
In January 2019, pursuant to the Company’s supply and commercialization with Illumina, which was entered into in January 2016 and subsequently amended in September 2017, the Company paid Illumina $15.0 million related to its data delivery requirements under a supply and commercialization agreement with Illumina. This amount was accrued as of December 31, 2018. In February 2019, pursuant to the terms of the Company’s supply and commercialization agreement with Illumina, the Company entered into two separate non-exclusive and non-sublicensable license agreements with Illumina. Under these license agreements, the Company sublicensed to Illumina rights to patents and technology in-licensed from other collaboration partners. Under these license agreements, Illumina is required to pay the Company (i) initial aggregate licensing fees of $50,000, (ii) annual minimum aggregate royalties of $50,000, increasing by $10,000 annually to a max of $100,000, and (iii) running royalties in the low single-digit percentages of net sales of products utilizing in-licensed technology. In addition, one of the license agreements includes a milestone of $50,000 tied to the first commercial sale of a product covered by a licensed patent. During 2019, Illumina paid the Company $0.2 million associated with licensing fees, minimum royalties, and achievement of the milestone. During 2020, Illumina paid the Company $0.1 million associated with minimum royalties for 2021, which was recorded in accrued liabilities -related parties in the consolidated balance sheet as of December 31, 2020.
39
Transactions with Illumina under a supply and commercialization agreement as well as for limited services rendered by Illumina on the Company’s behalf that have been reflected in the consolidated financial statements are as follows:
| As of December 31, | ||||||||
| 2019 | 2020 | |||||||
| (in thousands) | ||||||||
| Prepaid service arrangements |
$ | 567 | $ | 554 | ||||
| Property and equipment, net |
1,252 | 280 | ||||||
| Accounts payable |
151 | — | ||||||
| Accrued liabilities |
— | 70 | ||||||
| Year Ended December 31, | ||||||||
| 2019 | 2020 | |||||||
| (in thousands) | ||||||||
| Research and development |
$ | 7,520 | $ | 10,546 | ||||
Dr. Klausner Consulting Agreement
Effective May 2016, the Company entered into a consulting agreement with Richard Klausner, M.D.. Dr. Klausner is: (i) a member of the board of directors of the Company; and (ii) has performed advisory consulting services. The compensation under the consulting agreement consists of options to purchase 876,000 shares of Class A common stock at an exercise price of $0.23 per share that were granted in 2016 and reimbursement of certain out of pocket expenses. In May 2018, in connection with Dr. Klausner’s consulting service, the Company granted him additional options to purchase 450,000 shares of Class A common stock at an exercise price of $1.74 per share. In August 2020, in connection with Dr. Klausner’s consulting agreement, the Company granted him options to purchase 1,400,000 shares of Class A common stock at an exercise price of $2.09 per share.
Agilent Arrangements
Since August 2018, Hans Bishop has served as a member of the Company’s board of directors. In June 2019, Mr. Bishop was appointed as the Company’s chief executive officer. Mr. Bishop is also on the board of directors of Agilent Technologies, Inc. (Agilent). Agilent is a supplier to the Company. During 2019 and 2020, the Company placed purchase orders with Agilent pursuant to which the Company incurred $0.5 million and $0.6 million in research and development expenses, respectively. As of December 31, 2019 and 2020, $0.1 million and $0.1 million is reflected in accounts payable—related parties, respectively. As of December 31, 2019 and 2020, nil and $0.2 million is reflected in accrued liabilities—related parties, respectively. As of both December 31, 2019 and 2020, $0.1 million of property and equipment that the Company purchased from Agilent is reflected in the consolidated balance sheets.
Collaboration Agreement with Janssen Biotech, Inc.
Johnson & Johnson UK Treasury Company Limited (J&J UK Treasury) and Janssen Biotech, Inc. (Janssen) are subsidiaries of Johnson & Johnson Inc. (J&J). As of December 31, 2019 and December 31, 2020, J&J UK Treasury was a minority stockholder of the Company. In December 2019, the Company entered into a testing resources and collaboration agreement with Janssen. In January 2020, the Company received $2.5 million in payment for services to be performed under this agreement. As of December 31, 2020, $2.5 million is reflected in other current liabilities—related party in the consolidated balance sheet.
40
NOTE 13. NET LOSS PER SHARE ATTRIBUTABLE TO COMMON STOCKHOLDERS
The following table presents the calculation of basic and diluted net loss per share attributable to Class A and Class B common stockholders:
| Year Ended December 31, | ||||||||||||||||
| 2019 | 2020 | |||||||||||||||
| Class A | Class B | Class A | Class B | |||||||||||||
| (in thousands, except share and per share data) | ||||||||||||||||
| Numerator |
||||||||||||||||
| Net loss |
$ | (208,871 | ) | $ | (35,984 | ) | $ | (257,154 | ) | $ | (55,002 | ) | ||||
| Net loss attributable to Class A and Class B common stockholders |
||||||||||||||||
| Basic and diluted |
$ | (208,871 | ) | $ | (35,984 | ) | $ | (257,154 | ) | $ | (55,002 | ) | ||||
|
|
|
|
|
|
|
|
|
|||||||||
| Denominator |
||||||||||||||||
| Weighted-average shares of Class A and Class B common stock used in computing net loss per share attributable to Class A and Class B common stockholders |
||||||||||||||||
| Basic and diluted |
105,084,506 | 18,103,845 | 113,029,792 | 24,175,580 | ||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Net loss per share attributable to Class A and Class B common stockholders |
||||||||||||||||
| Basic |
$ | (1.99 | ) | $ | (1.99 | ) | $ | (2.28 | ) | $ | (2.28 | ) | ||||
|
|
|
|
|
|
|
|
|
|||||||||
| Diluted |
$ | (1.99 | ) | $ | (1.99 | ) | $ | (2.28 | ) | $ | (2.28 | ) | ||||
|
|
|
|
|
|
|
|
|
|||||||||
As the Company was in a net loss position for all periods presented, basic net loss per share is the same as diluted net loss per share because the inclusion of potential shares of common stock would have been anti-dilutive. The following common stock equivalents were therefore excluded from the computation of diluted net loss per share for the periods presented:
| Year Ended December 31, | ||||||||
| 2019 | 2020 | |||||||
| Redeemable convertible preferred stock (on an if-converted basis) |
488,724,604 | 534,145,027 | ||||||
| Options to purchase common stock and restricted stock units |
120,824,676 | 125,066,235 | ||||||
| Shares subject to repurchase |
7,145,211 | 790,745 | ||||||
|
|
|
|
|
|||||
| Total |
616,694,491 | 660,002,007 | ||||||
|
|
|
|
|
|||||
NOTE 14. DEFINED CONTRIBUTION PLAN
The Company sponsors a defined contribution plan under Section 401(k) of the Internal Revenue Code covering eligible employees. Contributions made by the Company are voluntary and are determined annually by the board of directors on an individual basis subject to the maximum allowable amount under federal tax regulations. The Company has made no contributions to the plan since its inception.
NOTE 15. SUBSEQUENT EVENTS
The Company has reviewed and evaluated subsequent events through March 29, 2021, the date the consolidated financial statements were available to be issued.
On January 1, 2021, the number of authorized shares of common stock that may be issued under the 2016 Plan increased by 27,062,279 shares pursuant to the automatic share increase provision of the plan.
Subsequent to December 31, 2020, the Company granted 10,461,718 restricted stock units (RSUs) of Class A common stock to employees. Subject to continued service, the RSUs will generally vest upon the satisfaction of certain performance- and service-based conditions, over a period of 4 to 5 years, and had a fair market value on the grant dates of $88.5 million.
41
Subsequent to December 31, 2020, in accordance with the terms of the Merger Agreement, the Company received Continuation Payments of $35 million each in January, February and March 2021.
42
Exhibit 99.2
GRAIL UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS AS OF JUNE 30,
2021 AND FOR THE SIX MONTHS ENDED JUNE 30, 2021 AND 2020
GRAIL, INC.
INDEX TO CONDENSED CONSOLIDATED FINANCIAL
STATEMENTS
| Page | ||||
| UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS: |
||||
| Condensed Consolidated Balance Sheets |
2 | |||
| Condensed Consolidated Statements Of Operations |
4 | |||
| Condensed Consolidated Statements Of Comprehensive Loss |
5 | |||
| Condensed Consolidated Statements Of Redeemable Convertible Preferred Stock And Stockholders’ Deficit |
6 | |||
| Condensed Consolidated Statements Of Cash Flows |
8 | |||
| Notes To Unaudited Condensed Consolidated Financial Statements |
9 | |||
1
GRAIL, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(in thousands, except share and per share data)
(unaudited)
| As of December 31, 2020 |
As of June 30, 2021 |
|||||||
| Assets |
||||||||
| Current assets: |
||||||||
| Cash and cash equivalents |
$ | 170,192 | $ | 578,085 | ||||
| Short-term marketable securities |
413,286 | — | ||||||
| Accounts receivable, net |
— | 385 | ||||||
| Inventory |
— | 1,852 | ||||||
| Prepaid expenses and other current assets |
12,444 | 10,015 | ||||||
|
|
|
|
|
|||||
| Total current assets |
595,922 | 590,337 | ||||||
| Property and equipment, net |
50,356 | 86,210 | ||||||
| Operating lease right-of-use assets |
51,030 | 48,435 | ||||||
| Long-term marketable securities |
2,051 | |||||||
| Restricted cash |
4,577 | 4,839 | ||||||
| Other non-current assets |
2,362 | 3,225 | ||||||
|
|
|
|
|
|||||
| Total assets |
$ | 706,298 | $ | 733,046 | ||||
|
|
|
|
|
|||||
| Liabilities, redeemable convertible preferred stock, and stockholders’ deficit |
||||||||
| Current liabilities: |
||||||||
| Accounts payable |
$ | 24,509 | $ | 15,246 | ||||
| Accrued liabilities |
50,861 | 41,510 | ||||||
| Operating lease liabilities, current portion |
5,449 | 6,112 | ||||||
| Other current liabilities |
3,152 | 2,764 | ||||||
|
|
|
|
|
|||||
| Total current liabilities |
83,971 | 65,632 | ||||||
| Operating lease liabilities, net of current portion |
57,537 | 73,622 | ||||||
| Other non-current liabilities |
2,954 | 3,544 | ||||||
|
|
|
|
|
|||||
| Total liabilities |
144,462 | 142,798 | ||||||
|
|
|
|
|
|||||
| Commitments and contingencies (Note 7) |
||||||||
| Redeemable convertible preferred stock: |
||||||||
| Series A redeemable convertible preferred stock, $0.001 par value, 85,000,000 shares authorized as of December 31, 2020 and June 30, 2021 ; 85,000,000 shares issued and outstanding as of December 31, 2020 and June 30, 2021; aggregate liquidation preference of $85,000 as of December 31, 2020 and June 30, 2021 |
$ | 68,263 | $ | 68,263 | ||||
| Series B redeemable convertible preferred stock, $0.001 par value, 309,256,591 shares authorized as of December 31, 2020 and June 30, 2021; 309,256,591 shares issued and outstanding as of December 31, 2020 and June 30, 2021; aggregate liquidation preference of $1,239,655 as of December 31, 2020 and June 30, 2021 |
1,235,404 | 1,235,404 | ||||||
| Series C redeemable convertible preferred stock, $0.001 par value, 63,144,600 shares authorized as of December 31, 2020 and June 30, 2021; 63,144,600 shares issued and outstanding as of December 31, 2020 and June 30, 2021; aggregate liquidation preference of $300,000 as of December 31, 2020 and June 30, 2021 |
299,557 | 299,557 | ||||||
| Series D redeemable convertible preferred stock, $0.001 par value, 76,743,836 shares authorized as of December 31, 2020 and June 30, 2021; 76,743,836 shares issued and outstanding as of December 31, 2020 and June 30, 2021; aggregate liquidation preference of $392,008 as of December 31, 2020 and June 30, 2021 |
391,694 | 391,694 | ||||||
|
|
|
|
|
|||||
| Total redeemable convertible preferred stock |
1,994,918 | 1,994,918 | ||||||
|
|
|
|
|
|||||
2
| As of December 31, 2020 |
As of June 30, 2021 |
|||||||
| Stockholders’ deficit: |
||||||||
| Common stock, $0.001 par value; 898,203,200(Class A—868,203,200 and Class B—30,000,000) shares authorized as of December 31, 2020 and June 30, 2021; 146,661,691 (Class A—121,672,294 and Class B— 24,989,397) shares and 153,139,727 (Class A—128,150,330 and Class B— 24,989,397) shares issued and outstanding as of December 31, 2020 and June 30, 2021, respectively |
151 | 157 | ||||||
| Additional paid-in capital |
180,952 | 421,759 | ||||||
| Accumulated other comprehensive income |
3,602 | 2,904 | ||||||
| Accumulated deficit |
(1,617,787 | ) | (1,829,490 | ) | ||||
|
|
|
|
|
|||||
| Total stockholders’ deficit |
(1,433,082 | ) | (1,404,670 | ) | ||||
|
|
|
|
|
|||||
| Total liabilities, redeemable convertible preferred stock, and stockholders’ deficit |
$ | 706,298 | $ | 733,046 | ||||
|
|
|
|
|
|||||
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
3
GRAIL, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(in thousands, except share and per share data)
(unaudited)
| Six Months Ended June 30, | ||||||||
| 2020 | 2021 | |||||||
| Revenue |
$ | — | $ | 660 | ||||
| Operating expenses: |
||||||||
| Cost of revenue |
— | 2,485 | ||||||
| Cost of revenue—related parties |
— | 203 | ||||||
| Research and development |
83,009 | 102,117 | ||||||
| Research and development—related parties |
4,190 | 8,088 | ||||||
| Sales and marketing |
4,690 | 17,835 | ||||||
| General and administrative |
47,304 | 82,218 | ||||||
|
|
|
|
|
|||||
| Total operating expenses |
139,193 | 212,946 | ||||||
|
|
|
|
|
|||||
| Loss from operations |
139,193 | 212,286 | ||||||
| Interest income, net |
(4,128 | ) | (282 | ) | ||||
| Other expense (income), net |
1,335 | (542 | ) | |||||
|
|
|
|
|
|||||
| Loss before provision for income taxes |
136,400 | 211,462 | ||||||
| Provision for income taxes |
16 | 77 | ||||||
|
|
|
|
|
|||||
| Net loss |
$ | 136,416 | $ | 211,539 | ||||
|
|
|
|
|
|||||
| Net loss attributable to Class A and Class B common stockholders |
||||||||
| Basic and diluted |
$ | 136,416 | $ | 211,539 | ||||
|
|
|
|
|
|||||
| Net loss per share attributable to Class A and Class B common stockholders |
||||||||
| Basic and diluted |
$ | (1.03 | ) | $ | (1.42 | ) | ||
|
|
|
|
|
|||||
| Weighted-average shares of Class A and Class B common stock used in computing net loss per share attributable to Class A and Class B common stockholders |
||||||||
| Basic and diluted |
132,864,532 | 148,695,563 | ||||||
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
4
GRAIL, INC.
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS
(in thousands)
(unaudited)
| Six Months Ended June 30, | ||||||||
| 2020 | 2021 | |||||||
| Net loss |
$ | 136,416 | $ | 211,539 | ||||
| Other comprehensive income: |
||||||||
| Net change in unrealized (gain) loss on marketable securities |
(535 | ) | 101 | |||||
| Foreign currency translation adjustment |
(1,419 | ) | 596 | |||||
|
|
|
|
|
|||||
| Comprehensive loss |
$ | 134,462 | $ | 212,236 | ||||
|
|
|
|
|
|||||
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
5
GRAIL, INC.
CONDENSED CONSOLIDATED STATEMENTS OF REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS’ DEFICIT
(in thousands, except share data)
(unaudited)
| Six Months Ended June 30, 2020 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Redeemable Convertible Preferred Stock | Common Stock | Additional Paid-In Capital |
Accumulated Other Comprehensive (Loss) Income |
Accumulated Deficit |
Total Stockholders’ Deficit |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Preferred Series A | Preferred Series B | Preferred Series C | Preferred Series D | Class A | Class B | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Shares | Amount | Shares | Amount | Shares | Amount | Shares | Amount | Shares | Amount | Shares | Amount | |||||||||||||||||||||||||||||||||||||||||||||||||||||
| Balance at December 31, 2019 |
85,000,000 | $ | 68,263 | 309,256,591 | $ | 1,235,404 | 63,144,600 | $ | 299,557 | 31,323,413 | $ | 159,836 | 109,673,700 | $ | 110 | 24,989,397 | $ | 28 | $ | 90,495 | $ | 2,465 | $ | (1,305,631 | ) | $ | (1,212,533 | ) | ||||||||||||||||||||||||||||||||||||
| Issuance of shares upon exercise of options |
— | — | — | — | — | — | — | — | 1,245,480 | 1 | — | — | 1,310 | — | — | 1,311 | ||||||||||||||||||||||||||||||||||||||||||||||||
| Repurchases of early exercised stock options |
— | — | — | — | — | — | — | — | (56,711 | ) | — | — | — | — | — | — | — | |||||||||||||||||||||||||||||||||||||||||||||||
| Vesting of early exercised stock options |
— | — | — | — | — | — | — | — | — | 1 | — | 1,208 | — | — | 1,209 | |||||||||||||||||||||||||||||||||||||||||||||||||
| Issuance of Series D redeemable convertible preferred stock, net of issuance costs of $147 |
— | — | — | — | — | — | 45,420,423 | 231,861 | — | — | — | — | — | — | — | — | ||||||||||||||||||||||||||||||||||||||||||||||||
| Stock-based compensation expense |
— | — | — | — | — | — | — | — | — | — | — | — | 23,947 | — | — | 23,947 | ||||||||||||||||||||||||||||||||||||||||||||||||
| Other comprehensive loss |
— | — | — | — | — | — | — | — | — | — | — | — | — | 1,954 | — | 1,954 | ||||||||||||||||||||||||||||||||||||||||||||||||
| Net loss |
— | — | — | — | — | — | — | — | — | — | — | — | — | — | (136,416 | ) | (136,416 | ) | ||||||||||||||||||||||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||||||||||||||
| Balance at June 30, 2020 |
85,000,000 | $ | 68,263 | 309,256,591 | $ | 1,235,404 | 63,144,600 | $ | 299,557 | 76,743,836 | $ | 391,697 | 110,862,469 | $ | 112 | 24,989,397 | $ | 28 | $ | 116,960 | $ | 4,419 | $ | (1,442,047 | ) | $ | (1,320,528 | ) | ||||||||||||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||||||||||||||
6
| Six Months Ended June 30, 2021 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Redeemable Convertible Preferred Stock | Common Stock | Additional Paid-In Capital |
Accumulated Other Comprehensive (Loss) Income |
Accumulated Deficit |
Total Stockholders’ Deficit |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Preferred Series A | Preferred Series B | Preferred Series C | Preferred Series D | Class A | Class B | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Shares | Amount | Shares | Amount | Shares | Amount | Shares | Amount | Shares | Amount | Shares | Amount | |||||||||||||||||||||||||||||||||||||||||||||||||||||
| Balance at December 31, 2020 |
85,000,000 | $ | 68,263 | 309,256,591 | $ | 1,235,404 | 63,144,600 | $ | 299,557 | 76,743,836 | $ | 391,694 | 121,672,294 | $ | 123 | 24,989,397 | $ | 28 | $ | 180,952 | $ | 3,602 | $ | (1,617,787 | ) | $ | (1,433,082 | ) | ||||||||||||||||||||||||||||||||||||
| Issuance of shares upon exercise of options |
— | — | — | — | — | — | — | — | 6,498,036 | 6 | — | — | 5,513 | — | — | 5,519 | ||||||||||||||||||||||||||||||||||||||||||||||||
| Repurchases of early exercised stock options |
— | — | — | — | — | — | — | — | (20,000 | ) | — | — | — | (5 | ) | — | (164 | ) | (169 | ) | ||||||||||||||||||||||||||||||||||||||||||||
| Vesting of early exercised stock options |
— | — | — | — | — | — | — | — | — | — | — | — | 378 | — | — | 378 | ||||||||||||||||||||||||||||||||||||||||||||||||
| Issuance of Series D redeemable convertible preferred stock, net of issuance costs of $147 |
— | — | — | — | — | — | — | — | — | — | — | — | 24,921 | — | — | 24,921 | ||||||||||||||||||||||||||||||||||||||||||||||||
| Stock-based compensation expense |
— | — | — | — | — | — | — | — | — | — | — | — | 210,000 | — | — | 210,000 | ||||||||||||||||||||||||||||||||||||||||||||||||
| Other comprehensive loss |
— | — | — | — | — | — | — | — | — | — | — | — | — | (698 | ) | — | (698 | ) | ||||||||||||||||||||||||||||||||||||||||||||||
| Net loss |
— | — | — | — | — | — | — | — | — | — | — | — | — | — | (211,539 | ) | (211,539 | ) | ||||||||||||||||||||||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||||||||||||||
| Balance at June 30, 2021 |
85,000,000 | $ | 68,263 | 309,256,591 | $ | 1,235,404 | 63,144,600 | $ | 299,557 | 76,743,836 | $ | 391,694 | 128,150,330 | $ | 129 | 24,989,397 | $ | 28 | $ | 421,759 | $ | 2,904 | $ | (1,829,490 | ) | $ | (1,404,670 | ) | ||||||||||||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||||||||||||||
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
7
GRAIL, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(in thousands)
(unaudited)
| Six Months Ended June 30, | ||||||||
| 2020 | 2021 | |||||||
| Cash flows from operating activities |
||||||||
| Net loss |
$ | (136,416 | ) | $ | (211,539 | ) | ||
| Adjustments to reconcile net loss to net cash used by operating activities: |
||||||||
| Depreciation and amortization |
4,326 | 5,063 | ||||||
| Stock-based compensation expense |
23,947 | 24,921 | ||||||
| Loss (gain) on foreign currency |
1,369 | (528 | ) | |||||
| Impairment of property and equipment and other long-term assets |
120 | — | ||||||
| Write off of deferred offering costs |
932 | — | ||||||
| Amortization of premium (discount) on marketable securities |
(295 | ) | 498 | |||||
| Changes in operating assets and liabilities: |
||||||||
| Accounts receivable |
— | (385 | ) | |||||
| Inventory |
— | (1,852 | ) | |||||
| Prepaid expenses and other assets |
5,286 | 1,566 | ||||||
| Operating lease right-of-use assets |
1,222 | 2,595 | ||||||
| Accounts payable |
2,637 | (341 | ) | |||||
| Accrued and other liabilities |
(3,274 | ) | (1,132 | ) | ||||
| Operating lease liabilities |
(1,367 | ) | 16,748 | |||||
|
|
|
|
|
|||||
| Net cash used by operating activities |
(101,513 | ) | (164,386 | ) | ||||
|
|
|
|
|
|||||
| Cash flows from investing activities |
||||||||
| Purchases of property and equipment |
(1,213 | ) | (57,481 | ) | ||||
| Purchases of marketable securities |
(202,263 | ) | (159,411 | ) | ||||
| Proceeds from the sale of marketable securities |
— | 400,367 | ||||||
| Proceeds from maturities of marketable securities |
273,951 | 173,782 | ||||||
|
|
|
|
|
|||||
| Net cash provided by investing activities |
70,475 | 357,257 | ||||||
|
|
|
|
|
|||||
| Cash flows from financing activities |
||||||||
| Proceeds from exercise of stock options |
1,311 | 5,519 | ||||||
| Proceeds from early exercise of unvested stock options |
— | 3 | ||||||
| Repurchases of early exercised stock options |
(23 | ) | — | |||||
| Repurchase of common stock |
— | (169 | ) | |||||
| Proceeds from issuance of Series D redeemable convertible preferred stock, net |
231,861 | — | ||||||
| Proceeds from Continuation payments received from Illumina- related party |
— | 210,000 | ||||||
| Repayments of borrowings from finance lease |
(660 | ) | — | |||||
|
|
|
|
|
|||||
| Net cash provided by financing activities |
232,489 | 215,353 | ||||||
|
|
|
|
|
|||||
| Effect of exchange rate changes on cash, cash equivalents, and restricted cash |
50 | (69 | ) | |||||
|
|
|
|
|
|||||
| Net increase in cash, cash equivalents, and restricted cash. |
201,501 | 408,155 | ||||||
| Cash, cash equivalents and restricted cash—beginning of period |
144,417 | 174,769 | ||||||
|
|
|
|
|
|||||
| Cash, cash equivalents and restricted cash—end of period |
$ | 345,918 | $ | 582,924 | ||||
|
|
|
|
|
|||||
| Represented by: |
||||||||
| Cash and cash equivalents |
$ | 341,341 | $ | 578,085 | ||||
| Restricted cash |
4,577 | 4,839 | ||||||
|
|
|
|
|
|||||
| Total |
$ | 345,918 | $ | 582,924 | ||||
|
|
|
|
|
|||||
| Supplemental cash flow information: |
||||||||
| Cash paid for interest |
$ | 11 | $ | — | ||||
| Supplemental disclosure of non-cash activities: |
||||||||
| Vesting of early exercised stock options |
1,215 | 378 | ||||||
| Right-of-use assets obtained in exchange for new operating lease liabilities |
868 | — | ||||||
| Property and equipment included in accounts payable and accrued liabilities |
1,076 | (5,538 | ) | |||||
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
8
GRAIL, INC.
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
NOTE 1. ORGANIZATION AND DESCRIPTION OF BUSINESS
GRAIL, Inc. (GRAIL or the Company) was incorporated in the State of Delaware in September 2015 and began operations as a stand-alone entity in February 2016. GRAIL is a healthcare company whose mission is to detect cancer early, when it can be cured. GRAIL is focused on saving lives and improving health by pioneering new technologies for early cancer detection. The Company has commercially launched GalleriTM, its multi-cancer early detection blood test. The Company is headquartered in Menlo Park, California.
Since inception, the Company has incurred losses from operations. The Company incurred losses from operations of $139.2 million and $212.3 million for the six months ended June 30, 2020 and 2021, respectively. The Company had an accumulated deficit of $1.8 billion as of June 30, 2021. Because the Company launched its first commercial product in the second quarter of 2021, the Company has only limited experience as a commercial company and may be unsuccessful in generating significant revenues, including in amounts that will be sufficient to fund operations. Accordingly, the Company has been dependent on its ability to raise capital through equity issuances.
The Company had $578.1 million of cash and cash equivalents as of June 30, 2021. Based on the Company’s business plans, which includes the receipt of certain continuation payments from Illumina in accordance with the terms of the Agreement and Plan of Merger with Illumina, Inc. (Illumina), SDG Ops, Inc., a wholly-owned subsidiary of Illumina, and SDG Ops, LLC, a Delaware limited liability company and a wholly-owned subsidiary of Illumina (Merger Agreement) discussed below, management believes that this is sufficient to meet its obligations for at least 12 months from the issuance date of these unaudited condensed consolidated financial statements.
Illumina Transaction
On September 20, 2020, the Company entered into the Merger Agreement, pursuant to which Illumina will acquire the Company for $8 billion upon closing of the transaction, consisting of $3.5 billion in cash and $4.5 billion in shares of Illumina common stock, subject to a collar. In addition, in lieu of certain cash payment, stockholders of the Company may elect to receive contingent value rights (CVR) to receive future payments representing a pro rata portion of certain revenues related to the Company over a twelve-year period. This will reflect a 2.5% payment right to the first $1 billion of revenue and a 9% payment right to revenues exceeding $1 billion during the same period each year for 12 years. Illumina will offer Company stockholders the option to receive additional cash and/or stock consideration, in an amount to be determined prior to closing, in lieu of the CVR. Since the transaction was not consummated on or prior to December 20, 2020, subject to certain terms and conditions, the Merger Agreement provides that Illumina will make cash payments to the Company in the amount of $35 million each month prior to the closing date of the transaction, commencing on December 21, 2020 until the earlier of (1) the closing date of the transaction or (2) the termination of the Merger Agreement (Continuation Payments). In accordance with the terms of the Merger Agreement, as of June 30, 2021, the Company has received Continuation Payments totaling $245 million from Illumina ($210 million was received during the six months ended June 30, 2021) which was recorded as additional paid in capital in the condensed consolidated balance sheet as of June 30, 2021.
Completion of the transaction is subject to terms and conditions set forth in the Merger Agreement, including (1) the receipt of required approvals from Company’s stockholders, (2) the receipt of required regulatory approvals, including the expiration or termination of the waiting period (and any extension thereof) under the Hart-Scott-Rodino Act, as amended (the HSR Act), (3) the absence of any law, whether temporary, preliminary or permanent, which is then in effect and has the effect of enjoining, restraining, prohibiting or otherwise preventing consummation of the transactions (4) the effectiveness of the Registration Statement to be filed by Illumina (together with all amendments thereto, the “Registration Statement”), pursuant to which the shares of Illumina common stock to be issued in connection with the transactions will be registered with the Securities and Exchange Commission and (5) the authorization for listing on NASDAQ of the shares of Illumina common stock to be issued in connection with the transactions. As of the date the financial statements are available to be issued, not all of the closing conditions have been satisfied.
9
No assurance can be given that the required conditions to closing will be satisfied, and, even if all such approvals are obtained and the conditions are satisfied, no assurance can be given as to the terms, conditions and timing of the approvals. The Merger Agreement contains certain termination rights for each of the Company and Illumina, including a termination right for each of the Company and Illumina if the consummation of the transaction does not occur on or before September 20, 2021, subject to a three-month extension for certain limited purposes in connection with obtaining certain required regulatory clearances. Upon termination of the Merger Agreement under specified circumstances, Illumina would be required to pay the Company a termination fee of $300 million and make an additional $300 million investment in the Company in exchange for shares of non-voting Company preferred stock, subject to certain terms and conditions. In the event that the Merger Agreement is terminated, with respect to all Continuation Payments in excess of $315 million, Illumina will receive an investment in the Company in exchange of shares of non-voting Company preferred stock, subject to certain terms and conditions. In connection with the completion of the transaction, approximately $48.5 million will become payable to the Company’s financial advisor to the transaction and $40.0 million to employees as part of a pre-closing cash retention program agreed between the parties. If the Company receives the termination fee of $300 million from Illumina, $25 million will become payable to the Company’s financial advisor to the transaction.
NOTE 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Basis of Presentation and Principles of Consolidation
The condensed consolidated financial statements as of June 30, 2021 and December 31, 2020 and for the six months ended June 30, 2021 and 2020 include the accounts of GRAIL, Inc. and its wholly-owned subsidiaries. The condensed consolidated financial statements are prepared in accordance with United States Generally Accepted Accounting Principles (U.S. GAAP). All intercompany balances and transactions have been eliminated on consolidation.
Certain reclassifications have been made to the prior period presentation to facilitate comparison with the current period presentation.
Unaudited Condensed Consolidated Financial Statements
The condensed consolidated balance sheet as of June 30, 2021 and the condensed consolidated statements of operations, of comprehensive loss, of cash flows, and of redeemable convertible preferred stock and stockholders’ deficit for the six months ended June 30, 2020 and 2021 are unaudited. The unaudited condensed consolidated financial statements have been prepared on the same basis as the annual consolidated financial statements and reflect, in the opinion of management, all adjustments of a normal and recurring nature that are necessary for the fair statement of the Company’s financial position as of June 30, 2021 and its results of operations and cash flows for the six months ended June 30, 2020 and 2021. The financial data and the other financial information disclosed in these notes to the condensed consolidated financial statements related to the six months ended June 30, 2020 and 2021 are also unaudited. The condensed consolidated results of operations for the six months ended June 30, 2021 are not necessarily indicative of the results to be expected for the year ending December 31, 2021 or for any other future annual or interim period. The condensed consolidated balance sheet as of December 31, 2020 included herein was derived from the audited consolidated financial statements as of that date, but does not include all disclosures required by U.S. GAAP. These condensed consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements and the related notes thereto as of and for the year ended December 31, 2020.
Use of Estimates
The preparation of the condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts of assets and liabilities, disclosure of contingent assets and liabilities, and the reported amounts of expenses in the condensed consolidated financial statements and accompanying notes. The Company bases its estimates on historical experience and other market-specific or other relevant assumptions that it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates, including, but not limited to, those related to estimation of variable consideration, estimation of credit losses, standalone selling price included in contracts with multiple performance obligations, net realizable value of inventory, accrued clinical studies and research and development expenses,
10
stock-based compensation expense, useful lives of intangible assets and property and equipment, determination of incremental borrowing rate for operating leases, contingencies, and the provision for income taxes. These estimates generally involve complex issues and require judgments, involve the analysis of historical results and prediction of future trends, can require extended periods of time to resolve and are subject to change from period to period. Actual results could differ from those estimates, and such differences could be material to the condensed consolidated financial statements.
Concentration of Credit Risk
Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash, cash equivalents, and marketable securities.
Substantially all the Company’s cash and cash equivalents are deposited in accounts with four accredited financial institutions that management believes are of high-credit quality. Such deposits have and will continue to exceed federally insured limits. The Company has not experienced any losses on its cash deposits.
The Company’s investment policy limits investments to certain types of securities issued by the U.S. government and its agencies and institutions with investment-grade credit ratings and places restrictions on maturities and concentration by type and issuer. The Company is exposed to credit risk in the event of a default by the financial institutions holding its cash, cash equivalents, and marketable securities, and by issuers of marketable securities to the extent recorded on the consolidated balance sheets. As of June 30, 2021, the Company had no off-balance sheet concentrations of credit risk.
Additionally, the Company is subject to credit risk related to its accounts receivable. The Company’s accounts receivable arise from cancer detection testing services in the United States and are primarily with biopharmaceutical companies, employers, healthcare organizations and individuals. The Company has not experienced any material losses related to receivables from its customers. The Company does not require collateral. Accounts receivable are recorded at the net amount.
A significant customer is a customer that represents 10% or more of the Company’s total revenue or accounts receivable balance. Revenue attributable to each significant customer, as a percentage of the Company’s total revenue, for the respective period, and the accounts receivable balance attributable to each significant customer, as a percentage of the Company’s total accounts receivable balance, as of the respective balance sheet dates, are as follows:
| Revenue | Accounts Receivable | |||||||||||||||
| Six Months Ended June 30, | As of | |||||||||||||||
| 2020 | 2021 | December 31, 2020 | June 30, 2021 | |||||||||||||
| Customer A |
* | 14.4 | % | * | 12.6 | % | ||||||||||
| * | N/A, as the Company did not have any revenue for the year ended December 31, 2020 or accounts receivable balance as of December 31, 2020. |
Risks and Uncertainties
The Company launched its first commercial product in the second quarter of 2021. It may not generate significant revenues, including in amounts that will be sufficient to fund operations. The market for which the Company is developing products is highly competitive and rapidly changing. Difficulties or delays in the Company’s clinical studies, delays in planned commercial launch of the Company’s other products under development, potential complications with the Company’s sole suppliers, complex regulatory regimes, regulatory issues and other factors could negatively impact the Company’s operating results.
The Company will need to raise additional equity or debt financing to fund future operations that may not be available at terms acceptable to the Company, if at all. If the Company does not generate significant revenues from its commercial product or successfully commercialize its products in development, it will be unable to achieve profitability.
11
In December 2019, a novel strain of coronavirus (COVID-19) was reported in Wuhan, China and has since become a global pandemic. The COVID-19 pandemic poses the risk that the Company, its personnel and other partners may be prevented from conducting business activities for an indefinite period of time, including due to spread of the disease within these groups or due to shutdowns that may be requested or mandated by governmental authorities. The COVID-19 pandemic has delayed anticipated completion of the Company’s clinical studies, as the Company had to suspend enrollment of the studies during the second quarter of 2020. While study sites have resumed enrollment, the Company may need to suspend enrollment again in the future, including if additional variants of the COVID-19 virus becomes more widespread. As of the date of issuance of these unaudited condensed consolidated financial statements, the Company is not aware of any specific event or circumstance related to COVID-19 that would require it to update its estimates or judgments or adjust the carrying value of its assets or liabilities. Actual results could differ from those estimates and any such differences may be material to the consolidated financial statements. The extent to which the COVID-19 outbreak may materially impact the Company’s financial condition, liquidity, or results of operations is uncertain.
The Coronavirus Aid, Relief, and Economic Security Act (the CARES Act) was enacted by the United States on March 27, 2020. The CARES Act did not have a material impact on the Company’s provision for income taxes for the six months ended June 30, 2021. On March 11, 2021 the American Rescue Plan Act of 2021 (“the Act”) was enacted and signed into law. The Act contains several tax provisions, including expansion of employment tax credits. The Company is currently evaluating the impact of the Act on its consolidated financial statements, but does not expect the tax provisions will result in a material impact to the Company’s tax position.
Significant Accounting Policies
Accounts Receivable, Net
Accounts receivable represent the Company’s unconditional right to consideration from customers. The Company evaluates the collectibility of its accounts receivable and provides for an allowance for potential credit losses based on management’s best estimate of the amount of expected credit losses. The allowance is evaluated on a regular basis and adjusted when trends, significant events or other evidence indicate that credit losses are probable. As of June 30, 2021, the Company had an immaterial allowance for doubtful accounts, respectively.
Revenue Recognition
The Company derives revenue from the provision of cancer detection testing services provided to biopharmaceutical companies, employers, healthcare organizations and patients. Cancer detection testing services includes the provision of testing on specimens received and the delivery of the test results. The Company currently receives payment for its cancer detection testing services directly from biopharmaceutical companies, employers, healthcare organizations and individuals.
The Company accounts for revenue in accordance with Accounting Standards Codification (ASC) Topic 606, Revenue from Contracts with Customers (ASC 606). Revenues are recognized when control of goods or services are transferred to customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those goods or services. ASC 606 provides for a five-step model that includes identifying the contract with a customer, identifying the performance obligations in the contract, determining the transaction price, allocating the transaction price to the performance obligations, and recognizing revenue when, or as, an entity satisfies a performance obligation.
Revenues recognized from the sale of cancer detection testing services is based on a negotiated price per specimen. For each specimen received, the Company will perform testing services and deliver test results. For each test performed, a customer is billed a fixed price per test when the test result is provided, and the transaction price is based on the fixed amount per test. Payment is generally due within 60 days of the invoice date. Data and the results of the Company’s testing services are delivered electronically, and therefore there are no shipping or handling fees incurred by the Company or billed to a customer.
12
Practical Expedients
The Company does not adjust the transaction price for the effects of a significant financing component, as at contract inception, the Company expects the collection cycle to be one year or less.
The Company elected to apply the practical expedient which allows the Company to expense contract costs when incurred, if the amortization period is one year or less.
Cost of Revenue
Cost of revenue generally consists of cost of materials, direct labor including bonus, benefits and stock-based compensation, royalty expenses primarily owing under the Company’s supply and commercialization agreement with Illumina, third party support services, equipment and allocated overhead expenses associated with processing specimens received from customers. Allocated overhead expenses include depreciation of laboratory equipment, rent expense, amortization of leasehold improvements and information technology costs. Costs associated with performing the Company’s cancer detection tests are recorded as the tests are performed regardless of whether revenue was recognized with respect to that test.
Inventory
Inventories are stated at the lower of cost or net realizable value on a first-in, first-out basis. Inventory consisted entirely of supplies, which are consumed when providing cancer detection testing services, and therefore the Company does not maintain any finished goods inventory.
In order to assess the ultimate realization of inventories, the Company is required to make judgments as to future demand requirements compared to current or committed inventory levels. The Company periodically reviews its inventories for excess or obsolescence and writes-down obsolete or otherwise unmarketable inventory to its estimated net realizable value. If the actual net realizable value is less than that estimated by the Company, or if it is determined that inventory utilization will further diminish based on estimates of demand, additional inventory writedowns may be required. Amounts written-down due to unmarketable inventory are recorded in cost of revenue.
There have been no material changes in the Company’s accounting policies from those disclosed in the audited consolidated financial statements and related notes thereto as of and for the year ended December 31, 2020.
Recently Adopted Accounting Pronouncements
Accounting Standards Update (ASU) 2016-13 and 2020-03, collectively implemented as Financial Accounting Standards Board (FASB) Accounting Standards Codification 326, Financial Instruments – Credit Losses (Topic 326), provides amended guidance for measuring current expected credit loss. In June 2016, FASB issued ASU 2016-13, Financial Instruments–Credit Losses (Topic 326). ASU 2016-13 requires measurement and recognition of expected credit losses for financial assets. On January 1, 2020, the Company adopted Topic 326 using a modified retrospective approach, which had no material impact on the Company’s condensed consolidated financial statements. In March 2020, the FASB issued ASU 2020-03, Codification Improvements to Financial Instruments, which makes improvements to financial instruments guidance. The adoption of this ASU did not have a material impact on the Company’s condensed consolidated financial statements.
In August 2018, the FASB issued ASU 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework —Changes to the Disclosure Requirements for Fair Value Measurement. The ASU improves the effectiveness of fair value measurements disclosures and modifies the disclosure requirements on fair value measurements in Topic 820, Fair Value Measurement, based on the concepts in the FASB Concepts Statement, Conceptual Framework for Financial Reporting—Chapter 8: Notes to Financial Statements, including the consideration of costs and benefits. On January 1, 2020, the Company adopted Topic 820. The adoption of this ASU did not have a material impact on the Company’s condensed consolidated financial statements.
13
In August 2018, the FASB issued ASU 2018-15, Intangibles—Goodwill and Other—Internal-Use Software (Subtopic 350-40), Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract. ASU 2018-15 amended guidance to align the accounting for costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing costs associated with developing or obtaining internal-use software. Capitalized implementation costs must be expensed over the term of the hosting arrangement and presented in the same line item in the statement of income as the fees associated with the hosting element (service) of the arrangement. The Company adopted ASU 2018-15 as of January 1, 2020 on a prospective basis, and the adoption of this ASU did not have a material impact on the Company’s condensed consolidated financial statements.
Recent Accounting Pronouncements Not Yet Adopted
In October 2020, the FASB issued ASU 2020-10, Codification Improvements. The purpose of the ASU is to clarify, correct errors in, or make minor improvements to a variety of ASC topics. The ASU is effective for fiscal years beginning after December 15, 2021 with early application permitted. The Company is currently assessing the impact of this update on its consolidated financial statements, but does not expect adoption will have a material impact on the Company’s financial statements.
NOTE 3. BALANCE SHEET COMPONENTS
Property and Equipment, Net
Property and equipment, net consisted of the following:
| Useful Life (In Years) |
As of | |||||||||
| December 31, 2020 |
June 30, 2021 |
|||||||||
| (in thousands) | ||||||||||
| Laboratory equipment |
3 | $ | 24,036 | $ | 31,955 | |||||
| Computer hardware |
3 | 5,958 | 7,884 | |||||||
| Computer software |
3 | 423 | 564 | |||||||
| Furniture and fixtures |
5 | 2,291 | 2,552 | |||||||
| Leasehold improvements |
Lease term | 22,055 | 64,682 | |||||||
|
Construction-in-process |
31,303 | 19,347 | ||||||||
|
|
|
|
|
|||||||
| Property and equipment, gross |
86,066 | 126,984 | ||||||||
| Less accumulated depreciation and amortization |
(35,710 | ) | (40,774 | ) | ||||||
|
|
|
|
|
|||||||
| Total property and equipment, net |
$ | 50,356 | $ | 86,210 | ||||||
|
|
|
|
|
|||||||
Included within property and equipment, net is $0.3 million and $2.4 million of laboratory equipment purchased from related parties as of December 31, 2020 and June 30, 2021, respectively.
During the six months ended June 30, 2020 and 2021, the Company recorded an impairment charge of $0.1 million and nil relating to laboratory equipment, in research and development expenses, respectively.
The Company recorded $4.3 million and $5.1 million of depreciation expense during the six months ended June 30, 2020 and 2021, respectively. For more information on the finance leases, see Note 6, Leases.
Accrued Liabilities
Accrued liabilities consists primarily of amounts owed to vendors, employees, and professional service firms and are based on the Company’s best estimate.
Accrued liabilities consisted of the following:
| As of | ||||||||
| December 31, 2020 |
June 30, 2021 |
|||||||
| Accrued compensation expenses |
$ | 21,392 | $ | 17,891 | ||||
| Accrued legal and professional expenses |
3,055 | 5,517 | ||||||
| Accrued clinical studies expenses |
6,097 | 5,536 | ||||||
| Accrued research and development expenses |
8,103 | 6,900 | ||||||
14
| As of | ||||||||
| December 31, 2020 |
June 30, 2021 |
|||||||
| Accrued construction-in-process |
9,893 | 2,250 | ||||||
| Accrued other expenses |
2,321 | 3,416 | ||||||
|
|
|
|
|
|||||
| Total accrued liabilities |
$ | 50,861 | $ | 41,510 | ||||
|
|
|
|
|
|||||
NOTE 4. FAIR VALUE MEASUREMENTS
The following tables represent the fair value hierarchy for the Company’s financial assets measured at fair value on a recurring basis as of December 31, 2020 and June 30, 2021:
| As of December 31, 2020 | ||||||||||||||||
| Level 1 | Level 2 | Level 3 | Total | |||||||||||||
| (in thousands) | ||||||||||||||||
| Cash equivalents: |
||||||||||||||||
| Money market funds |
$ | 90,747 | $ | — | $ | — | $ | 90,747 | ||||||||
| Commercial paper |
— | 13,996 | — | 13,996 | ||||||||||||
| Short-term marketable securities: |
||||||||||||||||
| U.S. government treasuries |
153,313 | — | — | 153,313 | ||||||||||||
| U.S. government agency securities |
— | 30,039 | — | 30,039 | ||||||||||||
| Corporate debt securities |
— | 78,532 | — | 78,532 | ||||||||||||
| Commercial paper |
— | 151,402 | — | 151,402 | ||||||||||||
| Long-term marketable securities: |
||||||||||||||||
| U.S. government agency securities |
— | 2,051 | — | 2,051 | ||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Total marketable securities |
153,313 | 262,024 | — | 415,337 | ||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Total |
$ | 244,060 | $ | 276,020 | $ | — | $ | 520,080 | ||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| As of June 30, 2021 | ||||||||||||||||
| Level 1 | Level 2 | Level 3 | Total | |||||||||||||
| (in thousands) | ||||||||||||||||
| Cash equivalents: |
||||||||||||||||
| Money market funds |
$ | 511,508 | $ | — | $ | — | $ | 511,508 | ||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Total |
$ | 511,508 | $ | — | $ | — | $ | 511,508 | ||||||||
|
|
|
|
|
|
|
|
|
|||||||||
NOTE 5. MARKETABLE SECURITIES
All marketable securities as of December 31, 2020 were considered available-for-sale, and the amortized costs, unrealized holding gains or losses, and the fair values of the Company’s marketable securities by major security type are summarized in the tables below. As of June 30, 2021, the Company had no marketable securities:
| As of December 31, 2020 | ||||||||||||||||
| Amortized Cost | Unrealized Holding Gains |
Unrealized Holding Losses |
Aggregate Fair Value |
|||||||||||||
| (in thousands) | ||||||||||||||||
| Cash equivalents: |
||||||||||||||||
| Money market funds |
$ | 90,747 | $ | — | $ | — | $ | 90,747 | ||||||||
| Commercial paper |
13,996 | — | — | 13,996 | ||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Total cash equivalents |
104,743 | — | — | 104,743 | ||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Short-term marketable securities: |
||||||||||||||||
| U.S. government treasuries |
153,261 | 53 | (1 | ) | 153,313 | |||||||||||
| U.S. government agency securities |
30,033 | 6 | — | 30,039 | ||||||||||||
| Corporate debt securities |
78,490 | 49 | (7 | ) | 78,532 | |||||||||||
| Commercial paper |
151,402 | — | — | 151,402 | ||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Total short-term marketable securities |
413,186 | 108 | (8 | ) | 413,286 | |||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Long-term marketable securities: |
||||||||||||||||
15
| As of December 31, 2020 | ||||||||||||||||
| Amortized Cost | Unrealized Holding Gains |
Unrealized Holding Losses |
Aggregate Fair Value |
|||||||||||||
| (in thousands) | ||||||||||||||||
| U.S. government agency securities |
2,051 | — | — | 2,051 | ||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Total long-term marketable securities |
2,051 | — | — | 2,051 | ||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Total marketable securities |
$ | 519,980 | $ | 108 | $ | (8 | ) | $ | 520,080 | |||||||
|
|
|
|
|
|
|
|
|
|||||||||
| As of June 30, 2021 | ||||||||||||||||
| Amortized Cost | Unrealized Holding Gains |
Unrealized Holding Losses |
Aggregate Fair Value |
|||||||||||||
| (in thousands) | ||||||||||||||||
| Cash equivalents: |
||||||||||||||||
| Money market funds |
$ | 511,508 | $ | — | $ | — | $ | 511,508 | ||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Total |
$ | 511,508 | $ | — | $ | — | $ | 511,508 | ||||||||
|
|
|
|
|
|
|
|
|
|||||||||
Interest income related to the Company’s cash equivalents and available-for-sale investments included in interest income, net, was $3.9 million and $0.3 million for the six months ended June 30, 2020 and 2021, respectively.
The following table summarizes the Company’s available-for-sale securities that were in a continuous unrealized loss position for less than 12 months as of December 31, 2020 and June 30, 2021.
| As of | ||||||||||||||||
| December 31, 2020 | June 30, 2021 | |||||||||||||||
| Aggregate Fair Value |
Aggregate Unrealized Losses |
Aggregate Fair Value |
Aggregate Unrealized Losses |
|||||||||||||
| (in thousands) | ||||||||||||||||
| U.S. government treasuries |
$ | 20,217 | $ | (1 | ) | $ | — | $ | — | |||||||
| Corporate debt securities |
30,716 | (5 | ) | — | — | |||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Total |
$ | 50,933 | $ | (6 | ) | $ | — | $ | — | |||||||
|
|
|
|
|
|
|
|
|
|||||||||
As of December 31, 2020, the Company held a total of 17 positions, which were in an unrealized loss position. The Company determined that no credit losses exist as of December 31, 2020 because the change in market value for those securities related primarily to interest rate shifts rather than significant changes in the underlying credit quality of the securities that it holds. The Company had the ability to hold all marketable securities that had been in a continuous loss position until maturity or recovery.
NOTE 6. LEASES
The Company has entered into operating and finance leases for facilities and research and development equipment. As of December 31, 2020 and June 30, 2021, the Company does not have any remaining finance leases. Operating leases have remaining lease terms which range from 1 years to 12.3 years, and often include one or more options to renew. These renewal terms can extend the lease term from 1 to 5 years and are included in the lease term when it is reasonably certain that the Company will exercise the option. One lease provides the option to terminate the lease under certain conditions with three months’ notice. The Company does not expect to exercise this termination option. The exercise of lease renewal and termination options is at the Company’s sole discretion. The Company also has variable lease payments that are primarily comprised of common area maintenance and utility charges.
In June 2020, the Company entered into a new agreement to lease approximately 200,000 square feet of laboratory and office space in North Carolina, which commenced in September 2020 for a term of 12.5 years with three five-year renewal options. Upon commencement, the Company recognized an operating lease ROU asset of $20.2 million and an operating lease liability of $20.2 million. The total estimated aggregate base rent payments, excluding the renewal options and any tenant improvement allowances, for the North Carolina laboratory and office space are $86.6 million.
16
Supplemental cash flow information related to leases was as follows:
| Six Months Ended June 30, |
||||||||
| 2020 | 2021 | |||||||
| (in thousands) | ||||||||
| Cash paid for amounts included in the measurement of lease liabilities: |
||||||||
| Operating cash flows from operating leases* |
$ | 3,641 | $ | 4,507 | ||||
| Financing cash flows from finance leases |
660 | — | ||||||
| Right-of-use assets obtained in exchange for new operating lease liabilities |
868 | — | ||||||
| (*) | Excludes $18.3 million cash received for tenant improvement allowance in 2021. |
The components of lease expense were as follows:
| Six Months Ended June 30, |
||||||||
| 2020 | 2021 | |||||||
| (in thousands) | ||||||||
| Operating lease cost |
$ | 3,518 | $ | 5,602 | ||||
| Finance lease cost |
||||||||
| Interest on lease liabilities |
11 | — | ||||||
| Short-term lease cost |
201 | 40 | ||||||
| Variable lease cost |
1,413 | 1,679 | ||||||
|
|
|
|
|
|||||
| Total lease cost |
$ | 5,143 | $ | 7,321 | ||||
|
|
|
|
|
|||||
| As of | ||||||||
| December 31, 2020 |
June 30, 2021 |
|||||||
| (in thousands) | ||||||||
| Weighted-average remaining lease term (years): |
||||||||
| Operating lease |
8.4 | 8.0 | ||||||
| Weighted-average discount rate: |
||||||||
| Operating leases |
7.0 | % | 7.0 | % | ||||
As of June 30, 2021, the maturities of the Company’s operating lease liabilities were as follows:
| As of June 30, 2021 |
Amount (in thousands) |
|||
| Remainder of 2021 |
$ | 5,216 | ||
| 2022 |
12,208 | |||
| 2023 |
12,324 | |||
| 2024 |
14,486 | |||
| 2025 |
15,348 | |||
| Thereafter |
69,026 | |||
|
|
|
|||
| Total undiscounted lease payments |
128,608 | |||
| Less: Imputed interest |
(36,366 | ) | ||
| Less: Tenant improvement allowance* |
(12,508 | ) | ||
|
|
|
|||
| Total operating lease liabilities |
$ | 79,734 | ||
|
|
|
|||
| (*) | Tenant improvement allowance is estimated to be received as follows: approximately $0.7 million in 2021, $3.9 million in 2023 and $7.9 million in 2024, respectively. |
During the six months ended June 30, 2021, the Company entered into two new lease agreements, which will be recognized as operating leases upon the lease commencement dates. The lease agreements have terms of approximately 3 years and the Company expects these leases to commence during the third quarter of 2021. As of June 30, 2021, the Company has additional future minimum lease payments relating to these two lease agreements that have not yet commenced amounting to $12.0 million.
17
NOTE 7. COMMITMENTS AND CONTINGENCIES
As of June 30, 2021, the Company’s future commitments over the next five years and thereafter were as follows:
| Minimum Royalties |
Purchase Commitments |
Total | ||||||||||
| (in thousands) | ||||||||||||
| 2021* |
$ | — | $ | 2,487 | $ | 2,487 | ||||||
| 2022 |
575 | 8,629 | 9,204 | |||||||||
| 2023 |
1,075 | 944 | 2,019 | |||||||||
| 2024 |
1,075 | 67 | 1,142 | |||||||||
| 2025 |
1,075 | 67 | 1,142 | |||||||||
| Thereafter |
5,675 | — | 5,675 | |||||||||
|
|
|
|
|
|
|
|||||||
| Total commitments |
$ | 9,475 | $ | 12,194 | $ | 21,669 | ||||||
|
|
|
|
|
|
|
|||||||
| (*) | Excluding the six months ending June 30, 2021. |
Minimum Royalty Commitments
The Company has certain minimum royalty commitments under licensing agreements related to its research efforts.
Purchase Commitments
The Company has open purchase orders primarily related to the purchase of laboratory supplies in the normal course of business.
Contingencies
The Company responds to claims arising in the ordinary course of business. If necessary, the Company will accrue estimates of the amounts it expects to pay when it is probable and the amount can be reasonably estimated, and such amounts will be included in other current liabilities. Should the Company not be able to secure the terms it expects, these estimates may change and will be recognized in the period in which they are identified.
Legal Matters
The Company is subject to various claims, complaints, and legal actions that arise from time to time. The Company does not believe it is a party to any currently pending or threatened legal proceedings that will result in a material adverse effect on its business. There can be no assurance that existing or future legal proceedings arising in the ordinary course of business or otherwise will not have a material adverse effect on the Company’s business, financial position, results of operations, or cash flows.
Indemnification
The Company has agreed to indemnify its directors and officers for certain events or occurrences while the director or officer is, or was serving, at the Company’s request in such capacity. The indemnification period covers all pertinent events and occurrences during the director’s or officer’s service. The maximum potential amount of future payments the Company could be required to make under the applicable indemnification agreements is not specified in the agreements; however, the Company has director and officer insurance coverage that reduces its exposure and enables the Company to recover a portion of any future amounts paid. The Company believes the estimated fair value of these indemnification agreements in excess of applicable insurance coverage is minimal.
The Company enters into standard indemnification arrangements in the ordinary course of business. Pursuant to these arrangements, the Company indemnifies, holds harmless, and agrees to reimburse the indemnified parties for losses suffered or incurred by the indemnified party, in connection with any trade secret, copyright, patent or other intellectual property infringement claim by any third party with respect to the Company’s technology. The term of these indemnification agreements is generally perpetual after the execution of the agreement. The maximum potential amount of future payments the Company could be required to make under these arrangements is not determinable. The Company has not incurred costs to defend lawsuits or settle claims related to these indemnification agreements. As a result, the Company believes the estimated fair value of these agreements is minimal.
18
NOTE 8. COMMON STOCK
The Company has two classes of common stock: Class A and Class B. The voting rights per share of Class A and Class B are 1:1 and 10:1, respectively. Common stockholders are entitled to dividends when and if declared by the board of directors subject to the prior rights of the preferred stockholders. As of June 30, 2021, no dividends have been declared. The shares of Class B common stock are convertible into shares of Class A common stock at a ratio of 0.44 shares of Class A common stock to 0.42 shares of Class B common stock.
As of December 31, 2020 and June 30, 2021, the Company has reserved shares of Class A common stock for issuance upon conversion of the redeemable convertible preferred stock and exercise of options. No shares of Class B common stock have been reserved. The Company has reserved shares of Class A common stock, on an as converted basis, for issuance as follows:
| As of December 31, 2020 |
As of June 30, 2021 |
|||||||
| (in thousands) | ||||||||
| Conversion of Series A redeemable convertible preferred stock |
85,000 | 85,000 | ||||||
| Conversion of Series B redeemable convertible preferred stock |
309,257 | 309,257 | ||||||
| Conversion of Series C redeemable convertible preferred stock |
63,145 | 63,145 | ||||||
| Conversion of Series D redeemable convertible preferred stock |
76,744 | 76,744 | ||||||
| Conversion of Class B common stock |
26,179 | 26,179 | ||||||
| Options and awards outstanding for the 2016 Equity Incentive Plan |
100,580 | 107,905 | ||||||
| Non-Plan Incentive Awards |
24,486 | 22,234 | ||||||
| Reserved for future grants |
5,438 | 20,929 | ||||||
|
|
|
|
|
|||||
| Total |
690,829 | 711,393 | ||||||
|
|
|
|
|
|||||
NOTE 9. REDEEMABLE CONVERTIBLE PREFERRED STOCK
The following tables represent the redeemable convertible preferred stock as of December 31, 2020 and June 30, 2021:
| As of December 31, 2020 | ||||||||||||||||||||
| Shares Authorized |
Original Issuance Price |
Shares Issued and Outstanding |
Net Proceeds | Liquidation Value |
||||||||||||||||
| (in thousands, except share and per share data) | ||||||||||||||||||||
| Series A |
85,000,000 | 1.0000 | 85,000,000 | $ | 120,000 | $ | 85,000 | |||||||||||||
| Series B |
309,256,591 | 4.0085 | 309,256,591 | 1,085,404 | 1,239,655 | |||||||||||||||
| Series C |
63,144,600 | 4.7510 | 63,144,600 | 299,557 | 300,000 | |||||||||||||||
| Series D |
76,743,836 | 5.1080 | 76,743,836 | 391,694 | 392,008 | |||||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||||||
| Total |
534,145,027 | 534,145,027 | $ | 1,896,655 | $ | 2,016,663 | ||||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||||||
| As of June 30, 2021 | ||||||||||||||||||||
| Shares Authorized |
Original Issuance Price |
Shares Issued and Outstanding |
Net Proceeds | Liquidation Value |
||||||||||||||||
| (in thousands, except share and per share data) | ||||||||||||||||||||
| Series A |
85,000,000 | 1.0000 | 85,000,000 | $ | 120,000 | $ | 85,000 | |||||||||||||
| Series B |
309,256,591 | 4.0085 | 309,256,591 | 1,085,404 | 1,239,655 | |||||||||||||||
| Series C |
63,144,600 | 4.7510 | 63,144,600 | 299,557 | 300,000 | |||||||||||||||
| Series D |
76,743,836 | 5.1080 | 76,743,836 | 391,694 | 392,008 | |||||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||||||
| Total |
534,145,027 | 534,145,027 | $ | 1,896,655 | $ | 2,016,663 | ||||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||||||
19
During the six months ended June 30, 2020, the Company issued 45,420,423 additional shares of Series D redeemable convertible preferred stock for gross proceeds of $232.0 million less $0.1 million of issuance costs. The Series D redeemable convertible preferred stock has substantially similar terms as the Company’s Series A, B and C redeemable convertible preferred stock except that it has a liquidation preference of $5.1080 per share.
Redemption
As of December 31, 2020 and June 30, 2021, the Company classified the convertible preferred stock as redeemable on the consolidated balance sheets. Upon the occurrence of certain change-in-control events that may be outside the Company’s control, including liquidation, sale, or transfer of the Company, holders of the convertible preferred stock could cause a redemption of their stock for cash. The preferred stock does not have a mandatory redemption date.
Conversion
Each share of preferred stock is convertible, at the option of the holder, according to a conversion ratio, which is subject to adjustment for dilutive share issuances as described in the next paragraph. The total number of shares of common stock into which the preferred stock may be converted is determined by dividing the then-applicable conversion price by the initial conversion price. The preferred stock automatically converts into shares of Class A common stock at the then-applicable conversion price in the event of an underwritten public offering of shares of common stock with aggregate gross proceeds of no less than $150 million (Qualifying IPO), provided that, prior to April 17, 2022 (24 months after the Series D extension closing), such automatic conversion shall also require either (i) the per share price of the Qualifying IPO to be at least $5.1080 per share (i.e., the Series D preferred stock original issue price) or (ii) the vote of the holders of a majority of the combined Series C and D preferred stock. The preferred stock also automatically converts into shares of Class A common stock at the then-applicable conversion price upon the vote of a majority of the holders of preferred stock and, if prior to April 17, 2022, the vote of the holders of two-thirds of the combined Series C and D preferred stock shall also be required. As of June 30, 2021, each share of Series A, B, C, and D preferred stock was convertible into one share of Class A common stock.
Subject to certain exceptions, including issuances of shares to employees or consultants pursuant to a stock option plan approved by the board of directors and issuances of shares to lenders or strategic partners or in connection with the acquisition of a company or technology, in each case approved by the board of directors, the conversion price of each applicable series of preferred stock is subject to adjustment to prevent dilution in the event that the Company issues additional shares at a purchase price less than the then-applicable conversion price.
Dividends
Any dividends paid in any fiscal year will be paid among the holders of redeemable convertible preferred stock and common stock then outstanding based on preferences and on an if-converted basis. Dividends are noncumulative, and none were declared as of December 31, 2020 or June 30, 2021.
Voting
Each share of redeemable convertible preferred stock is entitled to the number of votes equal to the number of shares of Class A common stock into which such shares could be converted. Holders of redeemable convertible preferred stock and common stock vote as a single class.
Liquidation Preference
In the event of any liquidation, dissolution or winding up of the Company, either voluntary or involuntary, including a merger, acquisition, or sale of assets where the holders of common stock and preferred stock own less than a majority of the resulting voting power of the surviving entity (Liquidation Transaction), the holders of preferred stock will receive in preference to the holders of common stock, an amount per share equal to the liquidation preference, plus any accrued but unpaid dividends. After payment of the liquidation preference to the holders of the preferred stock, the remaining assets of the Company are available for distribution to the holders of common stock on a pro rata basis. The vote of a majority of the holders of the preferred stock can waive the liquidation preference; provided that, prior to April 17, 2022, the vote of the holders of two-thirds of the combined Series C and D preferred stock shall also be required to waive such liquidation preference. These liquidation features cause the Series A, B, C, and D preferred stock to be classified as mezzanine equity rather than as a component of stockholders’ deficit.
20
NOTE 10. STOCK INCENTIVE AWARDS
The Company grants awards under the 2016 Equity Incentive Plan, as amended (2016 Plan) as well as incentive awards not under the 2016 Plan (Non-Plan Equity Incentive Awards).
2016 Equity Incentive Plan
The Company’s board of directors adopted, and its stockholders approved, the Company’s 2016 Plan in January 2016. The 2016 Plan was amended on February 6, 2017, February 27, 2017, September 18, 2019, November 21, 2019, November 25, 2019, May 7, 2020 and January 14, 2021. Unless the board of directors provides otherwise, beginning on January 1, 2018 and continuing each anniversary thereof, the number of shares of common stock reserved for issuance under the 2016 Plan will automatically increase, if and to the extent necessary, to ensure that the reserve represents at least 4% of the total number of issued and outstanding shares of common stock of the Company on a fully diluted basis as of December 31 of the immediately preceding year. Under the 2016 Plan, any shares that are forfeited or expired are added back to the shares available for issuance. On January 1, 2021, the number of authorized shares of common stock that may be issued under the 2016 Plan increased by 27,062,279 shares pursuant to the automatic share increase provision of the plan.
As of June 30, 2021, the Company had granted options or rights to obtain 183,218,289 shares of its Class A common stock and 24,989,397 shares of its Class B common stock under the Company’s 2016 Plan, of which options or rights to obtain 107,904,553 shares of Class A common stock and no shares of Class B common stock were outstanding. As of June 30, 2021, 20,929,810 shares of Class A common stock and no shares of Class B common stock remained available for future grants. The maximum contractual term of awards is generally ten years.
The Company’s 2016 Plan allows for the grant of awards in the form of: (i) incentive stock options, (ii) non-qualified stock options; (iii) stock appreciation rights; (iv) restricted stock (RSAs); (v) restricted stock units (RSUs); and (vi) unrestricted stock. Directors, employees, and consultants are eligible to participate in the 2016 Plan.
Stock Option Activity—A summary of all stock option activity for the 2016 Plan for the six months ended June 30, 2021 was as follows:
| Class A | ||||||||||||||||
| Number of Shares Underlying Outstanding Options |
Weighted-Average Exercise Price Per Share |
Weighted-Average Remaining Contractual Term (in Years) |
Aggregate Intrinsic Value |
|||||||||||||
| Balance as of January 1, 2021 |
81,813 | $ | 1.89 | 8.73 | $ | 537,108 | ||||||||||
| Granted |
— | — | ||||||||||||||
| Exercised |
(2,939 | ) | 1.56 | |||||||||||||
| Repurchased |
— | — | ||||||||||||||
| Forfeited |
(790 | ) | 1.85 | |||||||||||||
|
|
|
|
|
|||||||||||||
| Balance as of June 30, 2021 |
78,084 | 1.91 | 8.26 | 511,605 | ||||||||||||
|
|
|
|
|
|||||||||||||
| Options vested and expected to vest as of June 30, 2021 |
72,766 | 1.90 | 8.23 | 477,514 | ||||||||||||
|
|
|
|||||||||||||||
| Options vested and exercisable as of June 30, 2021 |
33,329 | $ | 1.74 | 7.86 | $ | 223,841 | ||||||||||
|
|
|
|||||||||||||||
21
Restricted Stock Unit Activity—A summary of all restricted stock units activity for the 2016 Plan for the six months ended June 30, 2021 was as follows:
| Class A Restricted Stock Units | ||||||||
| Restricted Stock Units Outstanding |
Weighted-Average Grant Date Fair Value Per Share |
|||||||
| (in thousands, except per share data) | ||||||||
| Unvested balance as of January 1, 2021 |
18,768 | $ | 2.71 | |||||
| Granted |
12,628 | 8.46 | ||||||
| Vested |
(8,831 | ) | 1.95 | |||||
| Forfeited |
(268 | ) | 8.33 | |||||
|
|
|
|||||||
| Unvested balance as of June 30, 2021 |
22,297 | $ | 6.20 | |||||
|
|
|
|||||||
As of June 30, 2021, there was $13.2 million of total unrecognized compensation cost related to restricted stock units that contain only service-based conditions granted under the 2016 Plan. That cost is expected to be recognized over a weighted-average period of 1.6 years. As of June 30, 2021, 8.8 million shares were vested. Of the 8.8 million shares that vested during the six months ended June 30, 2021, 1.3 million were released during the period, with the remainder to be released at a later date. As of June 30, 2021, the total unrecognized compensation cost related to restricted stock units that contain performance- and service- based condition granted under the 2016 Plan was $122.5 million.
Awards with Service-Based Vesting Conditions Granted under the 2016 Plan
During the six months ended June 30, 2020 and 2021, the Company granted 21,765,127 and 20,750 awards with service-based conditions, respectively.
During the six months ended June 30, 2020 and 2021, the Company granted 21,765,127 options and no options to purchase shares of Class A common stock under the 2016 Plan with only service-based vesting conditions, respectively. The aggregate intrinsic value of options exercised during the six months ended June 30, 2020 and 2021 was $1.4 million and $20.1 million, respectively.
During the six months ended June 30, 2020 and 2021, the Company modified options to purchase 1,450,451 and 635,704 shares of Class A common stock with service-based conditions from the 2016 Plan. See “Modification of Stock Awards”.
During the six months ended June 30, 2020, no RSUs issuable for Class A common stock under the 2016 Plan were granted. During the six months ended June 30, 2021, all of the 20,750 awards granted were RSUs issuable for Class A common stock under the 2016 Plan. These RSUs have an expiration term of 10 years. The weighted-average grant date fair value per share for these RSUs was $8.46 and the aggregate grant date fair value was $0.2 million. None of these units vested during the six months ended June 30, 2021.
Awards with Performance-Based Vesting Conditions Granted under the 2016 Plan
During 2019, the Company granted options to purchase 1,743,300 of Class A common stock to one of the Company’s executives. The options will commence vesting upon meeting certain performance-based conditions, over a period of four years, with 1/48th of the total award vesting upon each monthly anniversary of the vesting commencement date. The grant date fair value per share of these options was $1.69 and the aggregate grant date fair value was $3.0 million. As of June 30, 2021, no options have been exercised, no options have vested and no expense has been recognized for these awards as the performance-based conditions are not yet considered probable of being met.
During 2019, the Company granted options to purchase 3,506,222 of Class A common stock to two of the Company’s executives. The options will commence vesting upon the achievement of certain performance-based conditions, over a period of three years, with 1/36th vesting upon each monthly anniversary of such vesting commencement date. The grant date fair value per share of these options was $1.69 and the aggregate grant date fair value was $5.9 million. As of June 30, 2021, no options have been exercised, no options have vested. During the six month period ended June 30, 2021, an expense of $2.0 million has been recognized for these awards as the performance-based conditions are considered probable of being met.
22
During 2019, the Company granted a senior executive with 5,230,200 RSUs with service-based conditions. During 2020, the RSUs were modified to add a performance condition, which had no financial impact. 25% of the modified award will vest after the original service component time has passed on the earlier of (i) March 15, 2021, and (ii) the earlier to occur of the consummation of an initial public offering (IPO) or the closing of certain corporate transactions, and 1/16th of the shares will vest after the original service component time has passed on the earlier to occur of (x) March 15th of the year following completion of the original service component, and (y) the earlier to occur of the consummation of an IPO or the closing of certain corporate transactions. The grant date fair value per share of these awards was $2.09 and the aggregate grant date fair value was $10.9 million. During the six months ended June 30, 2021, 1,307,550 RSUs vested.
During the six months ended June 30, 2020, the Company granted options to purchase 1,700,000 shares of Class A common stock to one of the Company’s executives. The options will commence vesting upon the achievement of certain performance-based conditions, over a period of three years, with 1/36th vesting upon each monthly anniversary of such vesting commencement date. The grant date fair value per share of these options was $1.68 and the aggregate grant date fair value was $2.9 million. As of June 30, 2021, no options have been exercised, no options have vested and no expense has been recognized for these awards as the performance-based conditions are not yet considered probable of being met.
During the six months ended June 30, 2020, the Company granted options to purchase 750,000 shares of Class A common stock to one of the Company’s executives. The options will commence vesting upon meeting certain performance-based conditions, over a period of two years, with 25% vesting upon the vesting commencement date, and 3.125% vesting upon each monthly anniversary of such vesting commencement date. The grant date fair value per share of these options was $1.68 and the aggregate grant date fair value was $1.3 million. As of June 30, 2021, no options have been exercised, no options have vested and no expense has been recognized for these awards as the performance-based conditions are not yet considered probable of being met.
During the third quarter of 2020, the Company granted options to purchase 2,000,000 shares of Class A common stock to one of the Company’s executives. The grant date fair value per share of these options was $1.74 and the aggregate grant date fair value was $3.5 million. Of these awards, an option to purchase 1,000,000 will commence vesting upon the achievement of certain performance-based conditions, over a period of three years, with 1/36th vesting on the monthly anniversary of the vesting commencement date. As of June 30, 2021, no options have been exercised, no options have vested and no expense has been recorded for these awards as the performance condition was not probable of being met. The remaining option to purchase 1,000,000 awards vests over a period of a year, with 50% vesting upon the achievement of certain performance-based conditions and the remainder 50% vesting upon the first anniversary of such vesting commencement date. During the six month period ended June 30, 2021, options to purchase 500,000 options shares vested after the related performance-based condition was met. As of June 30, 2021, no options have been exercised.
During the six months ended June 30, 2020, no RSUs issuable for Class A Common stock under the 2016 Plan were granted. During the six months ended June 30, 2021, the Company granted RSUs issuable for 12,607,206 shares of Class A common stock upon satisfaction of certain performance- and service-based conditions. The service-based vesting condition for these awards is satisfied over a period of 4 to 5 years. The performance-based vesting condition occurs on the earlier to occur of the consummation of the Company’s IPO or the closing of certain corporate transactions. The grant date fair value per share of these awards was $8.46 and the aggregate grant date fair value was $106.7 million. As of June 30, 2021, no RSUs have vested as the performance-based conditions is not yet considered probable of being met. As of June 30, 2021, awards covering 268,152 shares have been forfeited.
Awards with Performance- and Market-Based Vesting Conditions Granted under the 2016 Plan
During 2018, the Company granted options to purchase 4,883,947 shares of Class A common stock that vest upon satisfaction of performance- and market-based conditions. The performance-based conditions are satisfied upon achieving certain performance conditions. The market-based condition is satisfied upon the Company maintaining certain market capitalization levels after an IPO of the Company’s common stock. For these options, the Company used a Monte Carlo simulation to determine the fair value at the grant date and the implied service period.
23
The weighted-average grant date fair value per share for these options was $0.22 and the aggregate grant date fair value was $1.1 million. As of June 30, 2021, options to purchase 14,250 shares have vested and options to purchase 29,933 shares have been exercised. An expense of an immaterial amount was recognized for these awards during the six month period ended June 30, 2021 as the achievement of one of the performance based conditions was deemed to be probable. As of June 30, 2021, options to purchase 4,602,945 shares have been forfeited.
Non-Plan Equity Incentive Awards
During 2018, the Company granted options to purchase 21,453,125 shares of Class A common stock outside of the 2016 Plan to two of the Company’s executives, of which options to purchase 476,191 shares were exercised. The options vest over a period of 4 years with 25% vesting upon the first anniversary of the grant date and 1/48th vesting at the end of each month thereafter. The grant date fair value per share was $0.45 and the aggregate grant date fair value was $9.7 million. During the six months ended June 30, 2020 and 2021, no options and 2.3 million options were exercised. As of June 30, 2021, options to purchase 10,318,720 shares were forfeited. The total grant date fair value of awards that vested during the six months ended June 30, 2020 and 2021 was $0.7 million and nil. During the six months ended June 30, 2021, the Company modified 5.6 million vested options outside of the 2016 Plan. See “Modification of Stock Awards”.
During 2019, the Company granted RSUs issuable for 13,827,568 shares of Class A common stock outside of the 2016 Plan. These units vest over a period of 3 years with 67% vesting upon the second anniversary of the vesting start date and the remaining 33% vesting on the third anniversary of the vesting start date. The weighted-average grant date fair value per share for these units was $1.92 and the aggregate grant date fair value was $26.5 million. During the six month period ended June 30, 2021, 9,218,379 of these RSUs vested and will be released at a later date.
The options granted outside the 2016 Plan outstanding as of June 30, 2021 had a weighted-average exercise price of $0.87 per share.
Early Exercise of Stock Options
Certain options granted under the 2016 Plan and Non-Plan Incentive Awards have been early exercised. The unvested shares are subject to a repurchase right held by the Company at the original purchase price. The proceeds initially are recorded as a liability for early exercise of unvested options and reclassified to additional paid-in capital as the repurchase right lapses.
The Company issued 14,167 and 6,329 shares of common stock upon the early exercise of options during the six months ended June 30, 2020 and 2021 for total exercise proceeds of immaterial amounts.
Shares Subject to Repurchase
As of December 31, 2020 and June 30, 2021, 790,745 and 520,841 shares, respectively, held by employees and directors were subject to the Company’s right of repurchase at an aggregate price of $1.3 million and $1.0 million, respectively.
Modification of Stock Options
During the six months ended June 30, 2020, the Company entered into agreements with four employees, as a result of which the terms of certain of their service-based options to purchase shares of Class A common stock were modified. As a result of these modifications, the vesting of 70,578 options were accelerated as of the date of the agreements, and 1,443,623 of the vested options had their exercise period extended. The Company accounted for the changes to the options as modifications, and the fair value of their service-based options was increased by $0.3 million which was recorded as an incremental expense during the six months ended June 30, 2020.
During the six months ended June 30, 2021, the Company entered into agreements with three employees, as a result of which the terms of certain of their awards were modified. As a result of these modifications, the vesting of awards covering 321,047 shares were accelerated and awards covering 6,187,092 shares had their exercise period extended as of the date of the agreements. The Company accounted for the changes to the awards as modifications, and the fair value of their service-based awards was increased by $2.1 million, which was recorded as an incremental expense during the six months ended June 30, 2021.
24
Stock-Based Compensation Expense
The following table is a summary of stock-based compensation expense recognized for the six month period ended June 30, 2020 and 2021 for employees and non-employees for both the 2016 Plan and Non-Plan Incentive Awards:
| Six Months Ended June 30, | ||||||||
| 2020 | 2021 | |||||||
| (in thousands) | ||||||||
| Research and development |
$ | 2,957 | $ | 3,748 | ||||
| Research and development—related parties |
30 | 282 | ||||||
| Sales and marketing |
1,230 | 2,357 | ||||||
| General and administrative |
19,730 | 18,534 | ||||||
|
|
|
|
|
|||||
| Total stock-based compensation expense |
$ | 23,947 | $ | 24,921 | ||||
|
|
|
|
|
|||||
As of June 30, 2021, the total unrecognized stock-based compensation expense for awards that contain only service-based conditions for both the 2016 Plan and Non-Plan Incentive Awards was $68.1 million, which is expected to be recognized over a weighted-average period of approximately 2.1 years. As of June 30, 2021, the total unrecognized stock-based compensation expense for awards that contain performance-based, performance- and service-based, or performance- and market-based conditions for both the 2016 Plan and Non-Plan Incentive Awards that are probable of being met was $4.3 million, which is expected to be recognized over a weighted-average period of approximately 3.7 years. As of June 30, 2021, the total unrecognized stock-based compensation expense for awards that contain performance-based, performance- and service-based, or performance- and market-based conditions for both the 2016 Plan and Non-Plan Incentive Awards was that are not probable of being met was $131.4 million.
Liability-Classified Awards with Performance-Based Vesting Conditions Granted under the 2016 Plan
In October 2017, the Company entered into a transition agreement with the vice chairperson of the board of directors. Under the transition agreement, the individual was eligible to receive up to $130.0 million in incentive awards. During 2020, the Company modified the transition agreement and the under the new agreement, he is eligible to receive up to $78.0 million in incentive awards.
The incentive awards for the vice chairperson of the board of directors are granted subject to the respective individual’s continued service to the Company. The awards are earned upon the satisfaction of certain performance-based conditions based on cumulative net revenues in any period of four consecutive quarters.
The above incentive awards for the vice chairperson of the board of directors will be paid, at the Company’s election, in fully vested shares of Class B common stock (or securities into which the Class B common stock has previously been converted) or in cash. The dollar value of these incentive awards is based on the achievement of the performance-based conditions described above. The number of shares is variable based on the per-share valuation at the time the performance- based conditions are met. Accordingly, these awards are accounted for as liability-classified awards, and, once the related performance-based conditions are deemed to be probable, the liability will be remeasured at fair value on each reporting date until the awards vest.
As of June 30, 2021, the Company had not recognized any compensation expense associated with these awards as the achievement of the performance-based condition was not deemed to be probable.
NOTE 11. RELATED-PARTY TRANSACTIONS
Illumina Agreements
Beginning May 4, 2020, Mostafa Ronaghi has served as a member of the Company’s board of directors. Dr. Ronaghi was also the Chief Technology Officer of Illumina through May 2020 and the senior vice president of entrepreneurial development of Illumina through January 2021. Illumina is a principal owner of the Company and is a major supplier of the Company’s reagents and capital equipment.
25
As discussed in Note 1, on September 20, 2020, the Company entered into the Merger Agreement pursuant to which Illumina will acquire the Company. Refer to Note 1 for additional details. In accordance with the terms of the Merger Agreement, as of June 30, 2021, the Company received Continuation Payments totaling $245 million from Illumina ($210 million was received during the six months ended June 30, 2021) which was recorded as additional paid in capital in the consolidated balance sheet as of June 30, 2021.
In February 2019, pursuant to the terms of the Company’s supply and commercialization agreement with Illumina, the Company entered into two separate non-exclusive and non-sublicensable license agreements with Illumina. Under these license agreements, the Company sublicensed to Illumina rights to patents and technology in-licensed from other collaboration partners. Under these license agreements, Illumina is required to pay the Company (i) an initial aggregate licensing fees of $50,000, (ii) an annual minimum aggregate royalties of $50,000, increasing by $10,000 annually to a max of $100,000, and (iii) running royalties in the low percentages of net sales of products utilizing in-licensed technology. In addition, one of the license agreements include a milestone of $50,000 tied to the first commercial sale of a product covered by a licensed patent. During the six months ended June 30, 2020 and 2021 the Company recognized $0.1 million and $0.1 million associated with licensing fees and minimum royalties from Illumina as an offset to research and development—related parties.
Transactions with Illumina under a supply and commercialization agreement as well as for limited services rendered by Illumina on the Company’s behalf that have been reflected in the condensed consolidated financial statements are as follows:
| As of | ||||||||
| December 31, 2020 | June 30, 2021 | |||||||
| (in thousands) | ||||||||
| Accounts receivable, net |
$ | — | $ | 3 | ||||
| Inventory |
— | 827 | ||||||
| Prepaid service arrangements |
554 | 258 | ||||||
| Property and equipment, net |
280 | 277 | ||||||
| Accrued liabilities |
70 | 66 | ||||||
| Six Months Ended June 30, | ||||||||
| 2020 | 2021 | |||||||
| (in thousands) | ||||||||
| Revenue |
$ | — | $ | 3 | ||||
| Cost of revenue |
— | 151 | ||||||
| Research and development |
4,063 | 7,171 | ||||||
Dr. Klausner Consulting Agreement
Effective May 2016, the Company entered into a consulting agreement with Richard Klausner, M.D. Dr. Klausner is: (i) a member of the board of directors of the Company and (ii) has performed advisory consulting services. The compensation under the consulting agreement consists of options to purchase 876,000 shares of Class A common stock at an exercise price of $0.23 per share that were granted in 2016. In May 2018, in connection with Dr. Klausner’s consulting service, the Company granted him additional options to purchase 450,000 shares of Class A common stock at an exercise price of $1.74 per share. In August 2020, in connection with Dr. Klausner’s consulting agreement, the Company granted him options to purchase 1,400,000 shares of Class A common stock at an exercise price of $2.09 per share.
Agilent Arrangements
Since August 2018, Hans Bishop has served as a member of the Company’s board of directors. During June 2019, Mr. Bishop was appointed as the Company’s chief executive officer. Mr. Bishop is also on the board of directors of Agilent Technologies, Inc. (Agilent). Agilent is a supplier to the Company.
26
Transactions with Agilent that have been reflected in the condensed consolidated financial statements are as follows:
| As of | ||||||||
| December 31, 2020 | June 30, 2021 | |||||||
| (in thousands) | ||||||||
| Inventory |
$ | — | $ | 48 | ||||
| Prepaid service arrangements |
10 | 1 | ||||||
| Property and equipment, net |
59 | 2,298 | ||||||
| Accounts payable |
52 | 1 | ||||||
| Accrued liabilities |
178 | 234 | ||||||
| Six Months Ended June 30, | ||||||||
| 2020 | 2021 | |||||||
| (in thousands) | ||||||||
| Cost of revenue |
$ | — | $ | 52 | ||||
| Research and development |
$ | 97 | $ | 635 | ||||
Collaboration Agreement with Janssen Biotech, Inc.
Johnson & Johnson UK Treasury Company Limited (J&J UK Treasury) and Janssen Biotech, Inc. (Janssen) are subsidiaries of Johnson & Johnson Inc. (J&J). As of December 31, 2020 and June 30, 2021, J&J UK Treasury was a minority stockholder of the Company. In December 2019, the Company entered into a testing resources and collaboration agreement with Janssen. In January 2020, the Company received $2.5 million in payment for services to be performed under this agreement. As of December 31, 2020 and June 30, 2021, $2.5 million is reflected in other current liabilities in the condensed consolidated balance sheet.
NOTE 12. NET LOSS PER SHARE ATTRIBUTABLE TO COMMON STOCKHOLDERS
The following table presents the calculation of basic and diluted net loss per share attributable to Class A and Class B common stockholders:
| Six Months Ended June 30, | ||||||||||||||||
| 2020 | 2021 | |||||||||||||||
| Class A | Class B | Class A | Class B | |||||||||||||
| (in thousands, except share and per share data) | ||||||||||||||||
| Numerator |
||||||||||||||||
| Net loss |
$ | (112,439 | ) | $ | (23,977 | ) | $ | (175,988 | ) | $ | (35,551 | ) | ||||
|
|
|
|
|
|
|
|
|
|||||||||
| Net loss attributable to Class A and Class B common stockholders |
||||||||||||||||
| Basic and diluted |
$ | (112,439 | ) | $ | (23,977 | ) | $ | (175,988 | ) | $ | (35,551 | ) | ||||
|
|
|
|
|
|
|
|
|
|||||||||
| Denominator |
||||||||||||||||
| Weighted-average shares of Class A and Class B common stock used in computing net loss per share attributable to Class A and Class B common stockholders |
||||||||||||||||
| Basic and diluted |
109,511,713 | 23,352,819 | 123,706,166 | 24,989,397 | ||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Net loss per share attributable to Class A and Class B common stockholders |
||||||||||||||||
| Basic |
$ | (1.03 | ) | $ | (1.03 | ) | $ | (1.42 | ) | $ | (1.42 | ) | ||||
|
|
|
|
|
|
|
|
|
|||||||||
| Diluted |
$ | (1.03 | ) | $ | (1.03 | ) | $ | (1.42 | ) | $ | (1.42 | ) | ||||
|
|
|
|
|
|
|
|
|
|||||||||
As the Company was in a net loss position for all periods presented, basic net loss per share is the same as diluted net loss per share because the inclusion of potential shares of common stock would have been anti-dilutive.
27
The following common stock equivalents were therefore excluded from the computation of diluted net loss per share for the periods presented:
| Six Months Ended | ||||||||
| 2020 | 2021 | |||||||
| Redeemable convertible preferred stock (on an if-converted basis) |
534,145,027 | 534,145,027 | ||||||
| Options to purchase common stock and restricted stock units |
128,377,377 | 130,138,415 | ||||||
| Shares subject to repurchase |
605,555 | 520,841 | ||||||
|
|
|
|
|
|||||
| Total |
663,127,959 | 664,804,283 | ||||||
|
|
|
|
|
|||||
NOTE 13. SUBSEQUENT EVENTS
The Company has reviewed and evaluated subsequent events through August 11, 2021, the date the unaudited condensed consolidated financial statements were available to be issued.
Subsequent to June 30, 2021, the Company granted 572,889 restricted stock units (RSUs) of Class A common stock to employees. Subject to continued service, the RSUs will generally vest upon the satisfaction of certain performance- and service-based conditions, over a period of 4 to 5 years, and had a fair market value on the grant date of $4.8 million.
Subsequent to June 30, 2021, in accordance with the terms of the Merger Agreement, the Company received a Continuation Payment of $35 million in July 2021.
28
Exhibit 99.3
UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION
On August 18, 2021 (the “Closing Date”), Illumina, Inc. (“Illumina” or the “Company”) completed the acquisition of GRAIL, Inc. (“GRAIL”). Pursuant to the Agreement and Plan of Merger, dated as of September 20, 2020 (the “Original Merger Agreement”), as amended on February 4, 2021 by the Amendment to the Agreement and Plan of Merger (the “Merger Agreement Amendment” and the Original Merger Agreement as amended by the Merger Agreement Amendment, the “Merger Agreement”), by and among Illumina, GRAIL, SDG Ops, Inc., a Delaware corporation and a direct, wholly owned subsidiary of Illumina (“First Merger Sub”), SDG Ops, LLC, a Delaware limited liability company and a direct, wholly owned subsidiary of Illumina (“Second Merger Sub” and now known as GRAIL, LLC), First Merger Sub merged with and into GRAIL, with GRAIL continuing as the surviving entity and as a direct, wholly owned subsidiary of Illumina (the “First Merger”). Immediately following the First Merger and as part of the same overall transaction as the First Merger, GRAIL merged with and into Second Merger Sub, with Second Merger Sub being renamed GRAIL, LLC and continuing as the surviving entity and as a direct, wholly owned subsidiary of Illumina (together with the First Merger, the “Mergers”).
At the effective time of the First Merger (the “Effective Time”), each issued and outstanding share of Class A Common Stock, par value $0.001 per share, Class B Common Stock, par value $0.001 per share, Series A Preferred Stock, par value $0.001 per share, Series B Preferred Stock, par value $0.001 per share, Series C Preferred Stock, par value $0.001 per share, and Series D Preferred Stock, par value $0.001 per share, of GRAIL (collectively, “GRAIL Stock”) (subject to limited exceptions, including shares with respect to which dissenters’ rights were validly exercised in accordance with Delaware law) was converted into, at the holder’s election, either:
| • | The right to receive (i) $4.46 in cash (the “Cash Consideration”), plus (ii) 0.0138 shares (the “Stock Consideration”) of common stock, par value $0.01 per share, of Illumina (“Illumina Common Stock”), plus (iii) one CVR issued by Illumina, subject to and in accordance with the CVR Agreement (clauses (i), (ii) and (iii), collectively, the “CVR Consideration”); or |
| • | The right to receive (i) the Cash Consideration, plus (ii) the Stock Consideration, plus (iii) 0.0022 additional shares (the “Alternative Consideration”) of Illumina Common Stock (clauses (i), (ii) and (iii), collectively, the “Non-CVR Consideration”). |
No fractional shares of Illumina Common Stock were (or will be) issued as Stock Consideration or Alternative Consideration, and GRAIL stockholders received (or will receive) cash in lieu of any fractional shares of Illumina Common Stock they otherwise would have been entitled to receive.
Immediately prior to the Effective Time, a portion, determined in accordance with the Merger Agreement, of each outstanding award of GRAIL restricted stock, restricted stock units and stock options vested. Vested equity awards were canceled for the right to receive, at the holder’s election, either the CVR Consideration or the Non-CVR Consideration. Unvested awards were converted into equivalent awards with respect to Illumina Common Stock in a manner intended to preserve their value, and generally subject to the same terms and conditions as the underlying GRAIL awards, except that the holder had the right to elect to receive a specified number of vested CVRs in respect of such award in exchange for fewer Illumina awards.
The following unaudited pro forma condensed combined financial information combines the historical financial statements of Illumina and GRAIL, after giving effect to the transactions contemplated by the Merger Agreement (such transactions, the “Transaction”). The unaudited pro forma condensed combined balance sheet is presented as if the Transaction occurred as of July 4, 2021. The unaudited pro forma condensed combined statement of operations for the six months ended July 4, 2021 and the twelve months ended January 3, 2021 give effect to the acquisition as if the Transaction had occurred on December 30, 2019, the beginning of the earliest period presented. The unaudited pro forma condensed combined financial information is based on the historical consolidated financial statements of Illumina and GRAIL, and the assumptions and adjustments set forth in the accompanying explanatory notes. The unaudited pro forma condensed combined financial information was prepared using the acquisition method of accounting for business combinations with Illumina considered the acquirer of GRAIL for accounting purposes. See “Note 2 – Basis of presentation” below.
Illumina’s fiscal year is the 52 or 53 weeks ending the Sunday closest to December 31, with quarters of 13 or 14 weeks ending closest to March 31, June 30, September 30 and December 31. GRAIL’s fiscal year is the calendar year. In accordance with the financial statement requirements contained in Article 11 of Regulation S-X, pro forma condensed combined financial information is presented as outlined below:
| • | The unaudited pro forma condensed combined balance sheet as of July 4, 2021 is presented as if Illumina’s acquisition of GRAIL had occurred on July 4, 2021, and combines the historical unaudited consolidated balance sheet of Illumina as of July 4, 2021 with the historical unaudited condensed consolidated balance sheet of GRAIL as of June 30, 2021. |
| • | The unaudited pro forma condensed statement of operations for the twelve months ended January 3, 2021 and the six months ended July 4, 2021 are presented as if Illumina’s acquisition of GRAIL had occurred on December 30, 2019, and combines the historical audited consolidated statement of income of Illumina for the twelve months ended January 3, 2021 with the historical audited consolidated statement of operations of GRAIL for the twelve months ended December 31, 2020 and the historical unaudited condensed consolidated statement of income of Illumina for the six months ended July 4, 2021 with the historical unaudited condensed consolidated statement of operations of GRAIL for the six months ended June 30, 2021 |
1
The unaudited pro forma condensed combined financial information was derived from and should be read in conjunction with the following historical financial statements and notes:
| • | the audited consolidated financial statements of Illumina as of and for the year ended January 3, 2021, contained in its Annual Report on Form 10-K for the fiscal year then ended filed with the Securities and Exchange Commission on February 17, 2021; |
| • | the unaudited condensed consolidated financial statements of Illumina as of and for the six months ended July 4, 2021, contained in its Quarterly Report on Form 10-Q for the fiscal quarter ended July 4, 2021 filed with the Securities and Exchange Commission on August 6, 2021; |
| • | the audited consolidated financial statements of GRAIL as of and for the year ended December 31, 2020, contained in Exhibit 99.1 to this Current Report on Form 8-K; |
| • | and the unaudited condensed consolidated financial statements of GRAIL as of and for the six months ended June 30, 2021, contained in Exhibit 99.2 of this Current Report on Form 8-K. |
The acquisition of GRAIL is accounted for as a business combination and reflects the application of acquisition accounting in accordance with Accounting Standards Codification (ASC) 805, Business Combinations (“ASC 805”). For purposes of developing the unaudited pro forma condensed combined balance sheet as of July 4, 2021, the acquired GRAIL assets, including identifiable intangible assets and liabilities assumed, have been recorded at their estimated fair values with the excess purchase price assigned to goodwill. The pro forma adjustments are based on estimates of the fair values of assets acquired and liabilities assumed and information available as of July 4, 2021. The allocation of the purchase price, therefore, the fair values assigned to intangible assets, goodwill, and deferred taxes, among other items, are subject to change as additional information is received and certain tax returns are finalized. It will be finalized as soon as practicable, but not later than one year from the acquisition date.
The pro forma financial information has been prepared by Illumina in accordance with Article 11 of Regulation S-X (Pro Forma Financial Information). The unaudited pro forma condensed combined financial information is provided for illustrative purposes only, does not necessarily reflect what the actual consolidated results of operations would have been had the acquisition occurred on the dates assumed and may not be useful in predicting the future consolidated results of operations or financial position. Illumina’s results of operations and actual financial position may differ significantly from the pro forma amounts reflected herein due to a variety of factors.
2
UNAUDITED PRO FORMA CONDENSED COMBINED BALANCE SHEET
AS OF JULY 4, 2021
(In millions)
| Historical | Pro Forma | |||||||||||||||||
| Illumina | GRAIL | Transaction accounting adjustments |
Notes | Pro forma combined |
||||||||||||||
| ASSETS |
||||||||||||||||||
| Current assets: |
||||||||||||||||||
| Cash, cash equivalents and short-term investments |
$ | 4,286 | $ | 578 | $ | (3,467 | ) | A | $ | 1,397 | ||||||||
| Accounts receivable, net |
540 | — | — | 540 | ||||||||||||||
| Inventory |
380 | 2 | — | 382 | ||||||||||||||
| Prepaid expenses and other current assets |
104 | 10 | — | 114 | ||||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||||
| Total current assets |
5,310 | 590 | (3,467 | ) | 2,433 | |||||||||||||
| Property and equipment, net |
915 | 86 | — | 1,001 | ||||||||||||||
| Operating lease right-of-use assets |
566 | 49 | 66 | B | 681 | |||||||||||||
| Goodwill |
966 | — | 6,034 | C | 7,000 | |||||||||||||
| Intangible assets, net |
162 | — | 3,180 | C | 3,342 | |||||||||||||
| Other assets |
756 | 8 | (250 | ) | D | 514 | ||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||||
| Total assets |
$ | 8,675 | $ | 733 | $ | 5,563 | $ | 14,971 | ||||||||||
|
|
|
|
|
|
|
|
|
|||||||||||
| LIABILITIES AND STOCKHOLDERS’ EQUITY |
||||||||||||||||||
| Current liabilities: |
||||||||||||||||||
| Accounts payable |
$ | 200 | $ | 15 | $ | — | $ | 215 | ||||||||||
| Accrued liabilities |
674 | 50 | 3 | B | 920 | |||||||||||||
| 193 | E | |||||||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||||
| Total current liabilities |
874 | 65 | 196 | 1,135 | ||||||||||||||
| Operating lease liabilities |
704 | 73 | 19 | B | 796 | |||||||||||||
| Term notes |
992 | — | — | 992 | ||||||||||||||
| Convertible senior notes |
687 | — | — | 687 | ||||||||||||||
| Other long-term liabilities |
238 | 4 | 154 | F | 1,158 | |||||||||||||
| 762 | G | |||||||||||||||||
| Redeemable convertible preferred stock: |
||||||||||||||||||
| Series A |
— | 68 | (68 | ) | H | — | ||||||||||||
| Series B |
— | 1,235 | (1,235 | ) | H | — | ||||||||||||
| Series C |
— | 300 | (300 | ) | H | — | ||||||||||||
| Series D |
— | 392 | (392 | ) | H | — | ||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||||
| Total redeemable convertible preferred stock |
— | 1,995 | (1,995 | ) | — | |||||||||||||
| Stockholders’ equity (deficit): |
||||||||||||||||||
| Common stock |
2 | — | — | 2 | ||||||||||||||
| Additional paid-in capital |
3,993 | 422 | 4,749 | H | 8,742 | |||||||||||||
| (422 | ) | H | ||||||||||||||||
| Accumulated other comprehensive income |
8 | 3 | (3 | ) | H | 8 | ||||||||||||
| Retained earnings (accumulated deficit) |
5,055 | (1,829 | ) | 900 | D | 5,092 | ||||||||||||
| (193 | ) | E | ||||||||||||||||
| (55 | ) | F | ||||||||||||||||
| 1,829 | H | |||||||||||||||||
| (615 | ) | I | ||||||||||||||||
| Treasury stock, at cost |
(3,878 | ) | — | 237 | H | (3,641 | ) | |||||||||||
|
|
|
|
|
|
|
|
|
|||||||||||
| Total stockholders’ equity (deficit) |
5,180 | (1,404 | ) | 6,427 | 10,203 | |||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||||
| Total liabilities, redeemable convertible preferred stock and stockholders’ equity (deficit) |
$ | 8,675 | $ | 733 | $ | 5,563 | $ | 14,971 | ||||||||||
|
|
|
|
|
|
|
|
|
|||||||||||
See accompanying notes to the Unaudited Pro Forma Condensed Combined Financial Information
3
UNAUDITED PRO FORMA CONDENSED COMBINED STATEMENT OF OPERATIONS
FOR THE TWELVE MONTHS ENDED JANUARY 3, 2021
(In millions, except per share amounts)
| Historical | Pro Forma | |||||||||||||||||
| Illumina | GRAIL | Transaction accounting adjustments |
Notes | Pro forma combined |
||||||||||||||
| Revenue: |
||||||||||||||||||
| Product revenue |
$ | 2,735 | $ | — | $ | — | $ | 2,735 | ||||||||||
| Service and other revenue |
504 | — | — | 504 | ||||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||||
| Total revenue |
3,239 | — | — | 3,239 | ||||||||||||||
| Cost of revenue: |
||||||||||||||||||
| Cost of product revenue |
788 | — | — | 788 | ||||||||||||||
| Cost of service and other revenue |
220 | — | 137 | J | 357 | |||||||||||||
| Amortization of acquired intangible assets |
28 | — | — | 28 | ||||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||||
| Total cost of revenue |
1,036 | — | 137 | 1,173 | ||||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||||
| Gross profit |
2,203 | — | (137 | ) | 2,066 | |||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||||
| Operating expense: |
||||||||||||||||||
| Research and development |
682 | 193 | 24 | E | 1,072 | |||||||||||||
| 6 | E | |||||||||||||||||
| 167 | I | |||||||||||||||||
| Selling, general and administrative |
941 | 124 | 148 | E | 1,645 | |||||||||||||
| 15 | E | |||||||||||||||||
| 448 | I | |||||||||||||||||
| 4 | J | |||||||||||||||||
| (35 | ) | K | ||||||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||||
| Total operating expense |
1,623 | 317 | 777 | 2,717 | ||||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||||
| Income (loss) from operations |
580 | (317 | ) | (915 | ) | (651 | ) | |||||||||||
| Other income (expense): |
||||||||||||||||||
| Interest income |
41 | 6 | — | 47 | ||||||||||||||
| Interest expense |
(49 | ) | — | — | (49 | ) | ||||||||||||
| Other income (expense), net |
284 | (1 | ) | 900 | D | 1,183 | ||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||||
| Total other income, net |
276 | 5 | 900 | 1,180 | ||||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||||
| Income (loss) before income taxes |
856 | (312 | ) | (15 | ) | 529 | ||||||||||||
| Provision for (benefit from) income taxes |
200 | — | (130 | ) | F | 70 | ||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||||
| Net income (loss) |
$ | 656 | $ | (312 | ) | $ | 115 | $ | 459 | |||||||||
|
|
|
|
|
|
|
|
|
|||||||||||
| Earnings per share: |
||||||||||||||||||
| Basic |
$ | 4.48 | $ | 2.93 | ||||||||||||||
| Diluted |
$ | 4.45 | $ | 2.91 | ||||||||||||||
| Shares used in computing earnings per share: |
||||||||||||||||||
| Basic |
147 | 10 | H | 157 | ||||||||||||||
| Diluted |
148 | 10 | H | 158 | ||||||||||||||
See accompanying notes to the Unaudited Pro Forma Condensed Combined Financial Information
4
UNAUDITED PRO FORMA CONDENSED COMBINED STATEMENT OF OPERATIONS
FOR THE SIX MONTHS ENDED JULY 4, 2021
(In millions, except per share amounts)
| Historical | Pro Forma | |||||||||||||||||
| Illumina | GRAIL | Transaction accounting adjustments |
Notes | Pro forma combined |
||||||||||||||
| Revenue: |
||||||||||||||||||
| Product revenue |
$ | 1,925 | $ | — | $ | — | $ | 1,925 | ||||||||||
| Service and other revenue |
294 | 1 | — | 295 | ||||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||||
| Total revenue |
2,219 | 1 | — | 2,220 | ||||||||||||||
| Cost of revenue: |
||||||||||||||||||
| Cost of product revenue |
519 | — | — | 519 | ||||||||||||||
| Cost of service and other revenue |
121 | 2 | 69 | J | 192 | |||||||||||||
| Amortization of acquired intangible assets |
13 | — | — | 13 | ||||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||||
| Total cost of revenue |
653 | 2 | 69 | 724 | ||||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||||
| Gross profit |
1,566 | (1 | ) | (69 | ) | 1,496 | ||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||||
| Operating expense: |
||||||||||||||||||
| Research and development |
398 | 110 | — | 508 | ||||||||||||||
| — | ||||||||||||||||||
| Selling, general and administrative |
787 | 100 | (210 | ) | K | 679 | ||||||||||||
| 2 | J | |||||||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||||
| Total operating expense |
1,185 | 210 | (208 | ) | 1,187 | |||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||||
| Income (loss) from operations |
381 | (211 | ) | 139 | 309 | |||||||||||||
| Other income (expense): |
||||||||||||||||||
| Interest income |
— | — | — | — | ||||||||||||||
| Interest expense |
(34 | ) | — | — | (34 | ) | ||||||||||||
| Other income, net |
31 | 1 | — | 32 | ||||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||||
| Total other (expense) income, net |
(3 | ) | 1 | — | (2 | ) | ||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||||
| Income (loss) before income taxes |
378 | (210 | ) | 139 | 307 | |||||||||||||
| Provision for (benefit from) income taxes |
45 | — | (40 | ) | F | 5 | ||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||||
| Net income (loss) |
$ | 333 | $ | (210 | ) | $ | 179 | $ | 302 | |||||||||
|
|
|
|
|
|
|
|
|
|||||||||||
| Earnings per share: |
||||||||||||||||||
| Basic |
$ | 2.28 | $ | 1.93 | ||||||||||||||
| Diluted |
$ | 2.26 | $ | 1.92 | ||||||||||||||
| Shares used in computing earnings per share: |
||||||||||||||||||
| Basic |
146 | 10 | H | 156 | ||||||||||||||
| Diluted |
147 | 10 | H | 157 | ||||||||||||||
See accompanying notes to the Unaudited Pro Forma Condensed Combined Financial Information
5
NOTES TO THE UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION
1. Description of the GRAIL acquisition
On August 18, 2021, the Company acquired GRAIL. In connection with the Mergers, (i) approximately $3.5 billion in cash was paid to former holders of GRAIL Stock (excluding Illumina) and/or former holders of GRAIL Equity Awards (as defined in the Merger Agreement) and to cover applicable tax withholding, and (ii) approximately 9.8 million shares of Illumina Common Stock and approximately 381.5 million CVRs were (or will be) issued to former holders of GRAIL Stock (excluding Illumina) and/or former holders of GRAIL Equity Awards.
In connection with the Transaction, GRAIL stockholders and holders of GRAIL Equity Awards had the option to elect to receive CVRs, which entitles holders to receive future payments representing a pro rata portion of certain revenues (calculated in accordance with the CVR Agreement) each year for a 12-year period. Each holder of a CVR is to receive a pro rata portion of 2.5% of Covered Revenues (as defined in the CVR Agreement), if any, up to and including $1 billion, plus 9.0% of Covered Revenues, if any, in excess of $1 billion, with such $1 billion threshold measured over an annual period to correspond with Illumina’s fiscal year. GRAIL stockholders and holders of vested GRAIL Equity Awards had the option to receive the Alternative Consideration, which is additional stock consideration, in an amount equal to $850 million in shares of Illumina Common Stock, subject to a floor price, divided by the GRAIL Fully Diluted Share Count, in lieu of the CVRs. Holders of unvested GRAIL Equity Awards had the right to receive an equity award with respect to a number of shares based on the Non-CVR Consideration Award Ratio, which resulted in a larger number of converted awards in lieu of holders’ receiving fully vested CVRs in addition to the converted awards.
2. Basis of presentation
The accompanying unaudited pro forma condensed combined financial information gives effect to the acquisition of GRAIL by Illumina. The unaudited pro forma condensed combined financial information is based on the historical consolidated financial statements of Illumina and GRAIL, and the assumptions and adjustments set forth in these notes. In accordance with the financial statement requirements contained in Article 11 of Regulation S-X, pro forma condensed combined financial information is presented as outlined below:
| • | The unaudited pro forma condensed combined balance sheet as of July 4, 2021 is presented as if Illumina’s acquisition of GRAIL had occurred on July 4, 2021 and combines the historical unaudited consolidated balance sheet of Illumina as of July 4, 2021 with the historical unaudited condensed consolidated balance sheet of GRAIL as of June 30, 2021. |
| • | The unaudited pro forma condensed statement of operations for the six months ended July 4, 2021 and the twelve months ended January 3, 2021 are presented as if Illumina’s acquisition of GRAIL had occurred on December 30, 2019, and combines the historical unaudited condensed consolidated statement of income of Illumina for the six months ended July 4, 2021 with the historical condensed consolidated statement of operations of GRAIL for the six months ended June 30, 2021, and the historical audited consolidated statement of income of Illumina for the twelve months ended January 3, 2021 with the historical audited consolidated statement of operations of GRAIL for the twelve months ended December 31, 2020. |
The unaudited pro forma condensed combined financial information is provided for informational purposes only and is based on available information and reasonable assumptions. It does not purport to represent what the actual consolidated results of operations or the consolidated financial position of Illumina would have been if the acquisition occurred on the dates indicated, nor is it necessarily indicative of future consolidated results of operations or consolidated financial position. The actual financial position and results of operations will differ, perhaps significantly, from the pro forma amounts reflected herein due to a variety of factors, including access to additional information, changes in value not currently identified and changes in financial position and operating results following the date of the unaudited pro forma condensed combined financial information.
Pro forma transaction accounting adjustments are included only to the extent they are adjustments that reflect the accounting for the Transaction in accordance with U.S. GAAP.
The acquisition is accounted for using the acquisition method of accounting with Illumina as the accounting acquirer and GRAIL as the accounting acquiree. The unaudited pro forma condensed combined financial information reflects the assessment of fair values assigned to components of the purchase price, share-based compensation awards, as well as fair values and useful lives assigned to assets acquired and liabilities assumed. Fair value estimates were based on discussions between Illumina and GRAIL and through due diligence efforts. The allocation of the purchase price, therefore, the fair values assigned to intangible assets, goodwill, and deferred taxes, among other items, are subject to change as additional information is received and certain tax returns are finalized. It will be finalized as soon as practicable, but not later than one year from the acquisition date. Changes to the purchase price and the fair values of these assets and liabilities would also result in changes to goodwill recorded from the acquisition, which could be material.
6
The unaudited pro forma condensed combined financial information should be read in conjunction with the historical consolidated financial statements and accompanying notes of Illumina included in its annual report on Form 10-K for the year ended January 3, 2021 and its quarterly report on Form 10-Q for the six months ended July 4, 2021 and the historical consolidated financial statements of GRAIL and related notes thereto for the year ended December 31, 2020 and the six months ended June 30, 2021.
3. Preliminary purchase price
The fair value of the purchase price in the unaudited pro forma condensed combined financial information below is based on the Illumina Common Stock’s closing price of $510.61 on August 18, 2021.
The following table summarizes the components of the estimated purchase price (in millions, except per-share information):
| Cash |
$ | 3,467 | ||
| Fair value of estimated share consideration* |
4,986 | |||
| Less: amounts excluded from purchase consideration |
(615 | ) | ||
| Fair value of contingent value rights |
762 | |||
| Fair value of previously held investment in GRAIL |
1,150 | |||
| Settlement of preexisting relationships |
1 | |||
|
|
|
|||
| $ | 9,751 |
| * | 9.8 million shares of Illumina Common Stock issued (or to be issued), including the alternative consideration, at a share price of $510.61 on August 18, 2021. |
The purchase price was dependent upon the number of shares of Illumina Common Stock issued, determined based on the weighted average trading price of Illumina Common Stock for the 20 consecutive trading days ending on (and including) the trading day that was 10 trading days prior to the Closing Date, subject, in the case of the Stock Consideration, to a collar of $295 to $399 and, in the case of the Alternative Consideration, to a floor of $280. The weighted average trading price was $482.58 on the Closing Date. The number of shares of Illumina Common Stock issued to holders of GRAIL Stock and converted share-based compensation awards was dependent on the number of GRAIL shares and share-based compensation awards outstanding on the Closing Date.
The acquisition date fair value of the contingent consideration liability related to the CVRs was measured using a Monte Carlo simulation. Key assumptions used in the fair value assessment included revenue projections, discount rate, volatility and risk-free rate. The fair value measurement of the contingent consideration is based on significant inputs not observed in the market and thus represents a Level 3 measurement. Level 3 instruments are valued based on unobservable inputs that are supported by little or no market activity and reflect Illumina’s own assumptions in measuring fair value.
Prior to the acquisition date, Illumina owned a 12% interest in GRAIL and accounted for the previously held investment under the measurement alternative at cost and adjusted for observable transactions for identical or similar investments of the same issuer or impairment. Authoritative guidance on accounting for business combinations requires that an acquirer remeasure its previously held equity interest in the acquiree at its acquisition date fair value and recognize the resulting gain or loss in earnings. Illumina remeasured the previously held equity interest to its fair value, as of the date of acquisition, based on the fair value of total consideration transferred and a discount for lack of control.
In connection with the closing of the acquisition, a portion, determined in accordance with the Merger Agreement, of each outstanding award of GRAIL restricted stock, restricted stock units and stock options vested. Vested equity awards were canceled for the right to receive, at the holder’s election, either the CVR Consideration or the Non-CVR Consideration. Unvested awards were converted into equivalent awards with respect to Illumina Common Stock in a manner intended to preserve their value, and generally subject to the same terms and conditions as the underlying GRAIL awards, except that the holder had the right to elect to receive a specified number of vested CVRs in respect of such award in exchange for fewer Illumina awards. The fair value of the converted share-based compensation awards attributable to pre-combination service is recognized as part of the purchase price, and the fair value of the converted share-based compensation awards attributable to post-combination service, excluding any CVRS, is recognized as expense over the post-combination service period.
For purposes of this pro forma analysis, the above purchase price has been allocated as follows based on a provisional estimate of the fair value of assets and liabilities to be acquired as of July 4, 2021:
| Assets acquired |
$ | 800 | ||
| Developed technology |
2,470 | |||
| In-process research and development (IPR&D) |
670 | |||
| Tradename |
40 | |||
| Goodwill |
6,034 | |||
| Deferred tax liability |
(99 | ) | ||
| Liabilities assumed |
(164 | ) | ||
| Total purchase price |
$ | 9,751 | ||
|
|
|
7
This purchase price allocation was used to prepare the Transaction accounting adjustments in the unaudited pro forma condensed combined financial information. The final purchase price allocation is expected to be completed within the measurement period, as defined in ASC 805, following the close of the Transaction and could differ materially from the provisional allocation used in the Transaction accounting adjustments detailed below.
The acquired GRAIL assets, including identifiable intangible assets and liabilities assumed, have been recorded at their estimated fair values with the excess purchase price assigned to goodwill. The pro forma adjustments are based on estimates of the fair values of assets acquired and liabilities assumed and information available as of July 4, 2021. The allocation of the purchase price, therefore, the fair values assigned to intangible assets, goodwill, and deferred taxes, among other items, are subject to change as additional information is received and certain tax returns are finalized. It will be finalized as soon as practicable, but not later than one year from the acquisition date.
Acquired intangible assets were valued using the discounted cash flow method. This method requires significant management judgment to forecast future operating results and establish residual growth rates and discount factors. The estimates used to value and amortize intangible assets are consistent with the plans and estimates that Illumina uses to manage the business and are based on available historical information and industry estimates and averages. If the subsequent actual results and updated projections of the underlying business activity change compared with the assumptions and projections used to develop these values, Illumina could experience impairment charges. In addition, Illumina has estimated the economic lives of certain acquired assets and these lives are used to calculate depreciation and amortization expense. If estimates of the economic lives change, depreciation or amortization expenses could be accelerated or slowed. In-process research and development (IPR&D) is capitalized and either amortized over the life of the product upon commercialization or impaired it if the project is abandoned.
4. Transaction accounting adjustments
The Transaction accounting adjustments included in the unaudited pro forma condensed combined financial information are as follows:
| A. | To reflect the approximately $3.5 billion in cash consideration paid to former holders of GRAIL Stock (excluding Illumina) and/or former holders of GRAIL Equity Awards (as defined in the Merger Agreement) and to cover applicable tax withholding. |
| B. | To remeasure GRAIL’s lease liabilities at the present value of the remaining lease payments, as if the acquired leases were new leases of Illumina at the acquisition date, and to remeasure the right-of-use assets at the same amount as the lease liabilities as adjusted to reflect favorable or unfavorable terms of the leases when compared with market terms. The difference is recorded to Goodwill. |
| C. | To reflect the estimated fair value of the intangible assets and goodwill from the acquisition. Goodwill, representing the excess of the purchase price over the fair value of the net assets to be acquired, as of July 4, 2021, is estimated to be $6 billion. These allocations are based on preliminary estimates and the final allocation may differ materially as changes to the initial valuation of the purchase price or net assets acquired will be allocated as an offset to goodwill. |
| D. | To remove Illumina’s investment in GRAIL of $250 million and reflect the estimated related gain on the GRAIL investment of $900 million in Retained earnings (accumulated deficit) as of July 4, 2021 and in Other income (expense), net, for the twelve months ended January 3, 2021. Illumina remeasured the previously held equity interest to its fair value, as of the date of acquisition, based on the fair value of total consideration transferred and a discount for lack of control. |
| E. | To reflect an accrual for additional Transaction costs of $193 million incurred as part of the closing of the Transaction. Transaction costs of $151 million are already included in the historical statements of operations. The Transaction costs include an accrual for retention bonuses triggered by the closing of the Transaction in the amount of $39 million, of which $24 million is recognized to research and development and $15 million is recognized to selling, general and administrative for the twelve months ended January 3, 2021. |
| F. | To record a deferred tax liability of $99 million for the net acquired intangibles, partially offset by net operating losses and tax credits. This also includes the elimination of the deferred tax impact of $55 million related to Illumina’s transaction costs and continuation payments partially offset by Illumina’s investment in GRAIL, which is included in retained earnings at July 4, 2021.The benefit from income taxes of $130 million and $40 million for the |
8
| twelve months ended January 3, 2021 and the six months ended July 4, 2021, respectively, are attributable to the losses from GRAIL and the transaction accounting adjustments. These estimates are based on a preliminary review that is subject to revision as further information is gathered and interpreted. |
| G. | To reflect the estimated fair value of $762 million for the CVRs payable to GRAIL stockholders and equity award holders, which is reflected in the purchase price. The acquisition date fair value of the contingent consideration liability was measured using a Monte Carlo simulation and could change materially based on actual outcomes. Key assumptions used in the fair value assessment included revenue projections, discount rate, volatility and risk-free rate. The fair value measurement of the contingent consideration is based on significant inputs not observed in the market and thus represents a Level 3 measurement. Level 3 instruments are valued based on unobservable inputs that are supported by little or no market activity and reflect our own assumptions in measuring fair value. |
| H. | To reflect the issuance of Illumina Common Stock for the Stock Consideration and the Alternative Consideration to GRAIL stockholders and holders of vested or accelerated share-based compensation awards and the elimination of GRAIL’s historical balances in redeemable convertible preferred stock and stockholders’ deficit balances. The issuance of 9.8 million shares of Stock Consideration and Alternative Consideration is reflected in the shares used to calculate earnings per share and was issued from Treasury stock, at cost of $237 million. The excess of fair value over cost of approximately $4.7 billion is reflected in additional paid in capital. |
| I. | To record the Day 1 compensation expense of $615 million attributable to the acceleration of unvested shared-based awards of GRAIL at the Closing Date attributable to the post-combination period for the twelve months ended January 3, 2021. $167 million is reflected in Research and development while the remaining $448 million is reflected in Selling, general and administrative in the statement of operations for the twelve months ended January 3, 2021. |
| J. | To record the amortization expense of $141 million for the twelve months ended January 3, 2021 and $71 million for the six months ended July 4, 2021, respectively, for the intangible assets acquired as part of the Mergers. The acquired intangible assets have been amortized using a weighted-average estimated useful life of approximately 18 years. |
Amortization expense of $137 million and $69 million for the developed technology intangible asset is recognized as cost of service and other revenue for the twelve months ended January 3, 2021 and the six months ended July 4, 2021, respectively, based on an estimated useful life of 18 years. The developed technology is related to GRAIL’s Galleri product that was launched in May 2021. The unaudited pro forma condensed combined statement of operations assumes the Galleri product was launched as of the beginning of the twelve months ended January 3, 2021.
Amortization expense of $4 million and $2 million for the tradename is recognized as selling, general and administrative expense for the twelve months ended January 3, 2021 and the six months ended July 4, 2021, respectively, based on an estimated useful life of 9 years.
The amortization of the intangible assets is based on a straight-line amortization method as this represents management’s best estimate of the pattern of utilization for the intangible assets. Illumina has not yet finalized the purchase price allocation, and any resulting change in the fair value or estimated useful lives would have a direct and potentially material impact to amortization expense.
| K. | To reflect the elimination of the monthly $35 million Continuation Payments made to GRAIL beginning in December 2020 as obligated per the Merger Agreement and ending in July 2021. One payment of $35 million is eliminated in the statement of operations for the twelve months ended January 3, 2021. Six payments totaling $210 million are eliminated in the statement of operations for the six months ended July 4, 2021. |
9